#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Cortical substrates of cue-reactivity in multiple substance dependent populations: transdiagnostic relevance of the medial prefrontal cortex
#Text=Elevated drug-cue elicited brain activity is one of the most widely cited, transdiagnostically relevant traits of substance dependent populations.
1-1	0-8	Cortical	_	
1-2	9-19	substrates	_	
1-3	20-22	of	_	
1-4	23-37	cue-reactivity	_	
1-5	38-40	in	_	
1-6	41-49	multiple	_	
1-7	50-59	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-8	60-69	dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-9	70-81	populations	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-10	81-82	:	_	
1-11	83-98	transdiagnostic	_	
1-12	99-108	relevance	_	
1-13	109-111	of	_	
1-14	112-115	the	_	
1-15	116-122	medial	_	
1-16	123-133	prefrontal	_	
1-17	134-140	cortex	_	
1-18	141-149	Elevated	_	
1-19	150-158	drug-cue	_	
1-20	159-167	elicited	_	
1-21	168-173	brain	_	
1-22	174-182	activity	_	
1-23	183-185	is	_	
1-24	186-189	one	_	
1-25	190-192	of	_	
1-26	193-196	the	_	
1-27	197-201	most	_	
1-28	202-208	widely	_	
1-29	209-214	cited	_	
1-30	214-215	,	_	
1-31	216-235	transdiagnostically	_	
1-32	236-244	relevant	_	
1-33	245-251	traits	_	
1-34	252-254	of	_	
1-35	255-264	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[2]	
1-36	265-274	dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[2]	
1-37	275-286	populations	_	
1-38	286-287	.	_	

#Text=These populations, however, are typically studied in isolation.
2-1	288-293	These	_	
2-2	294-305	populations	_	
2-3	305-306	,	_	
2-4	307-314	however	_	
2-5	314-315	,	_	
2-6	316-319	are	_	
2-7	320-329	typically	_	
2-8	330-337	studied	_	
2-9	338-340	in	_	
2-10	341-350	isolation	_	
2-11	350-351	.	_	

#Text=The goal of this study was to prospectively investigate the spatial topography of drug-cue reactivity in a large set of individuals dependent on either cocaine, alcohol, or nicotine.
3-1	352-355	The	_	
3-2	356-360	goal	_	
3-3	361-363	of	_	
3-4	364-368	this	_	
3-5	369-374	study	_	
3-6	375-378	was	_	
3-7	379-381	to	_	
3-8	382-395	prospectively	_	
3-9	396-407	investigate	_	
3-10	408-411	the	_	
3-11	412-419	spatial	_	
3-12	420-430	topography	_	
3-13	431-433	of	_	
3-14	434-442	drug-cue	_	
3-15	443-453	reactivity	_	
3-16	454-456	in	_	
3-17	457-458	a	_	
3-18	459-464	large	_	
3-19	465-468	set	_	
3-20	469-471	of	_	
3-21	472-483	individuals	_	
3-22	484-493	dependent	_	
3-23	494-496	on	_	
3-24	497-503	either	_	
3-25	504-511	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse	
3-26	511-512	,	_	
3-27	513-520	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]	
3-28	520-521	,	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]	
3-29	522-524	or	_	
3-30	525-533	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
3-31	533-534	.	_	

#Text=Functional MRI data was acquired from 156 substance dependent individuals (55 cocaine, 53 alcohol, and 48 nicotine) as they performed a standardized drug-cue exposure task.
4-1	535-545	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
4-2	546-549	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
4-3	550-554	data	_	
4-4	555-558	was	_	
4-5	559-567	acquired	_	
4-6	568-572	from	_	
4-7	573-576	156	_	
4-8	577-586	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[5]	
4-9	587-596	dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[5]	
4-10	597-608	individuals	_	
4-11	609-610	(	_	
4-12	610-612	55	_	
4-13	613-620	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse	
4-14	620-621	,	_	
4-15	622-624	53	_	
4-16	625-632	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
4-17	632-633	,	_	
4-18	634-637	and	_	
4-19	638-640	48	_	
4-20	641-649	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
4-21	649-650	)	_	
4-22	651-653	as	_	
4-23	654-658	they	_	
4-24	659-668	performed	_	
4-25	669-670	a	_	
4-26	671-683	standardized	_	
4-27	684-692	drug-cue	_	
4-28	693-701	exposure	_	
4-29	702-706	task	_	
4-30	706-707	.	_	

#Text=Clusters of significant activation to drug-cues relative to neutral cues (‘hot spots’) were isolated for each individual.
5-1	708-716	Clusters	_	
5-2	717-719	of	_	
5-3	720-731	significant	_	
5-4	732-742	activation	_	
5-5	743-745	to	_	
5-6	746-755	drug-cues	_	
5-7	756-764	relative	_	
5-8	765-767	to	_	
5-9	768-775	neutral	_	
5-10	776-780	cues	_	
5-11	781-782	(	_	
5-12	782-783	‘	_	
5-13	783-786	hot	_	
5-14	787-792	spots	_	
5-15	792-793	’	_	
5-16	793-794	)	_	
5-17	795-799	were	_	
5-18	800-808	isolated	_	
5-19	809-812	for	_	
5-20	813-817	each	_	
5-21	818-828	individual	_	
5-22	828-829	.	_	

#Text=K-means clustering was used to classify the spatial topography of the hotspots in the data set.
6-1	830-837	K-means	_	
6-2	838-848	clustering	_	
6-3	849-852	was	_	
6-4	853-857	used	_	
6-5	858-860	to	_	
6-6	861-869	classify	_	
6-7	870-873	the	_	
6-8	874-881	spatial	_	
6-9	882-892	topography	_	
6-10	893-895	of	_	
6-11	896-899	the	_	
6-12	900-908	hotspots	_	
6-13	909-911	in	_	
6-14	912-915	the	_	
6-15	916-920	data	_	
6-16	921-924	set	_	
6-17	924-925	.	_	

#Text=The percentage of hotspots that would be reached at several distances (2–5 cm) of transcranial magnetic stimulation (TMS) were calculated.
7-1	926-929	The	_	
7-2	930-940	percentage	_	
7-3	941-943	of	_	
7-4	944-952	hotspots	_	
7-5	953-957	that	_	
7-6	958-963	would	_	
7-7	964-966	be	_	
7-8	967-974	reached	_	
7-9	975-977	at	_	
7-10	978-985	several	_	
7-11	986-995	distances	_	
7-12	996-997	(	_	
7-13	997-998	2	_	
7-14	998-999	–	_	
7-15	999-1000	5	_	
7-16	1001-1003	cm	_	
7-17	1003-1004	)	_	
7-18	1005-1007	of	_	
7-19	1008-1020	transcranial	_	
7-20	1021-1029	magnetic	_	
7-21	1030-1041	stimulation	_	
7-22	1042-1043	(	_	
7-23	1043-1046	TMS	_	
7-24	1046-1047	)	_	
7-25	1048-1052	were	_	
7-26	1053-1063	calculated	_	
7-27	1063-1064	.	_	

#Text=One hundred and three participants had at least one cluster of significant frontal cortex activity (66%).
8-1	1065-1068	One	_	
8-2	1069-1076	hundred	_	
8-3	1077-1080	and	_	
8-4	1081-1086	three	_	
8-5	1087-1099	participants	_	
8-6	1100-1103	had	_	
8-7	1104-1106	at	_	
8-8	1107-1112	least	_	
8-9	1113-1116	one	_	
8-10	1117-1124	cluster	_	
8-11	1125-1127	of	_	
8-12	1128-1139	significant	_	
8-13	1140-1147	frontal	_	
8-14	1148-1154	cortex	_	
8-15	1155-1163	activity	_	
8-16	1164-1165	(	_	
8-17	1165-1168	66%	_	
8-18	1168-1169	)	_	
8-19	1169-1170	.	_	

#Text=K-means revealed 3 distinct clusters within the medial prefrontal cortex (MPFC), left inferior frontal gyrus/insula, right premotor cortex.
9-1	1171-1178	K-means	_	
9-2	1179-1187	revealed	_	
9-3	1188-1189	3	_	
9-4	1190-1198	distinct	_	
9-5	1199-1207	clusters	_	
9-6	1208-1214	within	_	
9-7	1215-1218	the	_	
9-8	1219-1225	medial	_	
9-9	1226-1236	prefrontal	_	
9-10	1237-1243	cortex	_	
9-11	1244-1245	(	_	
9-12	1245-1249	MPFC	_	
9-13	1249-1250	)	_	
9-14	1250-1251	,	_	
9-15	1252-1256	left	_	
9-16	1257-1265	inferior	_	
9-17	1266-1273	frontal	_	
9-18	1274-1279	gyrus	_	
9-19	1279-1280	/	_	
9-20	1280-1286	insula	_	
9-21	1286-1287	,	_	
9-22	1288-1293	right	_	
9-23	1294-1302	premotor	_	
9-24	1303-1309	cortex	_	
9-25	1309-1310	.	_	

#Text=For the group as a whole (and for alcohol users and nicotine users independently), medial prefrontal cortex (BA 10) was the location of the greatest number of hotspots.
10-1	1311-1314	For	_	
10-2	1315-1318	the	_	
10-3	1319-1324	group	_	
10-4	1325-1327	as	_	
10-5	1328-1329	a	_	
10-6	1330-1335	whole	_	
10-7	1336-1337	(	_	
10-8	1337-1340	and	_	
10-9	1341-1344	for	_	
10-10	1345-1352	alcohol	_	
10-11	1353-1358	users	_	
10-12	1359-1362	and	_	
10-13	1363-1371	nicotine	_	
10-14	1372-1377	users	_	
10-15	1378-1391	independently	_	
10-16	1391-1392	)	_	
10-17	1392-1393	,	_	
10-18	1394-1400	medial	_	
10-19	1401-1411	prefrontal	_	
10-20	1412-1418	cortex	_	
10-21	1419-1420	(	_	
10-22	1420-1422	BA	_	
10-23	1423-1425	10	_	
10-24	1425-1426	)	_	
10-25	1427-1430	was	_	
10-26	1431-1434	the	_	
10-27	1435-1443	location	_	
10-28	1444-1446	of	_	
10-29	1447-1450	the	_	
10-30	1451-1459	greatest	_	
10-31	1460-1466	number	_	
10-32	1467-1469	of	_	
10-33	1470-1478	hotspots	_	
10-34	1478-1479	.	_	

#Text=The frontal pole was cortical location closest to the largest percentage of hotspots.
11-1	1480-1483	The	_	
11-2	1484-1491	frontal	_	
11-3	1492-1496	pole	_	
11-4	1497-1500	was	_	
11-5	1501-1509	cortical	_	
11-6	1510-1518	location	_	
11-7	1519-1526	closest	_	
11-8	1527-1529	to	_	
11-9	1530-1533	the	_	
11-10	1534-1541	largest	_	
11-11	1542-1552	percentage	_	
11-12	1553-1555	of	_	
11-13	1556-1564	hotspots	_	
11-14	1564-1565	.	_	

#Text=While there is individual variability in the location of the cue-elicited ‘hot spot’ these data demonstrate that elevated BOLD signal to drug cues in the MPFC may be a transdiagnostic endophenotype of addiction which may also be a fruitful neuromodulation target.
12-1	1566-1571	While	_	
12-2	1572-1577	there	_	
12-3	1578-1580	is	_	
12-4	1581-1591	individual	_	
12-5	1592-1603	variability	_	
12-6	1604-1606	in	_	
12-7	1607-1610	the	_	
12-8	1611-1619	location	_	
12-9	1620-1622	of	_	
12-10	1623-1626	the	_	
12-11	1627-1639	cue-elicited	_	
12-12	1640-1641	‘	_	
12-13	1641-1644	hot	_	
12-14	1645-1649	spot	_	
12-15	1649-1650	’	_	
12-16	1651-1656	these	_	
12-17	1657-1661	data	_	
12-18	1662-1673	demonstrate	_	
12-19	1674-1678	that	_	
12-20	1679-1687	elevated	_	
12-21	1688-1692	BOLD	_	
12-22	1693-1699	signal	_	
12-23	1700-1702	to	_	
12-24	1703-1707	drug	_	
12-25	1708-1712	cues	_	
12-26	1713-1715	in	_	
12-27	1716-1719	the	_	
12-28	1720-1724	MPFC	_	
12-29	1725-1728	may	_	
12-30	1729-1731	be	_	
12-31	1732-1733	a	_	
12-32	1734-1749	transdiagnostic	_	
12-33	1750-1763	endophenotype	_	
12-34	1764-1766	of	_	
12-35	1767-1776	addiction	_	
12-36	1777-1782	which	_	
12-37	1783-1786	may	_	
12-38	1787-1791	also	_	
12-39	1792-1794	be	_	
12-40	1795-1796	a	_	
12-41	1797-1805	fruitful	_	
12-42	1806-1821	neuromodulation	_	
12-43	1822-1828	target	_	
12-44	1828-1829	.	_	

#Text=Introduction
#Text=Elevated drug-cue elicited brain activity is one of the most widely cited, transdiagnostically relevant traits of current substance dependent populations.
13-1	1830-1842	Introduction	_	
13-2	1843-1851	Elevated	_	
13-3	1852-1860	drug-cue	_	
13-4	1861-1869	elicited	_	
13-5	1870-1875	brain	_	
13-6	1876-1884	activity	_	
13-7	1885-1887	is	_	
13-8	1888-1891	one	_	
13-9	1892-1894	of	_	
13-10	1895-1898	the	_	
13-11	1899-1903	most	_	
13-12	1904-1910	widely	_	
13-13	1911-1916	cited	_	
13-14	1916-1917	,	_	
13-15	1918-1937	transdiagnostically	_	
13-16	1938-1946	relevant	_	
13-17	1947-1953	traits	_	
13-18	1954-1956	of	_	
13-19	1957-1964	current	_	
13-20	1965-1974	substance	_	
13-21	1975-1984	dependent	_	
13-22	1985-1996	populations	_	
13-23	1996-1997	.	_	

#Text=Many studies investigating cue-reactivity in either cocaine, nicotine, or alcohol dependent populations have independently demonstrated that drug-cues evoke elevated activity in the medial prefrontal cortex, anterior cingulate, and insula cortex.
14-1	1998-2002	Many	_	
14-2	2003-2010	studies	_	
14-3	2011-2024	investigating	_	
14-4	2025-2039	cue-reactivity	_	
14-5	2040-2042	in	_	
14-6	2043-2049	either	_	
14-7	2050-2057	cocaine	_	
14-8	2057-2058	,	_	
14-9	2059-2067	nicotine	_	
14-10	2067-2068	,	_	
14-11	2069-2071	or	_	
14-12	2072-2079	alcohol	_	
14-13	2080-2089	dependent	_	
14-14	2090-2101	populations	_	
14-15	2102-2106	have	_	
14-16	2107-2120	independently	_	
14-17	2121-2133	demonstrated	_	
14-18	2134-2138	that	_	
14-19	2139-2148	drug-cues	_	
14-20	2149-2154	evoke	_	
14-21	2155-2163	elevated	_	
14-22	2164-2172	activity	_	
14-23	2173-2175	in	_	
14-24	2176-2179	the	_	
14-25	2180-2186	medial	_	
14-26	2187-2197	prefrontal	_	
14-27	2198-2204	cortex	_	
14-28	2204-2205	,	_	
14-29	2206-2214	anterior	_	
14-30	2215-2224	cingulate	_	
14-31	2224-2225	,	_	
14-32	2226-2229	and	_	
14-33	2230-2236	insula	_	
14-34	2237-2243	cortex	_	
14-35	2243-2244	.	_	

#Text=Most of these studies focus on one substance using class, however, and therefore it is difficult to distinguish which aspects of cue-reactivity are transdiagnostic biomarkers of the addiction process versus those which are specific to alcohol, cocaine, or nicotine dependence.
15-1	2245-2249	Most	_	
15-2	2250-2252	of	_	
15-3	2253-2258	these	_	
15-4	2259-2266	studies	_	
15-5	2267-2272	focus	_	
15-6	2273-2275	on	_	
15-7	2276-2279	one	_	
15-8	2280-2289	substance	_	
15-9	2290-2295	using	_	
15-10	2296-2301	class	_	
15-11	2301-2302	,	_	
15-12	2303-2310	however	_	
15-13	2310-2311	,	_	
15-14	2312-2315	and	_	
15-15	2316-2325	therefore	_	
15-16	2326-2328	it	_	
15-17	2329-2331	is	_	
15-18	2332-2341	difficult	_	
15-19	2342-2344	to	_	
15-20	2345-2356	distinguish	_	
15-21	2357-2362	which	_	
15-22	2363-2370	aspects	_	
15-23	2371-2373	of	_	
15-24	2374-2388	cue-reactivity	_	
15-25	2389-2392	are	_	
15-26	2393-2408	transdiagnostic	_	
15-27	2409-2419	biomarkers	_	
15-28	2420-2422	of	_	
15-29	2423-2426	the	_	
15-30	2427-2436	addiction	_	
15-31	2437-2444	process	_	
15-32	2445-2451	versus	_	
15-33	2452-2457	those	_	
15-34	2458-2463	which	_	
15-35	2464-2467	are	_	
15-36	2468-2476	specific	_	
15-37	2477-2479	to	_	
15-38	2480-2487	alcohol	_	
15-39	2487-2488	,	_	
15-40	2489-2496	cocaine	_	
15-41	2496-2497	,	_	
15-42	2498-2500	or	_	
15-43	2501-2509	nicotine	_	
15-44	2510-2520	dependence	_	
15-45	2520-2521	.	_	

#Text=Several retrospective meta-analyses have demonstrated that the medial prefrontal cortex and cingulate cortex are reliably activated to drug cues.
16-1	2522-2529	Several	_	
16-2	2530-2543	retrospective	_	
16-3	2544-2557	meta-analyses	_	
16-4	2558-2562	have	_	
16-5	2563-2575	demonstrated	_	
16-6	2576-2580	that	_	
16-7	2581-2584	the	_	
16-8	2585-2591	medial	_	
16-9	2592-2602	prefrontal	_	
16-10	2603-2609	cortex	_	
16-11	2610-2613	and	_	
16-12	2614-2623	cingulate	_	
16-13	2624-2630	cortex	_	
16-14	2631-2634	are	_	
16-15	2635-2643	reliably	_	
16-16	2644-2653	activated	_	
16-17	2654-2656	to	_	
16-18	2657-2661	drug	_	
16-19	2662-2666	cues	_	
16-20	2666-2667	.	_	

#Text=Other meta-analyses have demonstrated that activity in these brain regions may predict relapse across multiple substances. ( Addiction Biology).
17-1	2668-2673	Other	_	
17-2	2674-2687	meta-analyses	_	
17-3	2688-2692	have	_	
17-4	2693-2705	demonstrated	_	
17-5	2706-2710	that	_	
17-6	2711-2719	activity	_	
17-7	2720-2722	in	_	
17-8	2723-2728	these	_	
17-9	2729-2734	brain	_	
17-10	2735-2742	regions	_	
17-11	2743-2746	may	_	
17-12	2747-2754	predict	_	
17-13	2755-2762	relapse	_	
17-14	2763-2769	across	_	
17-15	2770-2778	multiple	_	
17-16	2779-2789	substances	_	
17-17	2789-2790	.	_	
17-18	2791-2792	(	_	
17-19	2793-2802	Addiction	_	
17-20	2803-2810	Biology	_	
17-21	2810-2811	)	_	
17-22	2811-2812	.	_	

#Text=One challenge for retrospective reviews and meta-analyses however, is that different research institutions often use different drug-cue reactivity paradigms, have different inclusion/exclusion criteria, and do not analyze all of their data using the same analysis pipeline.
18-1	2813-2816	One	_	
18-2	2817-2826	challenge	_	
18-3	2827-2830	for	_	
18-4	2831-2844	retrospective	_	
18-5	2845-2852	reviews	_	
18-6	2853-2856	and	_	
18-7	2857-2870	meta-analyses	_	
18-8	2871-2878	however	_	
18-9	2878-2879	,	_	
18-10	2880-2882	is	_	
18-11	2883-2887	that	_	
18-12	2888-2897	different	_	
18-13	2898-2906	research	_	
18-14	2907-2919	institutions	_	
18-15	2920-2925	often	_	
18-16	2926-2929	use	_	
18-17	2930-2939	different	_	
18-18	2940-2948	drug-cue	_	
18-19	2949-2959	reactivity	_	
18-20	2960-2969	paradigms	_	
18-21	2969-2970	,	_	
18-22	2971-2975	have	_	
18-23	2976-2985	different	_	
18-24	2986-2995	inclusion	_	
18-25	2995-2996	/	_	
18-26	2996-3005	exclusion	_	
18-27	3006-3014	criteria	_	
18-28	3014-3015	,	_	
18-29	3016-3019	and	_	
18-30	3020-3022	do	_	
18-31	3023-3026	not	_	
18-32	3027-3034	analyze	_	
18-33	3035-3038	all	_	
18-34	3039-3041	of	_	
18-35	3042-3047	their	_	
18-36	3048-3052	data	_	
18-37	3053-3058	using	_	
18-38	3059-3062	the	_	
18-39	3063-3067	same	_	
18-40	3068-3076	analysis	_	
18-41	3077-3085	pipeline	_	
18-42	3085-3086	.	_	

#Text=Furthermore, even when these variables are controlled, there is a lot of individual variability in the brain response to drug-cues and that there may be drug-class specific patterns of cue-reactivity.
19-1	3087-3098	Furthermore	_	
19-2	3098-3099	,	_	
19-3	3100-3104	even	_	
19-4	3105-3109	when	_	
19-5	3110-3115	these	_	
19-6	3116-3125	variables	_	
19-7	3126-3129	are	_	
19-8	3130-3140	controlled	_	
19-9	3140-3141	,	_	
19-10	3142-3147	there	_	
19-11	3148-3150	is	_	
19-12	3151-3152	a	_	
19-13	3153-3156	lot	_	
19-14	3157-3159	of	_	
19-15	3160-3170	individual	_	
19-16	3171-3182	variability	_	
19-17	3183-3185	in	_	
19-18	3186-3189	the	_	
19-19	3190-3195	brain	_	
19-20	3196-3204	response	_	
19-21	3205-3207	to	_	
19-22	3208-3217	drug-cues	_	
19-23	3218-3221	and	_	
19-24	3222-3226	that	_	
19-25	3227-3232	there	_	
19-26	3233-3236	may	_	
19-27	3237-3239	be	_	
19-28	3240-3250	drug-class	_	
19-29	3251-3259	specific	_	
19-30	3260-3268	patterns	_	
19-31	3269-3271	of	_	
19-32	3272-3286	cue-reactivity	_	
19-33	3286-3287	.	_	

#Text=While the localization of cue-reactivity in the brain is important for many reasons, it is now particularly important as multiple fields are seeking to develop brain stimulation as a treatment tool.
20-1	3288-3293	While	_	
20-2	3294-3297	the	_	
20-3	3298-3310	localization	_	
20-4	3311-3313	of	_	
20-5	3314-3328	cue-reactivity	_	
20-6	3329-3331	in	_	
20-7	3332-3335	the	_	
20-8	3336-3341	brain	_	
20-9	3342-3344	is	_	
20-10	3345-3354	important	_	
20-11	3355-3358	for	_	
20-12	3359-3363	many	_	
20-13	3364-3371	reasons	_	
20-14	3371-3372	,	_	
20-15	3373-3375	it	_	
20-16	3376-3378	is	_	
20-17	3379-3382	now	_	
20-18	3383-3395	particularly	_	
20-19	3396-3405	important	_	
20-20	3406-3408	as	_	
20-21	3409-3417	multiple	_	
20-22	3418-3424	fields	_	
20-23	3425-3428	are	_	
20-24	3429-3436	seeking	_	
20-25	3437-3439	to	_	
20-26	3440-3447	develop	_	
20-27	3448-3453	brain	_	
20-28	3454-3465	stimulation	_	
20-29	3466-3468	as	_	
20-30	3469-3470	a	_	
20-31	3471-3480	treatment	_	
20-32	3481-3485	tool	_	
20-33	3485-3486	.	_	

#Text=Recent interest has developed in whether one can attenuate this cue-elicited craving through brain stimulation techniques such as transcranial magnetic stimulation (TMS).
21-1	3487-3493	Recent	_	
21-2	3494-3502	interest	_	
21-3	3503-3506	has	_	
21-4	3507-3516	developed	_	
21-5	3517-3519	in	_	
21-6	3520-3527	whether	_	
21-7	3528-3531	one	_	
21-8	3532-3535	can	_	
21-9	3536-3545	attenuate	_	
21-10	3546-3550	this	_	
21-11	3551-3563	cue-elicited	_	
21-12	3564-3571	craving	_	
21-13	3572-3579	through	_	
21-14	3580-3585	brain	_	
21-15	3586-3597	stimulation	_	
21-16	3598-3608	techniques	_	
21-17	3609-3613	such	_	
21-18	3614-3616	as	_	
21-19	3617-3629	transcranial	_	
21-20	3630-3638	magnetic	_	
21-21	3639-3650	stimulation	_	
21-22	3651-3652	(	_	
21-23	3652-3655	TMS	_	
21-24	3655-3656	)	_	
21-25	3656-3657	.	_	

#Text=The location of optimal repetitive TMS (rTMS) stimulation to attenuate cue-elicited craving, however, remains elusive.
22-1	3658-3661	The	_	
22-2	3662-3670	location	_	
22-3	3671-3673	of	_	
22-4	3674-3681	optimal	_	
22-5	3682-3692	repetitive	_	
22-6	3693-3696	TMS	_	
22-7	3697-3698	(	_	
22-8	3698-3702	rTMS	_	
22-9	3702-3703	)	_	
22-10	3704-3715	stimulation	_	
22-11	3716-3718	to	_	
22-12	3719-3728	attenuate	_	
22-13	3729-3741	cue-elicited	_	
22-14	3742-3749	craving	_	
22-15	3749-3750	,	_	
22-16	3751-3758	however	_	
22-17	3758-3759	,	_	
22-18	3760-3767	remains	_	
22-19	3768-3775	elusive	_	
22-20	3775-3776	.	_	

#Text=The primary aim of this investigation was to determine the spatial variability in peak cortical activity during cue-elicited craving across a large sample of individuals that performed a standardized drug cue-reactivity task tailored to their drug of dependence (cocaine, alcohol, nicotine).
23-1	3777-3780	The	_	
23-2	3781-3788	primary	_	
23-3	3789-3792	aim	_	
23-4	3793-3795	of	_	
23-5	3796-3800	this	_	
23-6	3801-3814	investigation	_	
23-7	3815-3818	was	_	
23-8	3819-3821	to	_	
23-9	3822-3831	determine	_	
23-10	3832-3835	the	_	
23-11	3836-3843	spatial	_	
23-12	3844-3855	variability	_	
23-13	3856-3858	in	_	
23-14	3859-3863	peak	_	
23-15	3864-3872	cortical	_	
23-16	3873-3881	activity	_	
23-17	3882-3888	during	_	
23-18	3889-3901	cue-elicited	_	
23-19	3902-3909	craving	_	
23-20	3910-3916	across	_	
23-21	3917-3918	a	_	
23-22	3919-3924	large	_	
23-23	3925-3931	sample	_	
23-24	3932-3934	of	_	
23-25	3935-3946	individuals	_	
23-26	3947-3951	that	_	
23-27	3952-3961	performed	_	
23-28	3962-3963	a	_	
23-29	3964-3976	standardized	_	
23-30	3977-3981	drug	_	
23-31	3982-3996	cue-reactivity	_	
23-32	3997-4001	task	_	
23-33	4002-4010	tailored	_	
23-34	4011-4013	to	_	
23-35	4014-4019	their	_	
23-36	4020-4024	drug	_	
23-37	4025-4027	of	_	
23-38	4028-4038	dependence	_	
23-39	4039-4040	(	_	
23-40	4040-4047	cocaine	_	
23-41	4047-4048	,	_	
23-42	4049-4056	alcohol	_	
23-43	4056-4057	,	_	
23-44	4058-4066	nicotine	_	
23-45	4066-4067	)	_	
23-46	4067-4068	.	_	

#Text=This was done in a cohort of non-treatment seeking individuals dependent on cocaine only, alcohol only, or nicotine only.
24-1	4069-4073	This	_	
24-2	4074-4077	was	_	
24-3	4078-4082	done	_	
24-4	4083-4085	in	_	
24-5	4086-4087	a	_	
24-6	4088-4094	cohort	_	
24-7	4095-4097	of	_	
24-8	4098-4111	non-treatment	_	
24-9	4112-4119	seeking	_	
24-10	4120-4131	individuals	_	
24-11	4132-4141	dependent	_	
24-12	4142-4144	on	_	
24-13	4145-4152	cocaine	_	
24-14	4153-4157	only	_	
24-15	4157-4158	,	_	
24-16	4159-4166	alcohol	_	
24-17	4167-4171	only	_	
24-18	4171-4172	,	_	
24-19	4173-4175	or	_	
24-20	4176-4184	nicotine	_	
24-21	4185-4189	only	_	
24-22	4189-4190	.	_	

#Text=A secondary aim was to calculate whether observed population variability could be captured by a single site of TMS simulation or if it requires within-individual functional mapping.
25-1	4191-4192	A	_	
25-2	4193-4202	secondary	_	
25-3	4203-4206	aim	_	
25-4	4207-4210	was	_	
25-5	4211-4213	to	_	
25-6	4214-4223	calculate	_	
25-7	4224-4231	whether	_	
25-8	4232-4240	observed	_	
25-9	4241-4251	population	_	
25-10	4252-4263	variability	_	
25-11	4264-4269	could	_	
25-12	4270-4272	be	_	
25-13	4273-4281	captured	_	
25-14	4282-4284	by	_	
25-15	4285-4286	a	_	
25-16	4287-4293	single	_	
25-17	4294-4298	site	_	
25-18	4299-4301	of	_	
25-19	4302-4305	TMS	_	
25-20	4306-4316	simulation	_	
25-21	4317-4319	or	_	
25-22	4320-4322	if	_	
25-23	4323-4325	it	_	
25-24	4326-4334	requires	_	
25-25	4335-4352	within-individual	_	
25-26	4353-4363	functional	_	
25-27	4364-4371	mapping	_	
25-28	4371-4372	.	_	

#Text=Method
#Text=Participants
#Text=Demographics of the substance dependent groups
#Text=\tn = 156Total sample\tn = 55 Cocaine\tn = 48 Nicotine\tn = 53 Alcohol\t \tDemographics\t \t Sex\t101 M, 55 F\t38 M, 17 F\t24 M, 24 F\t39 M, 14 F\t \t Age\t36.6 (±11.6)\t42.7 (±9.6)\t37.1 (±11.9)\t29.9 (±9.7)\t \t Ethnicity\t65 AA, 91 C\t48 AA, 7 C\t9 AA, 39 C\t8 AA, 45 C\t \t Education\t13.6 (±2.3)\t12.3 (±1.8)\t13.4 (±1.8)\t15.1 (±2.1)\t \tSubstance use profile\t \t Cocaine used in last 30 days (%)\t\t55 (100)\t0\t0\t \t Nicotine Cigarettes used in last 30 days (%)\t\t47 (85)\t48 (100)\t19 (36)\t \t Nicotine severity (Fagerström)\t\t3.5 (±2.4)\t4.4 (±2.2)\t2.1 (±2.7)\t \tAlcohol consumed in last 30 days (%)\t\t55 (100)\t48 (100)\t53 (100)\t \t Alcohol use severity (AUDIT)\t\t11 (±7.7)\t2.4 (±2.4)\t17.5 (±6.2)\t \t Marijuana used in last 30 days (%)\t\t23 (42)\t0\t9 (17)\t \tMood assessment\t \t Depressive symptoms (BDI)\t9.5 (±11.0)\t12.0 (±10.45)\t2.54 (±3.2)\t8.39 (±11.7)\t \t State anxiety (STAI-S)\t35.0 (±13)\t36.7 (±12.4)\t26.5 (±10.3)\t35.1 (±14.9)\t \tTrait anxiety (STAI-T)\t37.8 (±14.7)\t41.3 (±12.0)\t28.5 (±7.5)\t37.5 (±17.2)\t \t
#Text=Values either indicate mean (±standard deviation) or count (percent%).
26-1	4373-4379	Method	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
26-2	4380-4392	Participants	_	
26-3	4393-4405	Demographics	_	
26-4	4406-4408	of	_	
26-5	4409-4412	the	_	
26-6	4413-4422	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[6]	
26-7	4423-4432	dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[6]	
26-8	4433-4439	groups	_	
26-9	4441-4442	n	_	
26-10	4443-4444	=	_	
26-11	4445-4453	156Total	_	
26-12	4454-4460	sample	_	
26-13	4461-4462	n	_	
26-14	4463-4464	=	_	
26-15	4465-4467	55	_	
26-16	4468-4475	Cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse	
26-17	4476-4477	n	_	
26-18	4478-4479	=	_	
26-19	4480-4482	48	_	
26-20	4483-4491	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
26-21	4492-4493	n	_	
26-22	4494-4495	=	_	
26-23	4496-4498	53	_	
26-24	4499-4506	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
26-25	4509-4521	Demographics	_	
26-26	4525-4528	Sex	_	
26-27	4529-4532	101	_	
26-28	4533-4534	M	_	
26-29	4534-4535	,	_	
26-30	4536-4538	55	_	
26-31	4539-4540	F	_	
26-32	4541-4543	38	_	
26-33	4544-4545	M	_	
26-34	4545-4546	,	_	
26-35	4547-4549	17	_	
26-36	4550-4551	F	_	
26-37	4552-4554	24	_	
26-38	4555-4556	M	_	
26-39	4556-4557	,	_	
26-40	4558-4560	24	_	
26-41	4561-4562	F	_	
26-42	4563-4565	39	_	
26-43	4566-4567	M	_	
26-44	4567-4568	,	_	
26-45	4569-4571	14	_	
26-46	4572-4573	F	_	
26-47	4577-4580	Age	_	
26-48	4581-4585	36.6	_	
26-49	4586-4587	(	_	
26-50	4587-4588	±	_	
26-51	4588-4592	11.6	_	
26-52	4592-4593	)	_	
26-53	4594-4598	42.7	_	
26-54	4599-4600	(	_	
26-55	4600-4601	±	_	
26-56	4601-4604	9.6	_	
26-57	4604-4605	)	_	
26-58	4606-4610	37.1	_	
26-59	4611-4612	(	_	
26-60	4612-4613	±	_	
26-61	4613-4617	11.9	_	
26-62	4617-4618	)	_	
26-63	4619-4623	29.9	_	
26-64	4624-4625	(	_	
26-65	4625-4626	±	_	
26-66	4626-4629	9.7	_	
26-67	4629-4630	)	_	
26-68	4634-4643	Ethnicity	_	
26-69	4644-4646	65	_	
26-70	4647-4649	AA	_	
26-71	4649-4650	,	_	
26-72	4651-4653	91	_	
26-73	4654-4655	C	_	
26-74	4656-4658	48	_	
26-75	4659-4661	AA	_	
26-76	4661-4662	,	_	
26-77	4663-4664	7	_	
26-78	4665-4666	C	_	
26-79	4667-4668	9	_	
26-80	4669-4671	AA	_	
26-81	4671-4672	,	_	
26-82	4673-4675	39	_	
26-83	4676-4677	C	_	
26-84	4678-4679	8	_	
26-85	4680-4682	AA	_	
26-86	4682-4683	,	_	
26-87	4684-4686	45	_	
26-88	4687-4688	C	_	
26-89	4692-4701	Education	_	
26-90	4702-4706	13.6	_	
26-91	4707-4708	(	_	
26-92	4708-4709	±	_	
26-93	4709-4712	2.3	_	
26-94	4712-4713	)	_	
26-95	4714-4718	12.3	_	
26-96	4719-4720	(	_	
26-97	4720-4721	±	_	
26-98	4721-4724	1.8	_	
26-99	4724-4725	)	_	
26-100	4726-4730	13.4	_	
26-101	4731-4732	(	_	
26-102	4732-4733	±	_	
26-103	4733-4736	1.8	_	
26-104	4736-4737	)	_	
26-105	4738-4742	15.1	_	
26-106	4743-4744	(	_	
26-107	4744-4745	±	_	
26-108	4745-4748	2.1	_	
26-109	4748-4749	)	_	
26-110	4752-4761	Substance	_	
26-111	4762-4765	use	_	
26-112	4766-4773	profile	_	
26-113	4777-4784	Cocaine	_	
26-114	4785-4789	used	_	
26-115	4790-4792	in	_	
26-116	4793-4797	last	_	
26-117	4798-4800	30	_	
26-118	4801-4805	days	_	
26-119	4806-4807	(	_	
26-120	4807-4808	%	_	
26-121	4808-4809	)	_	
26-122	4811-4813	55	_	
26-123	4814-4815	(	_	
26-124	4815-4818	100	_	
26-125	4818-4819	)	_	
26-126	4820-4821	0	_	
26-127	4822-4823	0	_	
26-128	4827-4835	Nicotine	_	
26-129	4836-4846	Cigarettes	_	
26-130	4847-4851	used	_	
26-131	4852-4854	in	_	
26-132	4855-4859	last	_	
26-133	4860-4862	30	_	
26-134	4863-4867	days	_	
26-135	4868-4869	(	_	
26-136	4869-4870	%	_	
26-137	4870-4871	)	_	
26-138	4873-4875	47	_	
26-139	4876-4877	(	_	
26-140	4877-4879	85	_	
26-141	4879-4880	)	_	
26-142	4881-4883	48	_	
26-143	4884-4885	(	_	
26-144	4885-4888	100	_	
26-145	4888-4889	)	_	
26-146	4890-4892	19	_	
26-147	4893-4894	(	_	
26-148	4894-4896	36	_	
26-149	4896-4897	)	_	
26-150	4901-4909	Nicotine	_	
26-151	4910-4918	severity	_	
26-152	4919-4920	(	_	
26-153	4920-4930	Fagerström	_	
26-154	4930-4931	)	_	
26-155	4933-4936	3.5	_	
26-156	4937-4938	(	_	
26-157	4938-4939	±	_	
26-158	4939-4942	2.4	_	
26-159	4942-4943	)	_	
26-160	4944-4947	4.4	_	
26-161	4948-4949	(	_	
26-162	4949-4950	±	_	
26-163	4950-4953	2.2	_	
26-164	4953-4954	)	_	
26-165	4955-4958	2.1	_	
26-166	4959-4960	(	_	
26-167	4960-4961	±	_	
26-168	4961-4964	2.7	_	
26-169	4964-4965	)	_	
26-170	4968-4975	Alcohol	_	
26-171	4976-4984	consumed	_	
26-172	4985-4987	in	_	
26-173	4988-4992	last	_	
26-174	4993-4995	30	_	
26-175	4996-5000	days	_	
26-176	5001-5002	(	_	
26-177	5002-5003	%	_	
26-178	5003-5004	)	_	
26-179	5006-5008	55	_	
26-180	5009-5010	(	_	
26-181	5010-5013	100	_	
26-182	5013-5014	)	_	
26-183	5015-5017	48	_	
26-184	5018-5019	(	_	
26-185	5019-5022	100	_	
26-186	5022-5023	)	_	
26-187	5024-5026	53	_	
26-188	5027-5028	(	_	
26-189	5028-5031	100	_	
26-190	5031-5032	)	_	
26-191	5036-5043	Alcohol	_	
26-192	5044-5047	use	_	
26-193	5048-5056	severity	_	
26-194	5057-5058	(	_	
26-195	5058-5063	AUDIT	_	
26-196	5063-5064	)	_	
26-197	5066-5068	11	_	
26-198	5069-5070	(	_	
26-199	5070-5071	±	_	
26-200	5071-5074	7.7	_	
26-201	5074-5075	)	_	
26-202	5076-5079	2.4	_	
26-203	5080-5081	(	_	
26-204	5081-5082	±	_	
26-205	5082-5085	2.4	_	
26-206	5085-5086	)	_	
26-207	5087-5091	17.5	_	
26-208	5092-5093	(	_	
26-209	5093-5094	±	_	
26-210	5094-5097	6.2	_	
26-211	5097-5098	)	_	
26-212	5102-5111	Marijuana	_	
26-213	5112-5116	used	_	
26-214	5117-5119	in	_	
26-215	5120-5124	last	_	
26-216	5125-5127	30	_	
26-217	5128-5132	days	_	
26-218	5133-5134	(	_	
26-219	5134-5135	%	_	
26-220	5135-5136	)	_	
26-221	5138-5140	23	_	
26-222	5141-5142	(	_	
26-223	5142-5144	42	_	
26-224	5144-5145	)	_	
26-225	5146-5147	0	_	
26-226	5148-5149	9	_	
26-227	5150-5151	(	_	
26-228	5151-5153	17	_	
26-229	5153-5154	)	_	
26-230	5157-5161	Mood	_	
26-231	5162-5172	assessment	_	
26-232	5176-5186	Depressive	_	
26-233	5187-5195	symptoms	_	
26-234	5196-5197	(	_	
26-235	5197-5200	BDI	_	
26-236	5200-5201	)	_	
26-237	5202-5205	9.5	_	
26-238	5206-5207	(	_	
26-239	5207-5208	±	_	
26-240	5208-5212	11.0	_	
26-241	5212-5213	)	_	
26-242	5214-5218	12.0	_	
26-243	5219-5220	(	_	
26-244	5220-5221	±	_	
26-245	5221-5226	10.45	_	
26-246	5226-5227	)	_	
26-247	5228-5232	2.54	_	
26-248	5233-5234	(	_	
26-249	5234-5235	±	_	
26-250	5235-5238	3.2	_	
26-251	5238-5239	)	_	
26-252	5240-5244	8.39	_	
26-253	5245-5246	(	_	
26-254	5246-5247	±	_	
26-255	5247-5251	11.7	_	
26-256	5251-5252	)	_	
26-257	5256-5261	State	_	
26-258	5262-5269	anxiety	_	
26-259	5270-5271	(	_	
26-260	5271-5277	STAI-S	_	
26-261	5277-5278	)	_	
26-262	5279-5283	35.0	_	
26-263	5284-5285	(	_	
26-264	5285-5286	±	_	
26-265	5286-5288	13	_	
26-266	5288-5289	)	_	
26-267	5290-5294	36.7	_	
26-268	5295-5296	(	_	
26-269	5296-5297	±	_	
26-270	5297-5301	12.4	_	
26-271	5301-5302	)	_	
26-272	5303-5307	26.5	_	
26-273	5308-5309	(	_	
26-274	5309-5310	±	_	
26-275	5310-5314	10.3	_	
26-276	5314-5315	)	_	
26-277	5316-5320	35.1	_	
26-278	5321-5322	(	_	
26-279	5322-5323	±	_	
26-280	5323-5327	14.9	_	
26-281	5327-5328	)	_	
26-282	5331-5336	Trait	_	
26-283	5337-5344	anxiety	_	
26-284	5345-5346	(	_	
26-285	5346-5352	STAI-T	_	
26-286	5352-5353	)	_	
26-287	5354-5358	37.8	_	
26-288	5359-5360	(	_	
26-289	5360-5361	±	_	
26-290	5361-5365	14.7	_	
26-291	5365-5366	)	_	
26-292	5367-5371	41.3	_	
26-293	5372-5373	(	_	
26-294	5373-5374	±	_	
26-295	5374-5378	12.0	_	
26-296	5378-5379	)	_	
26-297	5380-5384	28.5	_	
26-298	5385-5386	(	_	
26-299	5386-5387	±	_	
26-300	5387-5390	7.5	_	
26-301	5390-5391	)	_	
26-302	5392-5396	37.5	_	
26-303	5397-5398	(	_	
26-304	5398-5399	±	_	
26-305	5399-5403	17.2	_	
26-306	5403-5404	)	_	
26-307	5408-5414	Values	_	
26-308	5415-5421	either	_	
26-309	5422-5430	indicate	_	
26-310	5431-5435	mean	_	
26-311	5436-5437	(	_	
26-312	5437-5438	±	_	
26-313	5438-5446	standard	_	
26-314	5447-5456	deviation	_	
26-315	5456-5457	)	_	
26-316	5458-5460	or	_	
26-317	5461-5466	count	_	
26-318	5467-5468	(	_	
26-319	5468-5475	percent	_	
26-320	5475-5476	%	_	
26-321	5476-5477	)	_	
26-322	5477-5478	.	_	

#Text=M male, F female, AA African-American, C Caucasian, MJ marijuana, AUDIT alcohol use disorders identification test, BDI Beck's depression inventory, STAI Spielberger state-trait anxiety inventory.
27-1	5479-5480	M	_	
27-2	5481-5485	male	_	
27-3	5485-5486	,	_	
27-4	5487-5488	F	_	
27-5	5489-5495	female	_	
27-6	5495-5496	,	_	
27-7	5497-5499	AA	_	
27-8	5500-5516	African-American	_	
27-9	5516-5517	,	_	
27-10	5518-5519	C	_	
27-11	5520-5529	Caucasian	_	
27-12	5529-5530	,	_	
27-13	5531-5533	MJ	_	
27-14	5534-5543	marijuana	_	
27-15	5543-5544	,	_	
27-16	5545-5550	AUDIT	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[7]	
27-17	5551-5558	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[7]	
27-18	5559-5562	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[7]	
27-19	5563-5572	disorders	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[7]	
27-20	5573-5587	identification	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[7]	
27-21	5588-5592	test	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[7]	
27-22	5592-5593	,	_	
27-23	5594-5597	BDI	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[8]	
27-24	5598-5604	Beck's	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[8]	
27-25	5605-5615	depression	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[8]	
27-26	5616-5625	inventory	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[8]	
27-27	5625-5626	,	_	
27-28	5627-5631	STAI	_	
27-29	5632-5643	Spielberger	_	
27-30	5644-5655	state-trait	_	
27-31	5656-5663	anxiety	_	
27-32	5664-5673	inventory	_	
27-33	5673-5674	.	_	

#Text=For this investigation data was aggregated from four separate investigations of drug cue-reactivity performed at the Medical University of South Carolina (MUSC) from 2012–2017.
28-1	5675-5678	For	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-2	5679-5683	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-3	5684-5697	investigation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-4	5698-5702	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-5	5703-5706	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-6	5707-5717	aggregated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-7	5718-5722	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-8	5723-5727	four	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-9	5728-5736	separate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-10	5737-5751	investigations	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-11	5752-5754	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-12	5755-5759	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-13	5760-5774	cue-reactivity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-14	5775-5784	performed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-15	5785-5787	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-16	5788-5791	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-17	5792-5799	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-18	5800-5810	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-19	5811-5813	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-20	5814-5819	South	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-21	5820-5828	Carolina	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-22	5829-5830	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-23	5830-5834	MUSC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-24	5834-5835	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-25	5836-5840	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-26	5841-5845	2012	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-27	5845-5846	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-28	5846-5850	2017	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-29	5850-5851	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=In each of these studies non-treatment drug users (chronic cocaine users (n = 55), heavy alcohol users (n = 53), and current cigarette smokers (n = 48)) were recruited from the Charleston, SC metropolitan area using word-of-mouth advertising and digital and print media.
29-1	5852-5854	In	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-2	5855-5859	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-3	5860-5862	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-4	5863-5868	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-5	5869-5876	studies	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-6	5877-5890	non-treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-7	5891-5895	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-8	5896-5901	users	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-9	5902-5903	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-10	5903-5910	chronic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[11]	
29-11	5911-5918	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[11]	
29-12	5919-5924	users	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[11]	
29-13	5925-5926	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-14	5926-5927	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-15	5928-5929	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-16	5930-5932	55	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-17	5932-5933	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-18	5933-5934	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-19	5935-5940	heavy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[12]	
29-20	5941-5948	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[12]	
29-21	5949-5954	users	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[12]	
29-22	5955-5956	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-23	5956-5957	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-24	5958-5959	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-25	5960-5962	53	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-26	5962-5963	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-27	5963-5964	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-28	5965-5968	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-29	5969-5976	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[13]	
29-30	5977-5986	cigarette	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[13]	
29-31	5987-5994	smokers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[13]	
29-32	5995-5996	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-33	5996-5997	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-34	5998-5999	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-35	6000-6002	48	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-36	6002-6003	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-37	6003-6004	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-38	6005-6009	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-39	6010-6019	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-40	6020-6024	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-41	6025-6028	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-42	6029-6039	Charleston	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-43	6039-6040	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-44	6041-6043	SC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-45	6044-6056	metropolitan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-46	6057-6061	area	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-47	6062-6067	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-48	6068-6081	word-of-mouth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-49	6082-6093	advertising	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-50	6094-6097	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-51	6098-6105	digital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-52	6106-6109	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-53	6110-6115	print	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-54	6116-6121	media	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-55	6121-6122	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=The recruitment, consent, and initial functional MRI scanning session for all of these studies was consistent.
30-1	6123-6126	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
30-2	6127-6138	recruitment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
30-3	6138-6139	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
30-4	6140-6147	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
30-5	6147-6148	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
30-6	6149-6152	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
30-7	6153-6160	initial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
30-8	6161-6171	functional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[15]	
30-9	6172-6175	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[15]	
30-10	6176-6184	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
30-11	6185-6192	session	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
30-12	6193-6196	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
30-13	6197-6200	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
30-14	6201-6203	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
30-15	6204-6209	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
30-16	6210-6217	studies	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
30-17	6218-6221	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
30-18	6222-6232	consistent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
30-19	6232-6233	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	

#Text=To be eligible participants needed to be 21–60 years old and meet criteria for nicotine, alcohol, or cocaine dependence.
31-1	6234-6236	To	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-2	6237-6239	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-3	6240-6248	eligible	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-4	6249-6261	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-5	6262-6268	needed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-6	6269-6271	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-7	6272-6274	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-8	6275-6277	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-9	6277-6278	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-10	6278-6280	60	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-11	6281-6286	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-12	6287-6290	old	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-13	6291-6294	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-14	6295-6299	meet	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-15	6300-6308	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-16	6309-6312	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-17	6313-6321	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[16]	
31-18	6321-6322	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-19	6323-6330	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[17]	
31-20	6330-6331	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-21	6332-6334	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-22	6335-6342	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[18]	
31-23	6343-6353	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[18]	
31-24	6353-6354	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	

#Text=Exclusionary criteria were related to medical history and MRI safety including known history of neurologic disease, currently meeting DSM-IV criteria for psychiatric disease (other than substance dependence), and metal implants above the waist or history of a gunshot or shrapnel in the skin.
32-1	6355-6367	Exclusionary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-2	6368-6376	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-3	6377-6381	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-4	6382-6389	related	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-5	6390-6392	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-6	6393-6400	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-7	6401-6408	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-8	6409-6412	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-9	6413-6416	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-10	6417-6423	safety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-11	6424-6433	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-12	6434-6439	known	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-13	6440-6447	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-14	6448-6450	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-15	6451-6461	neurologic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-16	6462-6469	disease	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-17	6469-6470	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-18	6471-6480	currently	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-19	6481-6488	meeting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-20	6489-6495	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-21	6496-6504	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-22	6505-6508	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-23	6509-6520	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-24	6521-6528	disease	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-25	6529-6530	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-26	6530-6535	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-27	6536-6540	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-28	6541-6550	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-29	6551-6561	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-30	6561-6562	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-31	6562-6563	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-32	6564-6567	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-33	6568-6573	metal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-34	6574-6582	implants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-35	6583-6588	above	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-36	6589-6592	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-37	6593-6598	waist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-38	6599-6601	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-39	6602-6609	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-40	6610-6612	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-41	6613-6614	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-42	6615-6622	gunshot	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-43	6623-6625	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-44	6626-6634	shrapnel	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-45	6635-6637	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-46	6638-6641	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-47	6642-6646	skin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
32-48	6646-6647	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=Specifically, after the initial phone contact all individuals were invited to a screening visit wherein they provided signed informed consent approved by the MUSC Institutional Review Board and completed a series of screening assessments which evaluated their medical health, psychiatric health, and drug use history.
33-1	6648-6660	Specifically	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-2	6660-6661	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-3	6662-6667	after	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-4	6668-6671	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-5	6672-6679	initial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-6	6680-6685	phone	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-7	6686-6693	contact	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-8	6694-6697	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-9	6698-6709	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-10	6710-6714	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-11	6715-6722	invited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-12	6723-6725	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-13	6726-6727	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-14	6728-6737	screening	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-15	6738-6743	visit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-16	6744-6751	wherein	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-17	6752-6756	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-18	6757-6765	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-19	6766-6772	signed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-20	6773-6781	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-21	6782-6789	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-22	6790-6798	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-23	6799-6801	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-24	6802-6805	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-25	6806-6810	MUSC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-26	6811-6824	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-27	6825-6831	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-28	6832-6837	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-29	6838-6841	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-30	6842-6851	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-31	6852-6853	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-32	6854-6860	series	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-33	6861-6863	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-34	6864-6873	screening	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-35	6874-6885	assessments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-36	6886-6891	which	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-37	6892-6901	evaluated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-38	6902-6907	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-39	6908-6915	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-40	6916-6922	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-41	6922-6923	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-42	6924-6935	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-43	6936-6942	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-44	6942-6943	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-45	6944-6947	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-46	6948-6952	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-47	6953-6956	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-48	6957-6964	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-49	6964-6965	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=Basic demographic and drug use history of these three groups are presented in Table 1.
34-1	6966-6971	Basic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
34-2	6972-6983	demographic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
34-3	6984-6987	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
34-4	6988-6992	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
34-5	6993-6996	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
34-6	6997-7004	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
34-7	7005-7007	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
34-8	7008-7013	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
34-9	7014-7019	three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
34-10	7020-7026	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
34-11	7027-7030	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
34-12	7031-7040	presented	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
34-13	7041-7043	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
34-14	7044-7049	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
34-15	7050-7051	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
34-16	7051-7052	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	

#Text=Following the screening visit, all participants were invited to a second visit wherein they would receive an MRI scan assessing their neural response to drug cues tailored to their stated drug of choice (cocaine, alcohol, or cigarette).
35-1	7053-7062	Following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-2	7063-7066	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-3	7067-7076	screening	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-4	7077-7082	visit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-5	7082-7083	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-6	7084-7087	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-7	7088-7100	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-8	7101-7105	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-9	7106-7113	invited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-10	7114-7116	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-11	7117-7118	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-12	7119-7125	second	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-13	7126-7131	visit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-14	7132-7139	wherein	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-15	7140-7144	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-16	7145-7150	would	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-17	7151-7158	receive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-18	7159-7161	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-19	7162-7165	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[21]	
35-20	7166-7170	scan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[21]	
35-21	7171-7180	assessing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-22	7181-7186	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-23	7187-7193	neural	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-24	7194-7202	response	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-25	7203-7205	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-26	7206-7210	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-27	7211-7215	cues	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-28	7216-7224	tailored	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-29	7225-7227	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-30	7228-7233	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-31	7234-7240	stated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-32	7241-7245	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-33	7246-7248	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-34	7249-7255	choice	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-35	7256-7257	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-36	7257-7264	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[22]	
35-37	7264-7265	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-38	7266-7273	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[23]	
35-39	7273-7274	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-40	7275-7277	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-41	7278-7287	cigarette	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[24]	
35-42	7287-7288	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
35-43	7288-7289	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	

#Text=All participants were asked to refrain from using cocaine or alcohol on the day of the MRI scanning session and smoking cigarettes 2 h before the scanning session.
36-1	7290-7293	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-2	7294-7306	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-3	7307-7311	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-4	7312-7317	asked	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-5	7318-7320	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-6	7321-7328	refrain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-7	7329-7333	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-8	7334-7339	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-9	7340-7347	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-10	7348-7350	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-11	7351-7358	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-12	7359-7361	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-13	7362-7365	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-14	7366-7369	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-15	7370-7372	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-16	7373-7376	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-17	7377-7380	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-18	7381-7389	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-19	7390-7397	session	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-20	7398-7401	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-21	7402-7409	smoking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-22	7410-7420	cigarettes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-23	7421-7422	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-24	7423-7424	h	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-25	7425-7431	before	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-26	7432-7435	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-27	7436-7444	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-28	7445-7452	session	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
36-29	7452-7453	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	

#Text=Urine drug screens were used to verify abstinence from cocaine.
37-1	7454-7459	Urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
37-2	7460-7464	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
37-3	7465-7472	screens	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
37-4	7473-7477	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
37-5	7478-7482	used	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
37-6	7483-7485	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
37-7	7486-7492	verify	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
37-8	7493-7503	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
37-9	7504-7508	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
37-10	7509-7516	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
37-11	7516-7517	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	

#Text=Exhaled carbon monoxide levels were measured with a Micro-Smokelyzer (Bedfont Scientific Ltd., Kent, UK) and exhaled alcohol was measured using Breathalyzer (BACTrack).
38-1	7518-7525	Exhaled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-2	7526-7532	carbon	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-3	7533-7541	monoxide	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-4	7542-7548	levels	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-5	7549-7553	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-6	7554-7562	measured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-7	7563-7567	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-8	7568-7569	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-9	7570-7586	Micro-Smokelyzer	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-10	7587-7588	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-11	7588-7595	Bedfont	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-12	7596-7606	Scientific	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-13	7607-7610	Ltd	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-14	7610-7611	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-15	7611-7612	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-16	7613-7617	Kent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-17	7617-7618	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-18	7619-7621	UK	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-19	7621-7622	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-20	7623-7626	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-21	7627-7634	exhaled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-22	7635-7642	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-23	7643-7646	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-24	7647-7655	measured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-25	7656-7661	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-26	7662-7674	Breathalyzer	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-27	7675-7676	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-28	7676-7684	BACTrack	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-29	7684-7685	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
38-30	7685-7686	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	

#Text=Drug/alcohol cue reactivity fMRI task
#Text=The drug-cue reactivity task was based on prior work [,].
39-1	7687-7691	Drug	_	
39-2	7691-7692	/	_	
39-3	7692-7699	alcohol	_	
39-4	7700-7703	cue	_	
39-5	7704-7714	reactivity	_	
39-6	7715-7719	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
39-7	7720-7724	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
39-8	7725-7728	The	_	
39-9	7729-7737	drug-cue	_	
39-10	7738-7748	reactivity	_	
39-11	7749-7753	task	_	
39-12	7754-7757	was	_	
39-13	7758-7763	based	_	
39-14	7764-7766	on	_	
39-15	7767-7772	prior	_	
39-16	7773-7777	work	_	
39-17	7778-7779	[	_	
39-18	7779-7780	,	_	
39-19	7780-7781	]	_	
39-20	7781-7782	.	_	

#Text=In the MRI environment participants viewed blocks of cocaine, alcohol, or smoking cues and neutral pictures (e.g. pencils, dishes) color matched for hue, brightness, and contrast.
40-1	7783-7785	In	_	
40-2	7786-7789	the	_	
40-3	7790-7793	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument	
40-4	7794-7805	environment	_	
40-5	7806-7818	participants	_	
40-6	7819-7825	viewed	_	
40-7	7826-7832	blocks	_	
40-8	7833-7835	of	_	
40-9	7836-7843	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse	
40-10	7843-7844	,	_	
40-11	7845-7852	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
40-12	7852-7853	,	_	
40-13	7854-7856	or	_	
40-14	7857-7864	smoking	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
40-15	7865-7869	cues	_	
40-16	7870-7873	and	_	
40-17	7874-7881	neutral	_	
40-18	7882-7890	pictures	_	
40-19	7891-7892	(	_	
40-20	7892-7895	e.g	_	
40-21	7895-7896	.	_	
40-22	7897-7904	pencils	_	
40-23	7904-7905	,	_	
40-24	7906-7912	dishes	_	
40-25	7912-7913	)	_	
40-26	7914-7919	color	_	
40-27	7920-7927	matched	_	
40-28	7928-7931	for	_	
40-29	7932-7935	hue	_	
40-30	7935-7936	,	_	
40-31	7937-7947	brightness	_	
40-32	7947-7948	,	_	
40-33	7949-7952	and	_	
40-34	7953-7961	contrast	_	
40-35	7961-7962	.	_	

#Text=These task blocks were interleaved with control blocks (fixation cross, blurred images).
41-1	7963-7968	These	_	
41-2	7969-7973	task	_	
41-3	7974-7980	blocks	_	
41-4	7981-7985	were	_	
41-5	7986-7997	interleaved	_	
41-6	7998-8002	with	_	
41-7	8003-8010	control	_	
41-8	8011-8017	blocks	_	
41-9	8018-8019	(	_	
41-10	8019-8027	fixation	_	
41-11	8028-8033	cross	_	
41-12	8033-8034	,	_	
41-13	8035-8042	blurred	_	
41-14	8043-8049	images	_	
41-15	8049-8050	)	_	
41-16	8050-8051	.	_	

#Text=The task was administered in the MRI scanner as a block design using E-Prime software (Psychology Software Tools, Inc.).
42-1	8052-8055	The	_	
42-2	8056-8060	task	_	
42-3	8061-8064	was	_	
42-4	8065-8077	administered	_	
42-5	8078-8080	in	_	
42-6	8081-8084	the	_	
42-7	8085-8088	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument	
42-8	8089-8096	scanner	_	
42-9	8097-8099	as	_	
42-10	8100-8101	a	_	
42-11	8102-8107	block	_	
42-12	8108-8114	design	_	
42-13	8115-8120	using	_	
42-14	8121-8128	E-Prime	_	
42-15	8129-8137	software	_	
42-16	8138-8139	(	_	
42-17	8139-8149	Psychology	_	
42-18	8150-8158	Software	_	
42-19	8159-8164	Tools	_	
42-20	8164-8165	,	_	
42-21	8166-8169	Inc	_	
42-22	8169-8170	.	_	
42-23	8170-8171	)	_	
42-24	8171-8172	.	_	

#Text=The total task time was 12 mins and consisted of six 120-second epochs.
43-1	8173-8176	The	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
43-2	8177-8182	total	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
43-3	8183-8187	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
43-4	8188-8192	time	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
43-5	8193-8196	was	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
43-6	8197-8199	12	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
43-7	8200-8204	mins	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
43-8	8205-8208	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
43-9	8209-8218	consisted	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
43-10	8219-8221	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
43-11	8222-8225	six	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
43-12	8226-8229	120	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
43-13	8229-8230	-	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
43-14	8230-8236	second	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
43-15	8237-8243	epochs	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
43-16	8243-8244	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	

#Text=Each epoch included alternating 24-second blocks of four task conditions: Drug, Neutral, Blur, and Rest.
44-1	8245-8249	Each	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-2	8250-8255	epoch	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-3	8256-8264	included	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-4	8265-8276	alternating	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-5	8277-8279	24	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-6	8279-8280	-	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-7	8280-8286	second	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-8	8287-8293	blocks	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-9	8294-8296	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-10	8297-8301	four	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-11	8302-8306	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-12	8307-8317	conditions	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-13	8317-8318	:	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-14	8319-8323	Drug	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-15	8323-8324	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-16	8325-8332	Neutral	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-17	8332-8333	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-18	8334-8338	Blur	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-19	8338-8339	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-20	8340-8343	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-21	8344-8348	Rest	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
44-22	8348-8349	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	

#Text=Respectively, these task conditions included images of cocaine- or alcohol-related stimuli customized for each group (e.g. crack pipe for cocaine users; liquor bottles for alcohol users); neutral stimuli (e.g. glass of water, cooking utensils, people eating dinner); blurred stimuli acting as visual controls by matching substance images in color and hue; and a fixation cross for alert rest periods.
45-1	8350-8362	Respectively	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-2	8362-8363	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-3	8364-8369	these	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-4	8370-8374	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-5	8375-8385	conditions	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-6	8386-8394	included	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-7	8395-8401	images	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-8	8402-8404	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-9	8405-8412	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-10	8412-8413	-	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-11	8414-8416	or	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-12	8417-8432	alcohol-related	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-13	8433-8440	stimuli	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-14	8441-8451	customized	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-15	8452-8455	for	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-16	8456-8460	each	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-17	8461-8466	group	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-18	8467-8468	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-19	8468-8471	e.g	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-20	8471-8472	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-21	8473-8478	crack	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-22	8479-8483	pipe	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-23	8484-8487	for	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-24	8488-8495	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-25	8496-8501	users	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-26	8501-8502	;	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-27	8503-8509	liquor	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-28	8510-8517	bottles	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-29	8518-8521	for	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-30	8522-8529	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-31	8530-8535	users	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-32	8535-8536	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-33	8536-8537	;	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-34	8538-8545	neutral	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-35	8546-8553	stimuli	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-36	8554-8555	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-37	8555-8558	e.g	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-38	8558-8559	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-39	8560-8565	glass	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-40	8566-8568	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-41	8569-8574	water	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-42	8574-8575	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-43	8576-8583	cooking	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-44	8584-8592	utensils	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-45	8592-8593	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-46	8594-8600	people	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-47	8601-8607	eating	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-48	8608-8614	dinner	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-49	8614-8615	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-50	8615-8616	;	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-51	8617-8624	blurred	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-52	8625-8632	stimuli	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-53	8633-8639	acting	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-54	8640-8642	as	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-55	8643-8649	visual	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-56	8650-8658	controls	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-57	8659-8661	by	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-58	8662-8670	matching	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-59	8671-8680	substance	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-60	8681-8687	images	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-61	8688-8690	in	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-62	8691-8696	color	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-63	8697-8700	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-64	8701-8704	hue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-65	8704-8705	;	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-66	8706-8709	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-67	8710-8711	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-68	8712-8720	fixation	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-69	8721-8726	cross	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-70	8727-8730	for	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-71	8731-8736	alert	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-72	8737-8741	rest	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-73	8742-8749	periods	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	
45-74	8749-8750	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[28]	

#Text=During each task block, 5 images were presented (4.8 s).
46-1	8751-8757	During	_	
46-2	8758-8762	each	_	
46-3	8763-8767	task	_	
46-4	8768-8773	block	_	
46-5	8773-8774	,	_	
46-6	8775-8776	5	_	
46-7	8777-8783	images	_	
46-8	8784-8788	were	_	
46-9	8789-8798	presented	_	
46-10	8799-8800	(	_	
46-11	8800-8803	4.8	_	
46-12	8804-8805	s	_	
46-13	8805-8806	)	_	
46-14	8806-8807	.	_	

#Text=Image acquisition
#Text=High-resolution T1-weighted anatomical images were acquired for each participant (3.0 T Siemens Trio, 3D SPGR, TR = 10 ms, TE = 3 ms, voxel dimensions 1.0 × 1.0 × 1.5 mm, 256 × 256 voxels, 124 slices).
47-1	8808-8813	Image	_	
47-2	8814-8825	acquisition	_	
47-3	8826-8841	High-resolution	_	
47-4	8842-8844	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[29]	
47-5	8844-8845	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[29]	
47-6	8845-8853	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[29]	
47-7	8854-8864	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[29]	
47-8	8865-8871	images	_	
47-9	8872-8876	were	_	
47-10	8877-8885	acquired	_	
47-11	8886-8889	for	_	
47-12	8890-8894	each	_	
47-13	8895-8906	participant	_	
47-14	8907-8908	(	_	
47-15	8908-8911	3.0	_	
47-16	8912-8913	T	_	
47-17	8914-8921	Siemens	_	
47-18	8922-8926	Trio	_	
47-19	8926-8927	,	_	
47-20	8928-8930	3D	_	
47-21	8931-8935	SPGR	_	
47-22	8935-8936	,	_	
47-23	8937-8939	TR	_	
47-24	8940-8941	=	_	
47-25	8942-8944	10	_	
47-26	8945-8947	ms	_	
47-27	8947-8948	,	_	
47-28	8949-8951	TE	_	
47-29	8952-8953	=	_	
47-30	8954-8955	3	_	
47-31	8956-8958	ms	_	
47-32	8958-8959	,	_	
47-33	8960-8965	voxel	_	
47-34	8966-8976	dimensions	_	
47-35	8977-8980	1.0	_	
47-36	8981-8982	×	_	
47-37	8983-8986	1.0	_	
47-38	8987-8988	×	_	
47-39	8989-8992	1.5	_	
47-40	8993-8995	mm	_	
47-41	8995-8996	,	_	
47-42	8997-9000	256	_	
47-43	9001-9002	×	_	
47-44	9003-9006	256	_	
47-45	9007-9013	voxels	_	
47-46	9013-9014	,	_	
47-47	9015-9018	124	_	
47-48	9019-9025	slices	_	
47-49	9025-9026	)	_	
47-50	9026-9027	.	_	

#Text=The head was positioned along the canthomeatal line.
48-1	9028-9031	The	_	
48-2	9032-9036	head	_	
48-3	9037-9040	was	_	
48-4	9041-9051	positioned	_	
48-5	9052-9057	along	_	
48-6	9058-9061	the	_	
48-7	9062-9074	canthomeatal	_	
48-8	9075-9079	line	_	
48-9	9079-9080	.	_	

#Text=Foam padding was used to limit head motion.
49-1	9081-9085	Foam	_	
49-2	9086-9093	padding	_	
49-3	9094-9097	was	_	
49-4	9098-9102	used	_	
49-5	9103-9105	to	_	
49-6	9106-9111	limit	_	
49-7	9112-9116	head	_	
49-8	9117-9123	motion	_	
49-9	9123-9124	.	_	

#Text=T2* weighted imaging data were acquired during the 12 min cue-reactivity task (TR = 2.2, TE = 35 ms, 64 × 64, 3 mm isotropic voxels).
50-1	9125-9127	T2	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[30]	
50-2	9127-9128	*	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[30]	
50-3	9129-9137	weighted	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[30]	
50-4	9138-9145	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[30]	
50-5	9146-9150	data	_	
50-6	9151-9155	were	_	
50-7	9156-9164	acquired	_	
50-8	9165-9171	during	_	
50-9	9172-9175	the	_	
50-10	9176-9178	12	_	
50-11	9179-9182	min	_	
50-12	9183-9197	cue-reactivity	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
50-13	9198-9202	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
50-14	9203-9204	(	_	
50-15	9204-9206	TR	_	
50-16	9207-9208	=	_	
50-17	9209-9212	2.2	_	
50-18	9212-9213	,	_	
50-19	9214-9216	TE	_	
50-20	9217-9218	=	_	
50-21	9219-9221	35	_	
50-22	9222-9224	ms	_	
50-23	9224-9225	,	_	
50-24	9226-9228	64	_	
50-25	9229-9230	×	_	
50-26	9231-9233	64	_	
50-27	9233-9234	,	_	
50-28	9235-9236	3	_	
50-29	9237-9239	mm	_	
50-30	9240-9249	isotropic	_	
50-31	9250-9256	voxels	_	
50-32	9256-9257	)	_	
50-33	9257-9258	.	_	

#Text=Neuroimaging data analysis
#Text=MRI data were preprocessed using SPM12 (Wellcome Department of Cognitive Neurology, London, UK) implemented in Matlab 7.14 (MathWorks, Inc., Natick, MA).
51-1	9259-9271	Neuroimaging	_	
51-2	9272-9276	data	_	
51-3	9277-9285	analysis	_	
51-4	9286-9289	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument	
51-5	9290-9294	data	_	
51-6	9295-9299	were	_	
51-7	9300-9312	preprocessed	_	
51-8	9313-9318	using	_	
51-9	9319-9324	SPM12	_	
51-10	9325-9326	(	_	
51-11	9326-9334	Wellcome	_	
51-12	9335-9345	Department	_	
51-13	9346-9348	of	_	
51-14	9349-9358	Cognitive	_	
51-15	9359-9368	Neurology	_	
51-16	9368-9369	,	_	
51-17	9370-9376	London	_	
51-18	9376-9377	,	_	
51-19	9378-9380	UK	_	
51-20	9380-9381	)	_	
51-21	9382-9393	implemented	_	
51-22	9394-9396	in	_	
51-23	9397-9403	Matlab	_	
51-24	9404-9408	7.14	_	
51-25	9409-9410	(	_	
51-26	9410-9419	MathWorks	_	
51-27	9419-9420	,	_	
51-28	9421-9424	Inc	_	
51-29	9424-9425	.	_	
51-30	9425-9426	,	_	
51-31	9427-9433	Natick	_	
51-32	9433-9434	,	_	
51-33	9435-9437	MA	_	
51-34	9437-9438	)	_	
51-35	9438-9439	.	_	

#Text=MR Images were first converted from DICOM format to 4D NIfTI files and motion corrected (Realign: 6 parameter rigid-body realignment to first image in each timeseries using a least-squares approach).
52-1	9440-9442	MR	_	
52-2	9443-9449	Images	_	
52-3	9450-9454	were	_	
52-4	9455-9460	first	_	
52-5	9461-9470	converted	_	
52-6	9471-9475	from	_	
52-7	9476-9481	DICOM	_	
52-8	9482-9488	format	_	
52-9	9489-9491	to	_	
52-10	9492-9494	4D	_	
52-11	9495-9500	NIfTI	_	
52-12	9501-9506	files	_	
52-13	9507-9510	and	_	
52-14	9511-9517	motion	_	
52-15	9518-9527	corrected	_	
52-16	9528-9529	(	_	
52-17	9529-9536	Realign	_	
52-18	9536-9537	:	_	
52-19	9538-9539	6	_	
52-20	9540-9549	parameter	_	
52-21	9550-9560	rigid-body	_	
52-22	9561-9572	realignment	_	
52-23	9573-9575	to	_	
52-24	9576-9581	first	_	
52-25	9582-9587	image	_	
52-26	9588-9590	in	_	
52-27	9591-9595	each	_	
52-28	9596-9606	timeseries	_	
52-29	9607-9612	using	_	
52-30	9613-9614	a	_	
52-31	9615-9628	least-squares	_	
52-32	9629-9637	approach	_	
52-33	9637-9638	)	_	
52-34	9638-9639	.	_	

#Text=Normalization parameters, bias correction and anatomical tissue maps were determined simultaneously, using the Segment toolbox.
53-1	9640-9653	Normalization	_	
53-2	9654-9664	parameters	_	
53-3	9664-9665	,	_	
53-4	9666-9670	bias	_	
53-5	9671-9681	correction	_	
53-6	9682-9685	and	_	
53-7	9686-9696	anatomical	_	
53-8	9697-9703	tissue	_	
53-9	9704-9708	maps	_	
53-10	9709-9713	were	_	
53-11	9714-9724	determined	_	
53-12	9725-9739	simultaneously	_	
53-13	9739-9740	,	_	
53-14	9741-9746	using	_	
53-15	9747-9750	the	_	
53-16	9751-9758	Segment	_	
53-17	9759-9766	toolbox	_	
53-18	9766-9767	.	_	

#Text=Individual anatomical images were stripped of their skulls by masking the bias-corrected image with the combined tissue masks of gray matter, white matter, and CSF.
54-1	9768-9778	Individual	_	
54-2	9779-9789	anatomical	_	
54-3	9790-9796	images	_	
54-4	9797-9801	were	_	
54-5	9802-9810	stripped	_	
54-6	9811-9813	of	_	
54-7	9814-9819	their	_	
54-8	9820-9826	skulls	_	
54-9	9827-9829	by	_	
54-10	9830-9837	masking	_	
54-11	9838-9841	the	_	
54-12	9842-9856	bias-corrected	_	
54-13	9857-9862	image	_	
54-14	9863-9867	with	_	
54-15	9868-9871	the	_	
54-16	9872-9880	combined	_	
54-17	9881-9887	tissue	_	
54-18	9888-9893	masks	_	
54-19	9894-9896	of	_	
54-20	9897-9901	gray	_	
54-21	9902-9908	matter	_	
54-22	9908-9909	,	_	
54-23	9910-9915	white	_	
54-24	9916-9922	matter	_	
54-25	9922-9923	,	_	
54-26	9924-9927	and	_	
54-27	9928-9931	CSF	_	
54-28	9931-9932	.	_	

#Text=The functional images derived from realignment were coregistered, through the mean image, to the skull-stripped anatomical image (Coregister: Estimate, using normalized mutual information).
55-1	9933-9936	The	_	
55-2	9937-9947	functional	_	
55-3	9948-9954	images	_	
55-4	9955-9962	derived	_	
55-5	9963-9967	from	_	
55-6	9968-9979	realignment	_	
55-7	9980-9984	were	_	
55-8	9985-9997	coregistered	_	
55-9	9997-9998	,	_	
55-10	9999-10006	through	_	
55-11	10007-10010	the	_	
55-12	10011-10015	mean	_	
55-13	10016-10021	image	_	
55-14	10021-10022	,	_	
55-15	10023-10025	to	_	
55-16	10026-10029	the	_	
55-17	10030-10044	skull-stripped	_	
55-18	10045-10055	anatomical	_	
55-19	10056-10061	image	_	
55-20	10062-10063	(	_	
55-21	10063-10073	Coregister	_	
55-22	10073-10074	:	_	
55-23	10075-10083	Estimate	_	
55-24	10083-10084	,	_	
55-25	10085-10090	using	_	
55-26	10091-10101	normalized	_	
55-27	10102-10108	mutual	_	
55-28	10109-10120	information	_	
55-29	10120-10121	)	_	
55-30	10121-10122	.	_	

#Text=Coregistered images were then normalized (Normalize: Write) to MNI template space with the nonlinear warps derived from the Segment tool.
56-1	10123-10135	Coregistered	_	
56-2	10136-10142	images	_	
56-3	10143-10147	were	_	
56-4	10148-10152	then	_	
56-5	10153-10163	normalized	_	
56-6	10164-10165	(	_	
56-7	10165-10174	Normalize	_	
56-8	10174-10175	:	_	
56-9	10176-10181	Write	_	
56-10	10181-10182	)	_	
56-11	10183-10185	to	_	
56-12	10186-10189	MNI	_	
56-13	10190-10198	template	_	
56-14	10199-10204	space	_	
56-15	10205-10209	with	_	
56-16	10210-10213	the	_	
56-17	10214-10223	nonlinear	_	
56-18	10224-10229	warps	_	
56-19	10230-10237	derived	_	
56-20	10238-10242	from	_	
56-21	10243-10246	the	_	
56-22	10247-10254	Segment	_	
56-23	10255-10259	tool	_	
56-24	10259-10260	.	_	

#Text=Finally, functional images were masked (to remove the skull) and smoothed (8 mm FWHM Gaussian kernel) to facilitate subsequent analysis.
57-1	10261-10268	Finally	_	
57-2	10268-10269	,	_	
57-3	10270-10280	functional	_	
57-4	10281-10287	images	_	
57-5	10288-10292	were	_	
57-6	10293-10299	masked	_	
57-7	10300-10301	(	_	
57-8	10301-10303	to	_	
57-9	10304-10310	remove	_	
57-10	10311-10314	the	_	
57-11	10315-10320	skull	_	
57-12	10320-10321	)	_	
57-13	10322-10325	and	_	
57-14	10326-10334	smoothed	_	
57-15	10335-10336	(	_	
57-16	10336-10337	8	_	
57-17	10338-10340	mm	_	
57-18	10341-10345	FWHM	_	
57-19	10346-10354	Gaussian	_	
57-20	10355-10361	kernel	_	
57-21	10361-10362	)	_	
57-22	10363-10365	to	_	
57-23	10366-10376	facilitate	_	
57-24	10377-10387	subsequent	_	
57-25	10388-10396	analysis	_	
57-26	10396-10397	.	_	

#Text=Inspection of motion correction parameters revealed that all corrections were <2 mm.
58-1	10398-10408	Inspection	_	
58-2	10409-10411	of	_	
58-3	10412-10418	motion	_	
58-4	10419-10429	correction	_	
58-5	10430-10440	parameters	_	
58-6	10441-10449	revealed	_	
58-7	10450-10454	that	_	
58-8	10455-10458	all	_	
58-9	10459-10470	corrections	_	
58-10	10471-10475	were	_	
58-11	10476-10477	<	_	
58-12	10477-10478	2	_	
58-13	10479-10481	mm	_	
58-14	10481-10482	.	_	

#Text=Analyses were done on individual level and a group level.
59-1	10483-10491	Analyses	_	
59-2	10492-10496	were	_	
59-3	10497-10501	done	_	
59-4	10502-10504	on	_	
59-5	10505-10515	individual	_	
59-6	10516-10521	level	_	
59-7	10522-10525	and	_	
59-8	10526-10527	a	_	
59-9	10528-10533	group	_	
59-10	10534-10539	level	_	
59-11	10539-10540	.	_	

#Text=Overall effects were calculated using second-level, random-effects analyses of this contrast for all individuals, with cocaine, alcohol, and nicotine users each represented as a unique column in the design matrix.
60-1	10541-10548	Overall	_	
60-2	10549-10556	effects	_	
60-3	10557-10561	were	_	
60-4	10562-10572	calculated	_	
60-5	10573-10578	using	_	
60-6	10579-10591	second-level	_	
60-7	10591-10592	,	_	
60-8	10593-10607	random-effects	_	
60-9	10608-10616	analyses	_	
60-10	10617-10619	of	_	
60-11	10620-10624	this	_	
60-12	10625-10633	contrast	_	
60-13	10634-10637	for	_	
60-14	10638-10641	all	_	
60-15	10642-10653	individuals	_	
60-16	10653-10654	,	_	
60-17	10655-10659	with	_	
60-18	10660-10667	cocaine	_	
60-19	10667-10668	,	_	
60-20	10669-10676	alcohol	_	
60-21	10676-10677	,	_	
60-22	10678-10681	and	_	
60-23	10682-10690	nicotine	_	
60-24	10691-10696	users	_	
60-25	10697-10701	each	_	
60-26	10702-10713	represented	_	
60-27	10714-10716	as	_	
60-28	10717-10718	a	_	
60-29	10719-10725	unique	_	
60-30	10726-10732	column	_	
60-31	10733-10735	in	_	
60-32	10736-10739	the	_	
60-33	10740-10746	design	_	
60-34	10747-10753	matrix	_	
60-35	10753-10754	.	_	

#Text=For each participant, first-level, fixed-effects comparisons were made to determine activation during drug/alcohol cue blocks relative to neutral blocks using the general linear model.
61-1	10755-10758	For	_	
61-2	10759-10763	each	_	
61-3	10764-10775	participant	_	
61-4	10775-10776	,	_	
61-5	10777-10788	first-level	_	
61-6	10788-10789	,	_	
61-7	10790-10803	fixed-effects	_	
61-8	10804-10815	comparisons	_	
61-9	10816-10820	were	_	
61-10	10821-10825	made	_	
61-11	10826-10828	to	_	
61-12	10829-10838	determine	_	
61-13	10839-10849	activation	_	
61-14	10850-10856	during	_	
61-15	10857-10861	drug	_	
61-16	10861-10862	/	_	
61-17	10862-10869	alcohol	_	
61-18	10870-10873	cue	_	
61-19	10874-10880	blocks	_	
61-20	10881-10889	relative	_	
61-21	10890-10892	to	_	
61-22	10893-10900	neutral	_	
61-23	10901-10907	blocks	_	
61-24	10908-10913	using	_	
61-25	10914-10917	the	_	
61-26	10918-10925	general	_	
61-27	10926-10932	linear	_	
61-28	10933-10938	model	_	
61-29	10938-10939	.	_	

#Text=Motion parameters (6 dimensions: x, y, z, yaw, pitch, roll) were included as covariates in the model.
62-1	10940-10946	Motion	_	
62-2	10947-10957	parameters	_	
62-3	10958-10959	(	_	
62-4	10959-10960	6	_	
62-5	10961-10971	dimensions	_	
62-6	10971-10972	:	_	
62-7	10973-10974	x	_	
62-8	10974-10975	,	_	
62-9	10976-10977	y	_	
62-10	10977-10978	,	_	
62-11	10979-10980	z	_	
62-12	10980-10981	,	_	
62-13	10982-10985	yaw	_	
62-14	10985-10986	,	_	
62-15	10987-10992	pitch	_	
62-16	10992-10993	,	_	
62-17	10994-10998	roll	_	
62-18	10998-10999	)	_	
62-19	11000-11004	were	_	
62-20	11005-11013	included	_	
62-21	11014-11016	as	_	
62-22	11017-11027	covariates	_	
62-23	11028-11030	in	_	
62-24	11031-11034	the	_	
62-25	11035-11040	model	_	
62-26	11040-11041	.	_	

#Text=Voxel-wise correction for multiple comparisons was done via AFNI’s 3dClustSim with the autocorrelation module enabled (2017 version; https://afni.nimh.nih.gov/pub/dist/doc).
63-1	11042-11052	Voxel-wise	_	
63-2	11053-11063	correction	_	
63-3	11064-11067	for	_	
63-4	11068-11076	multiple	_	
63-5	11077-11088	comparisons	_	
63-6	11089-11092	was	_	
63-7	11093-11097	done	_	
63-8	11098-11101	via	_	
63-9	11102-11106	AFNI	_	
63-10	11106-11107	’	_	
63-11	11107-11108	s	_	
63-12	11109-11119	3dClustSim	_	
63-13	11120-11124	with	_	
63-14	11125-11128	the	_	
63-15	11129-11144	autocorrelation	_	
63-16	11145-11151	module	_	
63-17	11152-11159	enabled	_	
63-18	11160-11161	(	_	
63-19	11161-11165	2017	_	
63-20	11166-11173	version	_	
63-21	11173-11174	;	_	
63-22	11175-11180	https	_	
63-23	11180-11181	:	_	
63-24	11181-11182	/	_	
63-25	11182-11183	/	_	
63-26	11183-11200	afni.nimh.nih.gov	_	
63-27	11200-11201	/	_	
63-28	11201-11204	pub	_	
63-29	11204-11205	/	_	
63-30	11205-11209	dist	_	
63-31	11209-11210	/	_	
63-32	11210-11213	doc	_	
63-33	11213-11214	)	_	
63-34	11214-11215	.	_	

#Text=Clusters with a p-value < 0.05 are reported (determined by Monte Carlo simulation; voxel-level threshold of p < 0.005 for at least 48 contiguous voxels).
64-1	11216-11224	Clusters	_	
64-2	11225-11229	with	_	
64-3	11230-11231	a	_	
64-4	11232-11239	p-value	_	
64-5	11240-11241	<	_	
64-6	11242-11246	0.05	_	
64-7	11247-11250	are	_	
64-8	11251-11259	reported	_	
64-9	11260-11261	(	_	
64-10	11261-11271	determined	_	
64-11	11272-11274	by	_	
64-12	11275-11280	Monte	_	
64-13	11281-11286	Carlo	_	
64-14	11287-11297	simulation	_	
64-15	11297-11298	;	_	
64-16	11299-11310	voxel-level	_	
64-17	11311-11320	threshold	_	
64-18	11321-11323	of	_	
64-19	11324-11325	p	_	
64-20	11326-11327	<	_	
64-21	11328-11333	0.005	_	
64-22	11334-11337	for	_	
64-23	11338-11340	at	_	
64-24	11341-11346	least	_	
64-25	11347-11349	48	_	
64-26	11350-11360	contiguous	_	
64-27	11361-11367	voxels	_	
64-28	11367-11368	)	_	
64-29	11368-11369	.	_	

#Text=To investigate individual variability, the primary locus of activity in the during drug-related cues relative to neutral cues (“hot spot”) was isolated for each individual by locating the local maximum voxel (x, y, z, MNI coordinates) within the most significant cluster of activity (p < 0.05, corrected at the cluster level).
65-1	11370-11372	To	_	
65-2	11373-11384	investigate	_	
65-3	11385-11395	individual	_	
65-4	11396-11407	variability	_	
65-5	11407-11408	,	_	
65-6	11409-11412	the	_	
65-7	11413-11420	primary	_	
65-8	11421-11426	locus	_	
65-9	11427-11429	of	_	
65-10	11430-11438	activity	_	
65-11	11439-11441	in	_	
65-12	11442-11445	the	_	
65-13	11446-11452	during	_	
65-14	11453-11465	drug-related	_	
65-15	11466-11470	cues	_	
65-16	11471-11479	relative	_	
65-17	11480-11482	to	_	
65-18	11483-11490	neutral	_	
65-19	11491-11495	cues	_	
65-20	11496-11497	(	_	
65-21	11497-11498	“	_	
65-22	11498-11501	hot	_	
65-23	11502-11506	spot	_	
65-24	11506-11507	”	_	
65-25	11507-11508	)	_	
65-26	11509-11512	was	_	
65-27	11513-11521	isolated	_	
65-28	11522-11525	for	_	
65-29	11526-11530	each	_	
65-30	11531-11541	individual	_	
65-31	11542-11544	by	_	
65-32	11545-11553	locating	_	
65-33	11554-11557	the	_	
65-34	11558-11563	local	_	
65-35	11564-11571	maximum	_	
65-36	11572-11577	voxel	_	
65-37	11578-11579	(	_	
65-38	11579-11580	x	_	
65-39	11580-11581	,	_	
65-40	11582-11583	y	_	
65-41	11583-11584	,	_	
65-42	11585-11586	z	_	
65-43	11586-11587	,	_	
65-44	11588-11591	MNI	_	
65-45	11592-11603	coordinates	_	
65-46	11603-11604	)	_	
65-47	11605-11611	within	_	
65-48	11612-11615	the	_	
65-49	11616-11620	most	_	
65-50	11621-11632	significant	_	
65-51	11633-11640	cluster	_	
65-52	11641-11643	of	_	
65-53	11644-11652	activity	_	
65-54	11653-11654	(	_	
65-55	11654-11655	p	_	
65-56	11656-11657	<	_	
65-57	11658-11662	0.05	_	
65-58	11662-11663	,	_	
65-59	11664-11673	corrected	_	
65-60	11674-11676	at	_	
65-61	11677-11680	the	_	
65-62	11681-11688	cluster	_	
65-63	11689-11694	level	_	
65-64	11694-11695	)	_	
65-65	11695-11696	.	_	

#Text=The analysis was limited to cortical areas as one of the aims of this study was to identify potential frontal targets for current noninvasive brain stimulation methods such as TMS.
66-1	11697-11700	The	_	
66-2	11701-11709	analysis	_	
66-3	11710-11713	was	_	
66-4	11714-11721	limited	_	
66-5	11722-11724	to	_	
66-6	11725-11733	cortical	_	
66-7	11734-11739	areas	_	
66-8	11740-11742	as	_	
66-9	11743-11746	one	_	
66-10	11747-11749	of	_	
66-11	11750-11753	the	_	
66-12	11754-11758	aims	_	
66-13	11759-11761	of	_	
66-14	11762-11766	this	_	
66-15	11767-11772	study	_	
66-16	11773-11776	was	_	
66-17	11777-11779	to	_	
66-18	11780-11788	identify	_	
66-19	11789-11798	potential	_	
66-20	11799-11806	frontal	_	
66-21	11807-11814	targets	_	
66-22	11815-11818	for	_	
66-23	11819-11826	current	_	
66-24	11827-11838	noninvasive	_	
66-25	11839-11844	brain	_	
66-26	11845-11856	stimulation	_	
66-27	11857-11864	methods	_	
66-28	11865-11869	such	_	
66-29	11870-11872	as	_	
66-30	11873-11876	TMS	_	
66-31	11876-11877	.	_	

#Text=The mask included the following bilateral regions of interest extracted from the standardized WFU_Pick atlas implemented in MATLAB (https://www.nitrc.org/projects/wfu_pickatlas): anterior cingulate cortex, middle frontal gyrus, medial frontal gyrus, inferior frontal gyrus, and superior frontal gyrus (2D dilation value: 3).
67-1	11878-11881	The	_	
67-2	11882-11886	mask	_	
67-3	11887-11895	included	_	
67-4	11896-11899	the	_	
67-5	11900-11909	following	_	
67-6	11910-11919	bilateral	_	
67-7	11920-11927	regions	_	
67-8	11928-11930	of	_	
67-9	11931-11939	interest	_	
67-10	11940-11949	extracted	_	
67-11	11950-11954	from	_	
67-12	11955-11958	the	_	
67-13	11959-11971	standardized	_	
67-14	11972-11980	WFU_Pick	_	
67-15	11981-11986	atlas	_	
67-16	11987-11998	implemented	_	
67-17	11999-12001	in	_	
67-18	12002-12008	MATLAB	_	
67-19	12009-12010	(	_	
67-20	12010-12015	https	_	
67-21	12015-12016	:	_	
67-22	12016-12017	/	_	
67-23	12017-12018	/	_	
67-24	12018-12031	www.nitrc.org	_	
67-25	12031-12032	/	_	
67-26	12032-12040	projects	_	
67-27	12040-12041	/	_	
67-28	12041-12054	wfu_pickatlas	_	
67-29	12054-12055	)	_	
67-30	12055-12056	:	_	
67-31	12057-12065	anterior	_	
67-32	12066-12075	cingulate	_	
67-33	12076-12082	cortex	_	
67-34	12082-12083	,	_	
67-35	12084-12090	middle	_	
67-36	12091-12098	frontal	_	
67-37	12099-12104	gyrus	_	
67-38	12104-12105	,	_	
67-39	12106-12112	medial	_	
67-40	12113-12120	frontal	_	
67-41	12121-12126	gyrus	_	
67-42	12126-12127	,	_	
67-43	12128-12136	inferior	_	
67-44	12137-12144	frontal	_	
67-45	12145-12150	gyrus	_	
67-46	12150-12151	,	_	
67-47	12152-12155	and	_	
67-48	12156-12164	superior	_	
67-49	12165-12172	frontal	_	
67-50	12173-12178	gyrus	_	
67-51	12179-12180	(	_	
67-52	12180-12182	2D	_	
67-53	12183-12191	dilation	_	
67-54	12192-12197	value	_	
67-55	12197-12198	:	_	
67-56	12199-12200	3	_	
67-57	12200-12201	)	_	
67-58	12201-12202	.	_	

#Text=Spatial dispersion of the “hot spots”, were characterized via k-means clustering (as implemented in MATLAB and cross-checked with R).
68-1	12203-12210	Spatial	_	
68-2	12211-12221	dispersion	_	
68-3	12222-12224	of	_	
68-4	12225-12228	the	_	
68-5	12229-12230	“	_	
68-6	12230-12233	hot	_	
68-7	12234-12239	spots	_	
68-8	12239-12240	”	_	
68-9	12240-12241	,	_	
68-10	12242-12246	were	_	
68-11	12247-12260	characterized	_	
68-12	12261-12264	via	_	
68-13	12265-12272	k-means	_	
68-14	12273-12283	clustering	_	
68-15	12284-12285	(	_	
68-16	12285-12287	as	_	
68-17	12288-12299	implemented	_	
68-18	12300-12302	in	_	
68-19	12303-12309	MATLAB	_	
68-20	12310-12313	and	_	
68-21	12314-12327	cross-checked	_	
68-22	12328-12332	with	_	
68-23	12333-12334	R	_	
68-24	12334-12335	)	_	
68-25	12335-12336	.	_	

#Text=K-means clustering as implemented in Matlab used the K + + algorithm, an iterative, data-partitioning algorithm that assigns the total number of observations (e.g.
69-1	12337-12344	K-means	_	
69-2	12345-12355	clustering	_	
69-3	12356-12358	as	_	
69-4	12359-12370	implemented	_	
69-5	12371-12373	in	_	
69-6	12374-12380	Matlab	_	
69-7	12381-12385	used	_	
69-8	12386-12389	the	_	
69-9	12390-12391	K	_	
69-10	12392-12393	+	_	
69-11	12394-12395	+	_	
69-12	12396-12405	algorithm	_	
69-13	12405-12406	,	_	
69-14	12407-12409	an	_	
69-15	12410-12419	iterative	_	
69-16	12419-12420	,	_	
69-17	12421-12438	data-partitioning	_	
69-18	12439-12448	algorithm	_	
69-19	12449-12453	that	_	
69-20	12454-12461	assigns	_	
69-21	12462-12465	the	_	
69-22	12466-12471	total	_	
69-23	12472-12478	number	_	
69-24	12479-12481	of	_	
69-25	12482-12494	observations	_	
69-26	12495-12496	(	_	
69-27	12496-12499	e.g	_	
69-28	12499-12500	.	_	

#Text=MNI coordinates for clusters significantly activated by drug-cues) to exactly one of ‘k’ clusters defined by centroids, where ‘k ‘ is chosen before the algorithm starts.
70-1	12501-12504	MNI	_	
70-2	12505-12516	coordinates	_	
70-3	12517-12520	for	_	
70-4	12521-12529	clusters	_	
70-5	12530-12543	significantly	_	
70-6	12544-12553	activated	_	
70-7	12554-12556	by	_	
70-8	12557-12566	drug-cues	_	
70-9	12566-12567	)	_	
70-10	12568-12570	to	_	
70-11	12571-12578	exactly	_	
70-12	12579-12582	one	_	
70-13	12583-12585	of	_	
70-14	12586-12587	‘	_	
70-15	12587-12588	k	_	
70-16	12588-12589	’	_	
70-17	12590-12598	clusters	_	
70-18	12599-12606	defined	_	
70-19	12607-12609	by	_	
70-20	12610-12619	centroids	_	
70-21	12619-12620	,	_	
70-22	12621-12626	where	_	
70-23	12627-12628	‘	_	
70-24	12628-12629	k	_	
70-25	12630-12631	‘	_	
70-26	12632-12634	is	_	
70-27	12635-12641	chosen	_	
70-28	12642-12648	before	_	
70-29	12649-12652	the	_	
70-30	12653-12662	algorithm	_	
70-31	12663-12669	starts	_	
70-32	12669-12670	.	_	

#Text=The K + + algorithm is a two-phase process which uses batch and online updates to minimize the sum of point-to-centroid distances in k clusters.
71-1	12671-12674	The	_	
71-2	12675-12676	K	_	
71-3	12677-12678	+	_	
71-4	12679-12680	+	_	
71-5	12681-12690	algorithm	_	
71-6	12691-12693	is	_	
71-7	12694-12695	a	_	
71-8	12696-12705	two-phase	_	
71-9	12706-12713	process	_	
71-10	12714-12719	which	_	
71-11	12720-12724	uses	_	
71-12	12725-12730	batch	_	
71-13	12731-12734	and	_	
71-14	12735-12741	online	_	
71-15	12742-12749	updates	_	
71-16	12750-12752	to	_	
71-17	12753-12761	minimize	_	
71-18	12762-12765	the	_	
71-19	12766-12769	sum	_	
71-20	12770-12772	of	_	
71-21	12773-12790	point-to-centroid	_	
71-22	12791-12800	distances	_	
71-23	12801-12803	in	_	
71-24	12804-12805	k	_	
71-25	12806-12814	clusters	_	
71-26	12814-12815	.	_	

#Text=Specifically, following the initial random seeding of k-centroids, a distance is calculated from each point to each centroid and that point is classified as a member of a given centroid.
72-1	12816-12828	Specifically	_	
72-2	12828-12829	,	_	
72-3	12830-12839	following	_	
72-4	12840-12843	the	_	
72-5	12844-12851	initial	_	
72-6	12852-12858	random	_	
72-7	12859-12866	seeding	_	
72-8	12867-12869	of	_	
72-9	12870-12881	k-centroids	_	
72-10	12881-12882	,	_	
72-11	12883-12884	a	_	
72-12	12885-12893	distance	_	
72-13	12894-12896	is	_	
72-14	12897-12907	calculated	_	
72-15	12908-12912	from	_	
72-16	12913-12917	each	_	
72-17	12918-12923	point	_	
72-18	12924-12926	to	_	
72-19	12927-12931	each	_	
72-20	12932-12940	centroid	_	
72-21	12941-12944	and	_	
72-22	12945-12949	that	_	
72-23	12950-12955	point	_	
72-24	12956-12958	is	_	
72-25	12959-12969	classified	_	
72-26	12970-12972	as	_	
72-27	12973-12974	a	_	
72-28	12975-12981	member	_	
72-29	12982-12984	of	_	
72-30	12985-12986	a	_	
72-31	12987-12992	given	_	
72-32	12993-13001	centroid	_	
72-33	13001-13002	.	_	

#Text=This is reseated, and centroid locations are reassigned if a reassignment decreases the sum of the within-cluster sum of squared point-to-centroid distance.
73-1	13003-13007	This	_	
73-2	13008-13010	is	_	
73-3	13011-13019	reseated	_	
73-4	13019-13020	,	_	
73-5	13021-13024	and	_	
73-6	13025-13033	centroid	_	
73-7	13034-13043	locations	_	
73-8	13044-13047	are	_	
73-9	13048-13058	reassigned	_	
73-10	13059-13061	if	_	
73-11	13062-13063	a	_	
73-12	13064-13076	reassignment	_	
73-13	13077-13086	decreases	_	
73-14	13087-13090	the	_	
73-15	13091-13094	sum	_	
73-16	13095-13097	of	_	
73-17	13098-13101	the	_	
73-18	13102-13116	within-cluster	_	
73-19	13117-13120	sum	_	
73-20	13121-13123	of	_	
73-21	13124-13131	squared	_	
73-22	13132-13149	point-to-centroid	_	
73-23	13150-13158	distance	_	
73-24	13158-13159	.	_	

#Text=For the present study this procedure was repeated 1000 times with random seeding.
74-1	13160-13163	For	_	
74-2	13164-13167	the	_	
74-3	13168-13175	present	_	
74-4	13176-13181	study	_	
74-5	13182-13186	this	_	
74-6	13187-13196	procedure	_	
74-7	13197-13200	was	_	
74-8	13201-13209	repeated	_	
74-9	13210-13214	1000	_	
74-10	13215-13220	times	_	
74-11	13221-13225	with	_	
74-12	13226-13232	random	_	
74-13	13233-13240	seeding	_	
74-14	13240-13241	.	_	

#Text=This was done for the full complement of points (n = 261) as well as for a restricted data set limited to one cluster per individual (n = 103).
75-1	13242-13246	This	_	
75-2	13247-13250	was	_	
75-3	13251-13255	done	_	
75-4	13256-13259	for	_	
75-5	13260-13263	the	_	
75-6	13264-13268	full	_	
75-7	13269-13279	complement	_	
75-8	13280-13282	of	_	
75-9	13283-13289	points	_	
75-10	13290-13291	(	_	
75-11	13291-13292	n	_	
75-12	13293-13294	=	_	
75-13	13295-13298	261	_	
75-14	13298-13299	)	_	
75-15	13300-13302	as	_	
75-16	13303-13307	well	_	
75-17	13308-13310	as	_	
75-18	13311-13314	for	_	
75-19	13315-13316	a	_	
75-20	13317-13327	restricted	_	
75-21	13328-13332	data	_	
75-22	13333-13336	set	_	
75-23	13337-13344	limited	_	
75-24	13345-13347	to	_	
75-25	13348-13351	one	_	
75-26	13352-13359	cluster	_	
75-27	13360-13363	per	_	
75-28	13364-13374	individual	_	
75-29	13375-13376	(	_	
75-30	13376-13377	n	_	
75-31	13378-13379	=	_	
75-32	13380-13383	103	_	
75-33	13383-13384	)	_	
75-34	13384-13385	.	_	

#Text=In this experiment we utilized k values of 2–10 to evaluate the possibility that there could be up to 10 unique clusters.
76-1	13386-13388	In	_	
76-2	13389-13393	this	_	
76-3	13394-13404	experiment	_	
76-4	13405-13407	we	_	
76-5	13408-13416	utilized	_	
76-6	13417-13418	k	_	
76-7	13419-13425	values	_	
76-8	13426-13428	of	_	
76-9	13429-13430	2	_	
76-10	13430-13431	–	_	
76-11	13431-13433	10	_	
76-12	13434-13436	to	_	
76-13	13437-13445	evaluate	_	
76-14	13446-13449	the	_	
76-15	13450-13461	possibility	_	
76-16	13462-13466	that	_	
76-17	13467-13472	there	_	
76-18	13473-13478	could	_	
76-19	13479-13481	be	_	
76-20	13482-13484	up	_	
76-21	13485-13487	to	_	
76-22	13488-13490	10	_	
76-23	13491-13497	unique	_	
76-24	13498-13506	clusters	_	
76-25	13506-13507	.	_	

#Text=The optimal solution was derived via the use of silhouette plots.
77-1	13508-13511	The	_	
77-2	13512-13519	optimal	_	
77-3	13520-13528	solution	_	
77-4	13529-13532	was	_	
77-5	13533-13540	derived	_	
77-6	13541-13544	via	_	
77-7	13545-13548	the	_	
77-8	13549-13552	use	_	
77-9	13553-13555	of	_	
77-10	13556-13566	silhouette	_	
77-11	13567-13572	plots	_	
77-12	13572-13573	.	_	

#Text=For each cluster the centroid vales was recorded as well as the average and maximum distance of any given point to the center of the centroid.
78-1	13574-13577	For	_	
78-2	13578-13582	each	_	
78-3	13583-13590	cluster	_	
78-4	13591-13594	the	_	
78-5	13595-13603	centroid	_	
78-6	13604-13609	vales	_	
78-7	13610-13613	was	_	
78-8	13614-13622	recorded	_	
78-9	13623-13625	as	_	
78-10	13626-13630	well	_	
78-11	13631-13633	as	_	
78-12	13634-13637	the	_	
78-13	13638-13645	average	_	
78-14	13646-13649	and	_	
78-15	13650-13657	maximum	_	
78-16	13658-13666	distance	_	
78-17	13667-13669	of	_	
78-18	13670-13673	any	_	
78-19	13674-13679	given	_	
78-20	13680-13685	point	_	
78-21	13686-13688	to	_	
78-22	13689-13692	the	_	
78-23	13693-13699	center	_	
78-24	13700-13702	of	_	
78-25	13703-13706	the	_	
78-26	13707-13715	centroid	_	
78-27	13715-13716	.	_	

#Text=Posthoc tests were performed to determine whether the areas of peak activity for cocaine cue-reactivity, alcohol cue-reactivity, and smoking cue-reactivity were equally distributed among the centroids (Chi-square, IBM SPSS Statistics ver.19, p < 0.05).
79-1	13717-13724	Posthoc	_	
79-2	13725-13730	tests	_	
79-3	13731-13735	were	_	
79-4	13736-13745	performed	_	
79-5	13746-13748	to	_	
79-6	13749-13758	determine	_	
79-7	13759-13766	whether	_	
79-8	13767-13770	the	_	
79-9	13771-13776	areas	_	
79-10	13777-13779	of	_	
79-11	13780-13784	peak	_	
79-12	13785-13793	activity	_	
79-13	13794-13797	for	_	
79-14	13798-13805	cocaine	_	
79-15	13806-13820	cue-reactivity	_	
79-16	13820-13821	,	_	
79-17	13822-13829	alcohol	_	
79-18	13830-13844	cue-reactivity	_	
79-19	13844-13845	,	_	
79-20	13846-13849	and	_	
79-21	13850-13857	smoking	_	
79-22	13858-13872	cue-reactivity	_	
79-23	13873-13877	were	_	
79-24	13878-13885	equally	_	
79-25	13886-13897	distributed	_	
79-26	13898-13903	among	_	
79-27	13904-13907	the	_	
79-28	13908-13917	centroids	_	
79-29	13918-13919	(	_	
79-30	13919-13929	Chi-square	_	
79-31	13929-13930	,	_	
79-32	13931-13934	IBM	_	
79-33	13935-13939	SPSS	_	
79-34	13940-13950	Statistics	_	
79-35	13951-13954	ver	_	
79-36	13954-13957	.19	_	
79-37	13957-13958	,	_	
79-38	13959-13960	p	_	
79-39	13961-13962	<	_	
79-40	13963-13967	0.05	_	
79-41	13967-13968	)	_	
79-42	13968-13969	.	_	

#Text=The distribution of gender was also investigated given prior study from our group which suggests males may have a more uniform distribution than females.
80-1	13970-13973	The	_	
80-2	13974-13986	distribution	_	
80-3	13987-13989	of	_	
80-4	13990-13996	gender	_	
80-5	13997-14000	was	_	
80-6	14001-14005	also	_	
80-7	14006-14018	investigated	_	
80-8	14019-14024	given	_	
80-9	14025-14030	prior	_	
80-10	14031-14036	study	_	
80-11	14037-14041	from	_	
80-12	14042-14045	our	_	
80-13	14046-14051	group	_	
80-14	14052-14057	which	_	
80-15	14058-14066	suggests	_	
80-16	14067-14072	males	_	
80-17	14073-14076	may	_	
80-18	14077-14081	have	_	
80-19	14082-14083	a	_	
80-20	14084-14088	more	_	
80-21	14089-14096	uniform	_	
80-22	14097-14109	distribution	_	
80-23	14110-14114	than	_	
80-24	14115-14122	females	_	
80-25	14122-14123	.	_	

#Text=TMS distance methods
#Text=The data from the individual level analysis (‘hotspots’) were used to determine the scalp locations (EEG 10-10 coordinates) that were closest to the greatest number of points significantly activated by drug cues.
81-1	14124-14127	TMS	_	
81-2	14128-14136	distance	_	
81-3	14137-14144	methods	_	
81-4	14145-14148	The	_	
81-5	14149-14153	data	_	
81-6	14154-14158	from	_	
81-7	14159-14162	the	_	
81-8	14163-14173	individual	_	
81-9	14174-14179	level	_	
81-10	14180-14188	analysis	_	
81-11	14189-14190	(	_	
81-12	14190-14191	‘	_	
81-13	14191-14199	hotspots	_	
81-14	14199-14200	’	_	
81-15	14200-14201	)	_	
81-16	14202-14206	were	_	
81-17	14207-14211	used	_	
81-18	14212-14214	to	_	
81-19	14215-14224	determine	_	
81-20	14225-14228	the	_	
81-21	14229-14234	scalp	_	
81-22	14235-14244	locations	_	
81-23	14245-14246	(	_	
81-24	14246-14249	EEG	_	
81-25	14250-14252	10	_	
81-26	14252-14253	-	_	
81-27	14253-14255	10	_	
81-28	14256-14267	coordinates	_	
81-29	14267-14268	)	_	
81-30	14269-14273	that	_	
81-31	14274-14278	were	_	
81-32	14279-14286	closest	_	
81-33	14287-14289	to	_	
81-34	14290-14293	the	_	
81-35	14294-14302	greatest	_	
81-36	14303-14309	number	_	
81-37	14310-14312	of	_	
81-38	14313-14319	points	_	
81-39	14320-14333	significantly	_	
81-40	14334-14343	activated	_	
81-41	14344-14346	by	_	
81-42	14347-14351	drug	_	
81-43	14352-14356	cues	_	
81-44	14356-14357	.	_	

#Text=The Euclidean distances from each hotspot to EEG 10-10 system coordinates were calculated.
82-1	14358-14361	The	_	
82-2	14362-14371	Euclidean	_	
82-3	14372-14381	distances	_	
82-4	14382-14386	from	_	
82-5	14387-14391	each	_	
82-6	14392-14399	hotspot	_	
82-7	14400-14402	to	_	
82-8	14403-14406	EEG	_	
82-9	14407-14409	10	_	
82-10	14409-14410	-	_	
82-11	14410-14412	10	_	
82-12	14413-14419	system	_	
82-13	14420-14431	coordinates	_	
82-14	14432-14436	were	_	
82-15	14437-14447	calculated	_	
82-16	14447-14448	.	_	

#Text=We evaluated the percentage of hotspots that would be reached at several distances (2–5 cm) given that the penetration characteristics of rTMS are dependent on coil size.
83-1	14449-14451	We	_	
83-2	14452-14461	evaluated	_	
83-3	14462-14465	the	_	
83-4	14466-14476	percentage	_	
83-5	14477-14479	of	_	
83-6	14480-14488	hotspots	_	
83-7	14489-14493	that	_	
83-8	14494-14499	would	_	
83-9	14500-14502	be	_	
83-10	14503-14510	reached	_	
83-11	14511-14513	at	_	
83-12	14514-14521	several	_	
83-13	14522-14531	distances	_	
83-14	14532-14533	(	_	
83-15	14533-14534	2	_	
83-16	14534-14535	–	_	
83-17	14535-14536	5	_	
83-18	14537-14539	cm	_	
83-19	14539-14540	)	_	
83-20	14541-14546	given	_	
83-21	14547-14551	that	_	
83-22	14552-14555	the	_	
83-23	14556-14567	penetration	_	
83-24	14568-14583	characteristics	_	
83-25	14584-14586	of	_	
83-26	14587-14591	rTMS	_	
83-27	14592-14595	are	_	
83-28	14596-14605	dependent	_	
83-29	14606-14608	on	_	
83-30	14609-14613	coil	_	
83-31	14614-14618	size	_	
83-32	14618-14619	.	_	

#Text=Analyses were done for the full complement of participants as well as subgroups defined by the individual’s drug of choice.
84-1	14620-14628	Analyses	_	
84-2	14629-14633	were	_	
84-3	14634-14638	done	_	
84-4	14639-14642	for	_	
84-5	14643-14646	the	_	
84-6	14647-14651	full	_	
84-7	14652-14662	complement	_	
84-8	14663-14665	of	_	
84-9	14666-14678	participants	_	
84-10	14679-14681	as	_	
84-11	14682-14686	well	_	
84-12	14687-14689	as	_	
84-13	14690-14699	subgroups	_	
84-14	14700-14707	defined	_	
84-15	14708-14710	by	_	
84-16	14711-14714	the	_	
84-17	14715-14725	individual	_	
84-18	14725-14726	’	_	
84-19	14726-14727	s	_	
84-20	14728-14732	drug	_	
84-21	14733-14735	of	_	
84-22	14736-14742	choice	_	
84-23	14742-14743	.	_	

#Text=Code availability
#Text=Computing programs and customized scripts used in this experiment are all available for free to the community by contacting the corresponding author.
85-1	14744-14748	Code	_	
85-2	14749-14761	availability	_	
85-3	14762-14771	Computing	_	
85-4	14772-14780	programs	_	
85-5	14781-14784	and	_	
85-6	14785-14795	customized	_	
85-7	14796-14803	scripts	_	
85-8	14804-14808	used	_	
85-9	14809-14811	in	_	
85-10	14812-14816	this	_	
85-11	14817-14827	experiment	_	
85-12	14828-14831	are	_	
85-13	14832-14835	all	_	
85-14	14836-14845	available	_	
85-15	14846-14849	for	_	
85-16	14850-14854	free	_	
85-17	14855-14857	to	_	
85-18	14858-14861	the	_	
85-19	14862-14871	community	_	
85-20	14872-14874	by	_	
85-21	14875-14885	contacting	_	
85-22	14886-14889	the	_	
85-23	14890-14903	corresponding	_	
85-24	14904-14910	author	_	
85-25	14910-14911	.	_	

#Text=Results
#Text=Brain reactivity to drug/alcohol versus neutral cues—group level analysis
#Text=Variability in peak location of craving.
86-1	14912-14919	Results	_	
86-2	14920-14925	Brain	_	
86-3	14926-14936	reactivity	_	
86-4	14937-14939	to	_	
86-5	14940-14944	drug	_	
86-6	14944-14945	/	_	
86-7	14945-14952	alcohol	_	
86-8	14953-14959	versus	_	
86-9	14960-14967	neutral	_	
86-10	14968-14978	cues—group	_	
86-11	14979-14984	level	_	
86-12	14985-14993	analysis	_	
86-13	14994-15005	Variability	_	
86-14	15006-15008	in	_	
86-15	15009-15013	peak	_	
86-16	15014-15022	location	_	
86-17	15023-15025	of	_	
86-18	15026-15033	craving	_	
86-19	15033-15034	.	_	

#Text=Locations of peak activity during a cue-induced craving task were isolated for the total sample (a) and independently for each drug-dependent group (b).
87-1	15035-15044	Locations	_	
87-2	15045-15047	of	_	
87-3	15048-15052	peak	_	
87-4	15053-15061	activity	_	
87-5	15062-15068	during	_	
87-6	15069-15070	a	_	
87-7	15071-15082	cue-induced	_	
87-8	15083-15090	craving	_	
87-9	15091-15095	task	_	
87-10	15096-15100	were	_	
87-11	15101-15109	isolated	_	
87-12	15110-15113	for	_	
87-13	15114-15117	the	_	
87-14	15118-15123	total	_	
87-15	15124-15130	sample	_	
87-16	15131-15132	(	_	
87-17	15132-15133	a	_	
87-18	15133-15134	)	_	
87-19	15135-15138	and	_	
87-20	15139-15152	independently	_	
87-21	15153-15156	for	_	
87-22	15157-15161	each	_	
87-23	15162-15176	drug-dependent	_	
87-24	15177-15182	group	_	
87-25	15183-15184	(	_	
87-26	15184-15185	b	_	
87-27	15185-15186	)	_	
87-28	15186-15187	.	_	

#Text=Considered as a group (a), individuals had significantly more activity in the medial prefrontal cortex, and left (BA 44) and right (BA 8) lateral prefrontal cortices during drug–related pictures relative to neutral pictures.
88-1	15188-15198	Considered	_	
88-2	15199-15201	as	_	
88-3	15202-15203	a	_	
88-4	15204-15209	group	_	
88-5	15210-15211	(	_	
88-6	15211-15212	a	_	
88-7	15212-15213	)	_	
88-8	15213-15214	,	_	
88-9	15215-15226	individuals	_	
88-10	15227-15230	had	_	
88-11	15231-15244	significantly	_	
88-12	15245-15249	more	_	
88-13	15250-15258	activity	_	
88-14	15259-15261	in	_	
88-15	15262-15265	the	_	
88-16	15266-15272	medial	_	
88-17	15273-15283	prefrontal	_	
88-18	15284-15290	cortex	_	
88-19	15290-15291	,	_	
88-20	15292-15295	and	_	
88-21	15296-15300	left	_	
88-22	15301-15302	(	_	
88-23	15302-15304	BA	_	
88-24	15305-15307	44	_	
88-25	15307-15308	)	_	
88-26	15309-15312	and	_	
88-27	15313-15318	right	_	
88-28	15319-15320	(	_	
88-29	15320-15322	BA	_	
88-30	15323-15324	8	_	
88-31	15324-15325	)	_	
88-32	15326-15333	lateral	_	
88-33	15334-15344	prefrontal	_	
88-34	15345-15353	cortices	_	
88-35	15354-15360	during	_	
88-36	15361-15373	drug–related	_	
88-37	15374-15382	pictures	_	
88-38	15383-15391	relative	_	
88-39	15392-15394	to	_	
88-40	15395-15402	neutral	_	
88-41	15403-15411	pictures	_	
88-42	15411-15412	.	_	

#Text=When each group was assessed independently (b) the location of peak activity was concentrated in the the medial prefrontal cortex/cingulate gyrus for the alcohol users (blue) and nicotine users (green).
89-1	15413-15417	When	_	
89-2	15418-15422	each	_	
89-3	15423-15428	group	_	
89-4	15429-15432	was	_	
89-5	15433-15441	assessed	_	
89-6	15442-15455	independently	_	
89-7	15456-15457	(	_	
89-8	15457-15458	b	_	
89-9	15458-15459	)	_	
89-10	15460-15463	the	_	
89-11	15464-15472	location	_	
89-12	15473-15475	of	_	
89-13	15476-15480	peak	_	
89-14	15481-15489	activity	_	
89-15	15490-15493	was	_	
89-16	15494-15506	concentrated	_	
89-17	15507-15509	in	_	
89-18	15510-15513	the	_	
89-19	15514-15517	the	_	
89-20	15518-15524	medial	_	
89-21	15525-15535	prefrontal	_	
89-22	15536-15542	cortex	_	
89-23	15542-15543	/	_	
89-24	15543-15552	cingulate	_	
89-25	15553-15558	gyrus	_	
89-26	15559-15562	for	_	
89-27	15563-15566	the	_	
89-28	15567-15574	alcohol	_	
89-29	15575-15580	users	_	
89-30	15581-15582	(	_	
89-31	15582-15586	blue	_	
89-32	15586-15587	)	_	
89-33	15588-15591	and	_	
89-34	15592-15600	nicotine	_	
89-35	15601-15606	users	_	
89-36	15607-15608	(	_	
89-37	15608-15613	green	_	
89-38	15613-15614	)	_	
89-39	15614-15615	.	_	

#Text=The cocaine users had significant clusters of activity in all three of the areas activated in the total group map (BA10, left BA 44, right BA8; red)
#Text=Drug class specific topography.
90-1	15616-15619	The	_	
90-2	15620-15627	cocaine	_	
90-3	15628-15633	users	_	
90-4	15634-15637	had	_	
90-5	15638-15649	significant	_	
90-6	15650-15658	clusters	_	
90-7	15659-15661	of	_	
90-8	15662-15670	activity	_	
90-9	15671-15673	in	_	
90-10	15674-15677	all	_	
90-11	15678-15683	three	_	
90-12	15684-15686	of	_	
90-13	15687-15690	the	_	
90-14	15691-15696	areas	_	
90-15	15697-15706	activated	_	
90-16	15707-15709	in	_	
90-17	15710-15713	the	_	
90-18	15714-15719	total	_	
90-19	15720-15725	group	_	
90-20	15726-15729	map	_	
90-21	15730-15731	(	_	
90-22	15731-15735	BA10	_	
90-23	15735-15736	,	_	
90-24	15737-15741	left	_	
90-25	15742-15744	BA	_	
90-26	15745-15747	44	_	
90-27	15747-15748	,	_	
90-28	15749-15754	right	_	
90-29	15755-15758	BA8	_	
90-30	15758-15759	;	_	
90-31	15760-15763	red	_	
90-32	15763-15764	)	_	
90-33	15765-15769	Drug	_	
90-34	15770-15775	class	_	
90-35	15776-15784	specific	_	
90-36	15785-15795	topography	_	
90-37	15795-15796	.	_	

#Text=In cocaine users (n = 55; red), cocaine cues led to significantly more BOLD signal than neutral cues in 3 clusters: (1) Left Brodmann 6 (−39,5,29; 1332, p < 0.000), (2) Right Brodmann 44 (45,8,29; 1057; p < 0.000), (3) Left Brodmann 10, ventral MPFC (−6,56, −10; 165, p = 0.039).
91-1	15797-15799	In	_	
91-2	15800-15807	cocaine	_	
91-3	15808-15813	users	_	
91-4	15814-15815	(	_	
91-5	15815-15816	n	_	
91-6	15817-15818	=	_	
91-7	15819-15821	55	_	
91-8	15821-15822	;	_	
91-9	15823-15826	red	_	
91-10	15826-15827	)	_	
91-11	15827-15828	,	_	
91-12	15829-15836	cocaine	_	
91-13	15837-15841	cues	_	
91-14	15842-15845	led	_	
91-15	15846-15848	to	_	
91-16	15849-15862	significantly	_	
91-17	15863-15867	more	_	
91-18	15868-15872	BOLD	_	
91-19	15873-15879	signal	_	
91-20	15880-15884	than	_	
91-21	15885-15892	neutral	_	
91-22	15893-15897	cues	_	
91-23	15898-15900	in	_	
91-24	15901-15902	3	_	
91-25	15903-15911	clusters	_	
91-26	15911-15912	:	_	
91-27	15913-15914	(	_	
91-28	15914-15915	1	_	
91-29	15915-15916	)	_	
91-30	15917-15921	Left	_	
91-31	15922-15930	Brodmann	_	
91-32	15931-15932	6	_	
91-33	15933-15934	(	_	
91-34	15934-15935	−	_	
91-35	15935-15942	39,5,29	_	
91-36	15942-15943	;	_	
91-37	15944-15948	1332	_	
91-38	15948-15949	,	_	
91-39	15950-15951	p	_	
91-40	15952-15953	<	_	
91-41	15954-15959	0.000	_	
91-42	15959-15960	)	_	
91-43	15960-15961	,	_	
91-44	15962-15963	(	_	
91-45	15963-15964	2	_	
91-46	15964-15965	)	_	
91-47	15966-15971	Right	_	
91-48	15972-15980	Brodmann	_	
91-49	15981-15983	44	_	
91-50	15984-15985	(	_	
91-51	15985-15992	45,8,29	_	
91-52	15992-15993	;	_	
91-53	15994-15998	1057	_	
91-54	15998-15999	;	_	
91-55	16000-16001	p	_	
91-56	16002-16003	<	_	
91-57	16004-16009	0.000	_	
91-58	16009-16010	)	_	
91-59	16010-16011	,	_	
91-60	16012-16013	(	_	
91-61	16013-16014	3	_	
91-62	16014-16015	)	_	
91-63	16016-16020	Left	_	
91-64	16021-16029	Brodmann	_	
91-65	16030-16032	10	_	
91-66	16032-16033	,	_	
91-67	16034-16041	ventral	_	
91-68	16042-16046	MPFC	_	
91-69	16047-16048	(	_	
91-70	16048-16049	−	_	
91-71	16049-16053	6,56	_	
91-72	16053-16054	,	_	
91-73	16055-16056	−	_	
91-74	16056-16058	10	_	
91-75	16058-16059	;	_	
91-76	16060-16063	165	_	
91-77	16063-16064	,	_	
91-78	16065-16066	p	_	
91-79	16067-16068	=	_	
91-80	16069-16074	0.039	_	
91-81	16074-16075	)	_	
91-82	16075-16076	.	_	

#Text=In alcohol users (n = 53; blue) alcohol cues led to a significant increase in BOLD signal relative to neutral cues in 1 cluster: Brodmann 24/32, anterior cingulate (1,32,8; 300; p = 0.008) which extended through the MPFC.
92-1	16077-16079	In	_	
92-2	16080-16087	alcohol	_	
92-3	16088-16093	users	_	
92-4	16094-16095	(	_	
92-5	16095-16096	n	_	
92-6	16097-16098	=	_	
92-7	16099-16101	53	_	
92-8	16101-16102	;	_	
92-9	16103-16107	blue	_	
92-10	16107-16108	)	_	
92-11	16109-16116	alcohol	_	
92-12	16117-16121	cues	_	
92-13	16122-16125	led	_	
92-14	16126-16128	to	_	
92-15	16129-16130	a	_	
92-16	16131-16142	significant	_	
92-17	16143-16151	increase	_	
92-18	16152-16154	in	_	
92-19	16155-16159	BOLD	_	
92-20	16160-16166	signal	_	
92-21	16167-16175	relative	_	
92-22	16176-16178	to	_	
92-23	16179-16186	neutral	_	
92-24	16187-16191	cues	_	
92-25	16192-16194	in	_	
92-26	16195-16196	1	_	
92-27	16197-16204	cluster	_	
92-28	16204-16205	:	_	
92-29	16206-16214	Brodmann	_	
92-30	16215-16217	24	_	
92-31	16217-16218	/	_	
92-32	16218-16220	32	_	
92-33	16220-16221	,	_	
92-34	16222-16230	anterior	_	
92-35	16231-16240	cingulate	_	
92-36	16241-16242	(	_	
92-37	16242-16248	1,32,8	_	
92-38	16248-16249	;	_	
92-39	16250-16253	300	_	
92-40	16253-16254	;	_	
92-41	16255-16256	p	_	
92-42	16257-16258	=	_	
92-43	16259-16264	0.008	_	
92-44	16264-16265	)	_	
92-45	16266-16271	which	_	
92-46	16272-16280	extended	_	
92-47	16281-16288	through	_	
92-48	16289-16292	the	_	
92-49	16293-16297	MPFC	_	
92-50	16297-16298	.	_	

#Text=In cigarette smokers (n = 48; green), cigarette cues also led to an increase in BOLD signal in 1 cluster: (1) Brodmann 24/32, anterior cingulate (−1, 36, 10; 210; p = 0.048) which extended through the MPFC.
93-1	16299-16301	In	_	
93-2	16302-16311	cigarette	_	
93-3	16312-16319	smokers	_	
93-4	16320-16321	(	_	
93-5	16321-16322	n	_	
93-6	16323-16324	=	_	
93-7	16325-16327	48	_	
93-8	16327-16328	;	_	
93-9	16329-16334	green	_	
93-10	16334-16335	)	_	
93-11	16335-16336	,	_	
93-12	16337-16346	cigarette	_	
93-13	16347-16351	cues	_	
93-14	16352-16356	also	_	
93-15	16357-16360	led	_	
93-16	16361-16363	to	_	
93-17	16364-16366	an	_	
93-18	16367-16375	increase	_	
93-19	16376-16378	in	_	
93-20	16379-16383	BOLD	_	
93-21	16384-16390	signal	_	
93-22	16391-16393	in	_	
93-23	16394-16395	1	_	
93-24	16396-16403	cluster	_	
93-25	16403-16404	:	_	
93-26	16405-16406	(	_	
93-27	16406-16407	1	_	
93-28	16407-16408	)	_	
93-29	16409-16417	Brodmann	_	
93-30	16418-16420	24	_	
93-31	16420-16421	/	_	
93-32	16421-16423	32	_	
93-33	16423-16424	,	_	
93-34	16425-16433	anterior	_	
93-35	16434-16443	cingulate	_	
93-36	16444-16445	(	_	
93-37	16445-16446	−	_	
93-38	16446-16447	1	_	
93-39	16447-16448	,	_	
93-40	16449-16451	36	_	
93-41	16451-16452	,	_	
93-42	16453-16455	10	_	
93-43	16455-16456	;	_	
93-44	16457-16460	210	_	
93-45	16460-16461	;	_	
93-46	16462-16463	p	_	
93-47	16464-16465	=	_	
93-48	16466-16471	0.048	_	
93-49	16471-16472	)	_	
93-50	16473-16478	which	_	
93-51	16479-16487	extended	_	
93-52	16488-16495	through	_	
93-53	16496-16499	the	_	
93-54	16500-16504	MPFC	_	
93-55	16504-16505	.	_	

#Text=The areas not included in the data analysis are shown with stippled boxes
#Text=In the population as a whole (n = 156), drug/alcohol cues led to a significant increase in BOLD signal relative to neutral cues in three distinct clusters, given as Brodmann Area, name (xyz coordinate; cluster size, uncorrected p-value): (1) Left Brodmann 10, medial prefrontal cortex (−3, 53, −4; 1253; p < 0.001), (2) Right Brodmann 44, inferior frontal gyrus/pars opercularis (51,11,26; 216; p = 0.02), 3) Left BA 8, premotor cortex (−18, 41, 41; 147; p = 0.05) (Fig. 1a).
94-1	16506-16509	The	_	
94-2	16510-16515	areas	_	
94-3	16516-16519	not	_	
94-4	16520-16528	included	_	
94-5	16529-16531	in	_	
94-6	16532-16535	the	_	
94-7	16536-16540	data	_	
94-8	16541-16549	analysis	_	
94-9	16550-16553	are	_	
94-10	16554-16559	shown	_	
94-11	16560-16564	with	_	
94-12	16565-16573	stippled	_	
94-13	16574-16579	boxes	_	
94-14	16580-16582	In	_	
94-15	16583-16586	the	_	
94-16	16587-16597	population	_	
94-17	16598-16600	as	_	
94-18	16601-16602	a	_	
94-19	16603-16608	whole	_	
94-20	16609-16610	(	_	
94-21	16610-16611	n	_	
94-22	16612-16613	=	_	
94-23	16614-16617	156	_	
94-24	16617-16618	)	_	
94-25	16618-16619	,	_	
94-26	16620-16624	drug	_	
94-27	16624-16625	/	_	
94-28	16625-16632	alcohol	_	
94-29	16633-16637	cues	_	
94-30	16638-16641	led	_	
94-31	16642-16644	to	_	
94-32	16645-16646	a	_	
94-33	16647-16658	significant	_	
94-34	16659-16667	increase	_	
94-35	16668-16670	in	_	
94-36	16671-16675	BOLD	_	
94-37	16676-16682	signal	_	
94-38	16683-16691	relative	_	
94-39	16692-16694	to	_	
94-40	16695-16702	neutral	_	
94-41	16703-16707	cues	_	
94-42	16708-16710	in	_	
94-43	16711-16716	three	_	
94-44	16717-16725	distinct	_	
94-45	16726-16734	clusters	_	
94-46	16734-16735	,	_	
94-47	16736-16741	given	_	
94-48	16742-16744	as	_	
94-49	16745-16753	Brodmann	_	
94-50	16754-16758	Area	_	
94-51	16758-16759	,	_	
94-52	16760-16764	name	_	
94-53	16765-16766	(	_	
94-54	16766-16769	xyz	_	
94-55	16770-16780	coordinate	_	
94-56	16780-16781	;	_	
94-57	16782-16789	cluster	_	
94-58	16790-16794	size	_	
94-59	16794-16795	,	_	
94-60	16796-16807	uncorrected	_	
94-61	16808-16815	p-value	_	
94-62	16815-16816	)	_	
94-63	16816-16817	:	_	
94-64	16818-16819	(	_	
94-65	16819-16820	1	_	
94-66	16820-16821	)	_	
94-67	16822-16826	Left	_	
94-68	16827-16835	Brodmann	_	
94-69	16836-16838	10	_	
94-70	16838-16839	,	_	
94-71	16840-16846	medial	_	
94-72	16847-16857	prefrontal	_	
94-73	16858-16864	cortex	_	
94-74	16865-16866	(	_	
94-75	16866-16867	−	_	
94-76	16867-16868	3	_	
94-77	16868-16869	,	_	
94-78	16870-16872	53	_	
94-79	16872-16873	,	_	
94-80	16874-16875	−	_	
94-81	16875-16876	4	_	
94-82	16876-16877	;	_	
94-83	16878-16882	1253	_	
94-84	16882-16883	;	_	
94-85	16884-16885	p	_	
94-86	16886-16887	<	_	
94-87	16888-16893	0.001	_	
94-88	16893-16894	)	_	
94-89	16894-16895	,	_	
94-90	16896-16897	(	_	
94-91	16897-16898	2	_	
94-92	16898-16899	)	_	
94-93	16900-16905	Right	_	
94-94	16906-16914	Brodmann	_	
94-95	16915-16917	44	_	
94-96	16917-16918	,	_	
94-97	16919-16927	inferior	_	
94-98	16928-16935	frontal	_	
94-99	16936-16941	gyrus	_	
94-100	16941-16942	/	_	
94-101	16942-16946	pars	_	
94-102	16947-16958	opercularis	_	
94-103	16959-16960	(	_	
94-104	16960-16968	51,11,26	_	
94-105	16968-16969	;	_	
94-106	16970-16973	216	_	
94-107	16973-16974	;	_	
94-108	16975-16976	p	_	
94-109	16977-16978	=	_	
94-110	16979-16983	0.02	_	
94-111	16983-16984	)	_	
94-112	16984-16985	,	_	
94-113	16986-16987	3	_	
94-114	16987-16988	)	_	
94-115	16989-16993	Left	_	
94-116	16994-16996	BA	_	
94-117	16997-16998	8	_	
94-118	16998-16999	,	_	
94-119	17000-17008	premotor	_	
94-120	17009-17015	cortex	_	
94-121	17016-17017	(	_	
94-122	17017-17018	−	_	
94-123	17018-17020	18	_	
94-124	17020-17021	,	_	
94-125	17022-17024	41	_	
94-126	17024-17025	,	_	
94-127	17026-17028	41	_	
94-128	17028-17029	;	_	
94-129	17030-17033	147	_	
94-130	17033-17034	;	_	
94-131	17035-17036	p	_	
94-132	17037-17038	=	_	
94-133	17039-17043	0.05	_	
94-134	17043-17044	)	_	
94-135	17045-17046	(	_	
94-136	17046-17049	Fig	_	
94-137	17049-17050	.	_	
94-138	17051-17053	1a	_	
94-139	17053-17054	)	_	
94-140	17054-17055	.	_	

#Text=In alcohol users (n = 53) alcohol cues led to a significant increase in BOLD signal relative to neutral cues in 1 cluster: Brodmann 24/32, anterior cingulate (1,32,8; 300; p = 0.008) which extended through the MPFC.
95-1	17056-17058	In	_	
95-2	17059-17066	alcohol	_	
95-3	17067-17072	users	_	
95-4	17073-17074	(	_	
95-5	17074-17075	n	_	
95-6	17076-17077	=	_	
95-7	17078-17080	53	_	
95-8	17080-17081	)	_	
95-9	17082-17089	alcohol	_	
95-10	17090-17094	cues	_	
95-11	17095-17098	led	_	
95-12	17099-17101	to	_	
95-13	17102-17103	a	_	
95-14	17104-17115	significant	_	
95-15	17116-17124	increase	_	
95-16	17125-17127	in	_	
95-17	17128-17132	BOLD	_	
95-18	17133-17139	signal	_	
95-19	17140-17148	relative	_	
95-20	17149-17151	to	_	
95-21	17152-17159	neutral	_	
95-22	17160-17164	cues	_	
95-23	17165-17167	in	_	
95-24	17168-17169	1	_	
95-25	17170-17177	cluster	_	
95-26	17177-17178	:	_	
95-27	17179-17187	Brodmann	_	
95-28	17188-17190	24	_	
95-29	17190-17191	/	_	
95-30	17191-17193	32	_	
95-31	17193-17194	,	_	
95-32	17195-17203	anterior	_	
95-33	17204-17213	cingulate	_	
95-34	17214-17215	(	_	
95-35	17215-17221	1,32,8	_	
95-36	17221-17222	;	_	
95-37	17223-17226	300	_	
95-38	17226-17227	;	_	
95-39	17228-17229	p	_	
95-40	17230-17231	=	_	
95-41	17232-17237	0.008	_	
95-42	17237-17238	)	_	
95-43	17239-17244	which	_	
95-44	17245-17253	extended	_	
95-45	17254-17261	through	_	
95-46	17262-17265	the	_	
95-47	17266-17270	MPFC	_	
95-48	17270-17271	.	_	

#Text=In cigarette smokers, cigarette cues also led to an increase in BOLD signal in 1 cluster: (1) Brodmann 24/32, anterior cingulate (−1, 36, 10; 210; p = 0.048) which extended through the MPFC.
96-1	17272-17274	In	_	
96-2	17275-17284	cigarette	_	
96-3	17285-17292	smokers	_	
96-4	17292-17293	,	_	
96-5	17294-17303	cigarette	_	
96-6	17304-17308	cues	_	
96-7	17309-17313	also	_	
96-8	17314-17317	led	_	
96-9	17318-17320	to	_	
96-10	17321-17323	an	_	
96-11	17324-17332	increase	_	
96-12	17333-17335	in	_	
96-13	17336-17340	BOLD	_	
96-14	17341-17347	signal	_	
96-15	17348-17350	in	_	
96-16	17351-17352	1	_	
96-17	17353-17360	cluster	_	
96-18	17360-17361	:	_	
96-19	17362-17363	(	_	
96-20	17363-17364	1	_	
96-21	17364-17365	)	_	
96-22	17366-17374	Brodmann	_	
96-23	17375-17377	24	_	
96-24	17377-17378	/	_	
96-25	17378-17380	32	_	
96-26	17380-17381	,	_	
96-27	17382-17390	anterior	_	
96-28	17391-17400	cingulate	_	
96-29	17401-17402	(	_	
96-30	17402-17403	−	_	
96-31	17403-17404	1	_	
96-32	17404-17405	,	_	
96-33	17406-17408	36	_	
96-34	17408-17409	,	_	
96-35	17410-17412	10	_	
96-36	17412-17413	;	_	
96-37	17414-17417	210	_	
96-38	17417-17418	;	_	
96-39	17419-17420	p	_	
96-40	17421-17422	=	_	
96-41	17423-17428	0.048	_	
96-42	17428-17429	)	_	
96-43	17430-17435	which	_	
96-44	17436-17444	extended	_	
96-45	17445-17452	through	_	
96-46	17453-17456	the	_	
96-47	17457-17461	MPFC	_	
96-48	17461-17462	.	_	

#Text=In cocaine users, cocaine cues led to significantly more BOLD signal than neutral cues in 3 clusters: (1) Left Brodmann 6 (−39,5,29; 1332, p < 0.001), (2) Right Brodmann 44 (45,8,29; 1057; p < 0.000), (3) Left Brodmann 10, ventral MPFC (−6,56, −10; 165, p = 0.039) (Fig. 1b).
97-1	17463-17465	In	_	
97-2	17466-17473	cocaine	_	
97-3	17474-17479	users	_	
97-4	17479-17480	,	_	
97-5	17481-17488	cocaine	_	
97-6	17489-17493	cues	_	
97-7	17494-17497	led	_	
97-8	17498-17500	to	_	
97-9	17501-17514	significantly	_	
97-10	17515-17519	more	_	
97-11	17520-17524	BOLD	_	
97-12	17525-17531	signal	_	
97-13	17532-17536	than	_	
97-14	17537-17544	neutral	_	
97-15	17545-17549	cues	_	
97-16	17550-17552	in	_	
97-17	17553-17554	3	_	
97-18	17555-17563	clusters	_	
97-19	17563-17564	:	_	
97-20	17565-17566	(	_	
97-21	17566-17567	1	_	
97-22	17567-17568	)	_	
97-23	17569-17573	Left	_	
97-24	17574-17582	Brodmann	_	
97-25	17583-17584	6	_	
97-26	17585-17586	(	_	
97-27	17586-17587	−	_	
97-28	17587-17594	39,5,29	_	
97-29	17594-17595	;	_	
97-30	17596-17600	1332	_	
97-31	17600-17601	,	_	
97-32	17602-17603	p	_	
97-33	17604-17605	<	_	
97-34	17606-17611	0.001	_	
97-35	17611-17612	)	_	
97-36	17612-17613	,	_	
97-37	17614-17615	(	_	
97-38	17615-17616	2	_	
97-39	17616-17617	)	_	
97-40	17618-17623	Right	_	
97-41	17624-17632	Brodmann	_	
97-42	17633-17635	44	_	
97-43	17636-17637	(	_	
97-44	17637-17644	45,8,29	_	
97-45	17644-17645	;	_	
97-46	17646-17650	1057	_	
97-47	17650-17651	;	_	
97-48	17652-17653	p	_	
97-49	17654-17655	<	_	
97-50	17656-17661	0.000	_	
97-51	17661-17662	)	_	
97-52	17662-17663	,	_	
97-53	17664-17665	(	_	
97-54	17665-17666	3	_	
97-55	17666-17667	)	_	
97-56	17668-17672	Left	_	
97-57	17673-17681	Brodmann	_	
97-58	17682-17684	10	_	
97-59	17684-17685	,	_	
97-60	17686-17693	ventral	_	
97-61	17694-17698	MPFC	_	
97-62	17699-17700	(	_	
97-63	17700-17701	−	_	
97-64	17701-17705	6,56	_	
97-65	17705-17706	,	_	
97-66	17707-17708	−	_	
97-67	17708-17710	10	_	
97-68	17710-17711	;	_	
97-69	17712-17715	165	_	
97-70	17715-17716	,	_	
97-71	17717-17718	p	_	
97-72	17719-17720	=	_	
97-73	17721-17726	0.039	_	
97-74	17726-17727	)	_	
97-75	17728-17729	(	_	
97-76	17729-17732	Fig	_	
97-77	17732-17733	.	_	
97-78	17734-17736	1b	_	
97-79	17736-17737	)	_	
97-80	17737-17738	.	_	

#Text=A more comprehensive view of the spatial topography is displayed in Fig. 2 and the whole brain data is displayed in Supplementary Figure S1 (all 156 individuals) and Figure S2 (individuals divided by substance dependence group).
98-1	17739-17740	A	_	
98-2	17741-17745	more	_	
98-3	17746-17759	comprehensive	_	
98-4	17760-17764	view	_	
98-5	17765-17767	of	_	
98-6	17768-17771	the	_	
98-7	17772-17779	spatial	_	
98-8	17780-17790	topography	_	
98-9	17791-17793	is	_	
98-10	17794-17803	displayed	_	
98-11	17804-17806	in	_	
98-12	17807-17810	Fig	_	
98-13	17810-17811	.	_	
98-14	17812-17813	2	_	
98-15	17814-17817	and	_	
98-16	17818-17821	the	_	
98-17	17822-17827	whole	_	
98-18	17828-17833	brain	_	
98-19	17834-17838	data	_	
98-20	17839-17841	is	_	
98-21	17842-17851	displayed	_	
98-22	17852-17854	in	_	
98-23	17855-17868	Supplementary	_	
98-24	17869-17875	Figure	_	
98-25	17876-17878	S1	_	
98-26	17879-17880	(	_	
98-27	17880-17883	all	_	
98-28	17884-17887	156	_	
98-29	17888-17899	individuals	_	
98-30	17899-17900	)	_	
98-31	17901-17904	and	_	
98-32	17905-17911	Figure	_	
98-33	17912-17914	S2	_	
98-34	17915-17916	(	_	
98-35	17916-17927	individuals	_	
98-36	17928-17935	divided	_	
98-37	17936-17938	by	_	
98-38	17939-17948	substance	_	
98-39	17949-17959	dependence	_	
98-40	17960-17965	group	_	
98-41	17965-17966	)	_	
98-42	17966-17967	.	_	

#Text=Brain reactivity to drug/alcohol versus neutral cues—individual level analysis
#Text=Cluster analysis of peak craving locations. a Silhouette plot of the optimal hotspot clustering solution.
99-1	17968-17973	Brain	_	
99-2	17974-17984	reactivity	_	
99-3	17985-17987	to	_	
99-4	17988-17992	drug	_	
99-5	17992-17993	/	_	
99-6	17993-18000	alcohol	_	
99-7	18001-18007	versus	_	
99-8	18008-18015	neutral	_	
99-9	18016-18031	cues—individual	_	
99-10	18032-18037	level	_	
99-11	18038-18046	analysis	_	
99-12	18047-18054	Cluster	_	
99-13	18055-18063	analysis	_	
99-14	18064-18066	of	_	
99-15	18067-18071	peak	_	
99-16	18072-18079	craving	_	
99-17	18080-18089	locations	_	
99-18	18089-18090	.	_	
99-19	18091-18092	a	_	
99-20	18093-18103	Silhouette	_	
99-21	18104-18108	plot	_	
99-22	18109-18111	of	_	
99-23	18112-18115	the	_	
99-24	18116-18123	optimal	_	
99-25	18124-18131	hotspot	_	
99-26	18132-18142	clustering	_	
99-27	18143-18151	solution	_	
99-28	18151-18152	.	_	

#Text=Spatial dispersion of the hotspots were characterized via k-means clustering (MATLAB, k + + algorithm cross-checked with R; 1000 repeats, random seeding, 1–10 clusters evaluated).
100-1	18153-18160	Spatial	_	
100-2	18161-18171	dispersion	_	
100-3	18172-18174	of	_	
100-4	18175-18178	the	_	
100-5	18179-18187	hotspots	_	
100-6	18188-18192	were	_	
100-7	18193-18206	characterized	_	
100-8	18207-18210	via	_	
100-9	18211-18218	k-means	_	
100-10	18219-18229	clustering	_	
100-11	18230-18231	(	_	
100-12	18231-18237	MATLAB	_	
100-13	18237-18238	,	_	
100-14	18239-18240	k	_	
100-15	18241-18242	+	_	
100-16	18243-18244	+	_	
100-17	18245-18254	algorithm	_	
100-18	18255-18268	cross-checked	_	
100-19	18269-18273	with	_	
100-20	18274-18275	R	_	
100-21	18275-18276	;	_	
100-22	18277-18281	1000	_	
100-23	18282-18289	repeats	_	
100-24	18289-18290	,	_	
100-25	18291-18297	random	_	
100-26	18298-18305	seeding	_	
100-27	18305-18306	,	_	
100-28	18307-18308	1	_	
100-29	18308-18309	–	_	
100-30	18309-18311	10	_	
100-31	18312-18320	clusters	_	
100-32	18321-18330	evaluated	_	
100-33	18330-18331	)	_	
100-34	18331-18332	.	_	

#Text=K-means clustering for the full complement of hotspots revealed an optimal solution at 3 clusters (MNI Coordinates (x,y,z): 30, 18, 41; −40, 24, 25; 7, 50, 4).
101-1	18333-18340	K-means	_	
101-2	18341-18351	clustering	_	
101-3	18352-18355	for	_	
101-4	18356-18359	the	_	
101-5	18360-18364	full	_	
101-6	18365-18375	complement	_	
101-7	18376-18378	of	_	
101-8	18379-18387	hotspots	_	
101-9	18388-18396	revealed	_	
101-10	18397-18399	an	_	
101-11	18400-18407	optimal	_	
101-12	18408-18416	solution	_	
101-13	18417-18419	at	_	
101-14	18420-18421	3	_	
101-15	18422-18430	clusters	_	
101-16	18431-18432	(	_	
101-17	18432-18435	MNI	_	
101-18	18436-18447	Coordinates	_	
101-19	18448-18449	(	_	
101-20	18449-18450	x	_	
101-21	18450-18451	,	_	
101-22	18451-18452	y	_	
101-23	18452-18453	,	_	
101-24	18453-18454	z	_	
101-25	18454-18455	)	_	
101-26	18455-18456	:	_	
101-27	18457-18459	30	_	
101-28	18459-18460	,	_	
101-29	18461-18463	18	_	
101-30	18463-18464	,	_	
101-31	18465-18467	41	_	
101-32	18467-18468	;	_	
101-33	18469-18470	−	_	
101-34	18470-18472	40	_	
101-35	18472-18473	,	_	
101-36	18474-18476	24	_	
101-37	18476-18477	,	_	
101-38	18478-18480	25	_	
101-39	18480-18481	;	_	
101-40	18482-18483	7	_	
101-41	18483-18484	,	_	
101-42	18485-18487	50	_	
101-43	18487-18488	,	_	
101-44	18489-18490	4	_	
101-45	18490-18491	)	_	
101-46	18491-18492	.	_	

#Text=The cocaine, alcohol, and tobacco subgroups were evenly distributed through the clusters. b When considered as full complement, the EEG 10-10 coordinate FPz had the largest percentage of hotspots within a 2 cm (11%, red), 3 cm (19%, yellow), 4 cm (32%, green), and 5 cm (49%, blue) distance.
102-1	18493-18496	The	_	
102-2	18497-18504	cocaine	_	
102-3	18504-18505	,	_	
102-4	18506-18513	alcohol	_	
102-5	18513-18514	,	_	
102-6	18515-18518	and	_	
102-7	18519-18526	tobacco	_	
102-8	18527-18536	subgroups	_	
102-9	18537-18541	were	_	
102-10	18542-18548	evenly	_	
102-11	18549-18560	distributed	_	
102-12	18561-18568	through	_	
102-13	18569-18572	the	_	
102-14	18573-18581	clusters	_	
102-15	18581-18582	.	_	
102-16	18583-18584	b	_	
102-17	18585-18589	When	_	
102-18	18590-18600	considered	_	
102-19	18601-18603	as	_	
102-20	18604-18608	full	_	
102-21	18609-18619	complement	_	
102-22	18619-18620	,	_	
102-23	18621-18624	the	_	
102-24	18625-18628	EEG	_	
102-25	18629-18631	10	_	
102-26	18631-18632	-	_	
102-27	18632-18634	10	_	
102-28	18635-18645	coordinate	_	
102-29	18646-18649	FPz	_	
102-30	18650-18653	had	_	
102-31	18654-18657	the	_	
102-32	18658-18665	largest	_	
102-33	18666-18676	percentage	_	
102-34	18677-18679	of	_	
102-35	18680-18688	hotspots	_	
102-36	18689-18695	within	_	
102-37	18696-18697	a	_	
102-38	18698-18699	2	_	
102-39	18700-18702	cm	_	
102-40	18703-18704	(	_	
102-41	18704-18707	11%	_	
102-42	18707-18708	,	_	
102-43	18709-18712	red	_	
102-44	18712-18713	)	_	
102-45	18713-18714	,	_	
102-46	18715-18716	3	_	
102-47	18717-18719	cm	_	
102-48	18720-18721	(	_	
102-49	18721-18724	19%	_	
102-50	18724-18725	,	_	
102-51	18726-18732	yellow	_	
102-52	18732-18733	)	_	
102-53	18733-18734	,	_	
102-54	18735-18736	4	_	
102-55	18737-18739	cm	_	
102-56	18740-18741	(	_	
102-57	18741-18744	32%	_	
102-58	18744-18745	,	_	
102-59	18746-18751	green	_	
102-60	18751-18752	)	_	
102-61	18752-18753	,	_	
102-62	18754-18757	and	_	
102-63	18758-18759	5	_	
102-64	18760-18762	cm	_	
102-65	18763-18764	(	_	
102-66	18764-18767	49%	_	
102-67	18767-18768	,	_	
102-68	18769-18773	blue	_	
102-69	18773-18774	)	_	
102-70	18775-18783	distance	_	
102-71	18783-18784	.	_	

#Text=This was also the best location for alcohol cues and smoking cues.
103-1	18785-18789	This	_	
103-2	18790-18793	was	_	
103-3	18794-18798	also	_	
103-4	18799-18802	the	_	
103-5	18803-18807	best	_	
103-6	18808-18816	location	_	
103-7	18817-18820	for	_	
103-8	18821-18828	alcohol	_	
103-9	18829-18833	cues	_	
103-10	18834-18837	and	_	
103-11	18838-18845	smoking	_	
103-12	18846-18850	cues	_	
103-13	18850-18851	.	_	

#Text=The hotspots associated with cocaine cue-reactivity were closest to AF3, AF7, and AF5 (Red C)
#Text=Of the entire sample of 156 individuals, 103 had at least 1 cluster which was significantly elevated to the drug versus neutral cues (41 of 55 cocaine (74%), 32 of 53 alcohol (60%), 30 of 48 nicotine (63%)).
104-1	18852-18855	The	_	
104-2	18856-18864	hotspots	_	
104-3	18865-18875	associated	_	
104-4	18876-18880	with	_	
104-5	18881-18888	cocaine	_	
104-6	18889-18903	cue-reactivity	_	
104-7	18904-18908	were	_	
104-8	18909-18916	closest	_	
104-9	18917-18919	to	_	
104-10	18920-18923	AF3	_	
104-11	18923-18924	,	_	
104-12	18925-18928	AF7	_	
104-13	18928-18929	,	_	
104-14	18930-18933	and	_	
104-15	18934-18937	AF5	_	
104-16	18938-18939	(	_	
104-17	18939-18942	Red	_	
104-18	18943-18944	C	_	
104-19	18944-18945	)	_	
104-20	18946-18948	Of	_	
104-21	18949-18952	the	_	
104-22	18953-18959	entire	_	
104-23	18960-18966	sample	_	
104-24	18967-18969	of	_	
104-25	18970-18973	156	_	
104-26	18974-18985	individuals	_	
104-27	18985-18986	,	_	
104-28	18987-18990	103	_	
104-29	18991-18994	had	_	
104-30	18995-18997	at	_	
104-31	18998-19003	least	_	
104-32	19004-19005	1	_	
104-33	19006-19013	cluster	_	
104-34	19014-19019	which	_	
104-35	19020-19023	was	_	
104-36	19024-19037	significantly	_	
104-37	19038-19046	elevated	_	
104-38	19047-19049	to	_	
104-39	19050-19053	the	_	
104-40	19054-19058	drug	_	
104-41	19059-19065	versus	_	
104-42	19066-19073	neutral	_	
104-43	19074-19078	cues	_	
104-44	19079-19080	(	_	
104-45	19080-19082	41	_	
104-46	19083-19085	of	_	
104-47	19086-19088	55	_	
104-48	19089-19096	cocaine	_	
104-49	19097-19098	(	_	
104-50	19098-19101	74%	_	
104-51	19101-19102	)	_	
104-52	19102-19103	,	_	
104-53	19104-19106	32	_	
104-54	19107-19109	of	_	
104-55	19110-19112	53	_	
104-56	19113-19120	alcohol	_	
104-57	19121-19122	(	_	
104-58	19122-19125	60%	_	
104-59	19125-19126	)	_	
104-60	19126-19127	,	_	
104-61	19128-19130	30	_	
104-62	19131-19133	of	_	
104-63	19134-19136	48	_	
104-64	19137-19145	nicotine	_	
104-65	19146-19147	(	_	
104-66	19147-19150	63%	_	
104-67	19150-19151	)	_	
104-68	19151-19152	)	_	
104-69	19152-19153	.	_	

#Text=K-means clustering for the full complement of points revealed an optimal solution at 3 clusters which were centered in the MPFC/ACC cortex (Cluster 1: MNI coordinates: 7, 50, 4; 40% of points, Brodmann Areas (BA): 10, 32), left lateral prefrontal cortex (Cluster 2: MNI: −40, 24, 25; 32% of the points, BA: 9,44,45, 46) and right lateral prefrontal cortex (Cluster 3: MNI: 30,18,41; 28% of the points, BA: 8,9) (Fig. 3a).
105-1	19154-19161	K-means	_	
105-2	19162-19172	clustering	_	
105-3	19173-19176	for	_	
105-4	19177-19180	the	_	
105-5	19181-19185	full	_	
105-6	19186-19196	complement	_	
105-7	19197-19199	of	_	
105-8	19200-19206	points	_	
105-9	19207-19215	revealed	_	
105-10	19216-19218	an	_	
105-11	19219-19226	optimal	_	
105-12	19227-19235	solution	_	
105-13	19236-19238	at	_	
105-14	19239-19240	3	_	
105-15	19241-19249	clusters	_	
105-16	19250-19255	which	_	
105-17	19256-19260	were	_	
105-18	19261-19269	centered	_	
105-19	19270-19272	in	_	
105-20	19273-19276	the	_	
105-21	19277-19281	MPFC	_	
105-22	19281-19282	/	_	
105-23	19282-19285	ACC	_	
105-24	19286-19292	cortex	_	
105-25	19293-19294	(	_	
105-26	19294-19301	Cluster	_	
105-27	19302-19303	1	_	
105-28	19303-19304	:	_	
105-29	19305-19308	MNI	_	
105-30	19309-19320	coordinates	_	
105-31	19320-19321	:	_	
105-32	19322-19323	7	_	
105-33	19323-19324	,	_	
105-34	19325-19327	50	_	
105-35	19327-19328	,	_	
105-36	19329-19330	4	_	
105-37	19330-19331	;	_	
105-38	19332-19335	40%	_	
105-39	19336-19338	of	_	
105-40	19339-19345	points	_	
105-41	19345-19346	,	_	
105-42	19347-19355	Brodmann	_	
105-43	19356-19361	Areas	_	
105-44	19362-19363	(	_	
105-45	19363-19365	BA	_	
105-46	19365-19366	)	_	
105-47	19366-19367	:	_	
105-48	19368-19370	10	_	
105-49	19370-19371	,	_	
105-50	19372-19374	32	_	
105-51	19374-19375	)	_	
105-52	19375-19376	,	_	
105-53	19377-19381	left	_	
105-54	19382-19389	lateral	_	
105-55	19390-19400	prefrontal	_	
105-56	19401-19407	cortex	_	
105-57	19408-19409	(	_	
105-58	19409-19416	Cluster	_	
105-59	19417-19418	2	_	
105-60	19418-19419	:	_	
105-61	19420-19423	MNI	_	
105-62	19423-19424	:	_	
105-63	19425-19426	−	_	
105-64	19426-19428	40	_	
105-65	19428-19429	,	_	
105-66	19430-19432	24	_	
105-67	19432-19433	,	_	
105-68	19434-19436	25	_	
105-69	19436-19437	;	_	
105-70	19438-19441	32%	_	
105-71	19442-19444	of	_	
105-72	19445-19448	the	_	
105-73	19449-19455	points	_	
105-74	19455-19456	,	_	
105-75	19457-19459	BA	_	
105-76	19459-19460	:	_	
105-77	19461-19468	9,44,45	_	
105-78	19468-19469	,	_	
105-79	19470-19472	46	_	
105-80	19472-19473	)	_	
105-81	19474-19477	and	_	
105-82	19478-19483	right	_	
105-83	19484-19491	lateral	_	
105-84	19492-19502	prefrontal	_	
105-85	19503-19509	cortex	_	
105-86	19510-19511	(	_	
105-87	19511-19518	Cluster	_	
105-88	19519-19520	3	_	
105-89	19520-19521	:	_	
105-90	19522-19525	MNI	_	
105-91	19525-19526	:	_	
105-92	19527-19535	30,18,41	_	
105-93	19535-19536	;	_	
105-94	19537-19540	28%	_	
105-95	19541-19543	of	_	
105-96	19544-19547	the	_	
105-97	19548-19554	points	_	
105-98	19554-19555	,	_	
105-99	19556-19558	BA	_	
105-100	19558-19559	:	_	
105-101	19560-19563	8,9	_	
105-102	19563-19564	)	_	
105-103	19565-19566	(	_	
105-104	19566-19569	Fig	_	
105-105	19569-19570	.	_	
105-106	19571-19573	3a	_	
105-107	19573-19574	)	_	
105-108	19574-19575	.	_	

#Text=There was no difference in the likelihood of classification based on drug-cue reactivity group (cocaine, alcohol, cigarettes).
106-1	19576-19581	There	_	
106-2	19582-19585	was	_	
106-3	19586-19588	no	_	
106-4	19589-19599	difference	_	
106-5	19600-19602	in	_	
106-6	19603-19606	the	_	
106-7	19607-19617	likelihood	_	
106-8	19618-19620	of	_	
106-9	19621-19635	classification	_	
106-10	19636-19641	based	_	
106-11	19642-19644	on	_	
106-12	19645-19653	drug-cue	_	
106-13	19654-19664	reactivity	_	
106-14	19665-19670	group	_	
106-15	19671-19672	(	_	
106-16	19672-19679	cocaine	_	
106-17	19679-19680	,	_	
106-18	19681-19688	alcohol	_	
106-19	19688-19689	,	_	
106-20	19690-19700	cigarettes	_	
106-21	19700-19701	)	_	
106-22	19701-19702	.	_	

#Text=There was also no difference in the distribution of males and females between the clusters.
107-1	19703-19708	There	_	
107-2	19709-19712	was	_	
107-3	19713-19717	also	_	
107-4	19718-19720	no	_	
107-5	19721-19731	difference	_	
107-6	19732-19734	in	_	
107-7	19735-19738	the	_	
107-8	19739-19751	distribution	_	
107-9	19752-19754	of	_	
107-10	19755-19760	males	_	
107-11	19761-19764	and	_	
107-12	19765-19772	females	_	
107-13	19773-19780	between	_	
107-14	19781-19784	the	_	
107-15	19785-19793	clusters	_	
107-16	19793-19794	.	_	

#Text=TMS distance results
#Text=The percentage of hotspots within several fixed distances from the closed cortical location as defined by the Euclidean projections of EEG 10-10 coordinate system (a system often used for targeting neuromodulation strategies)
#Text=\t2 cm\t3 cm\t4 cm\t5 cm\t \tAll hotspots\t11% FPz\t19% FPz\t32% FPz/FP2\t49% FPz\t \tSubgroups:\t \tCocaine cues\t17% AF7/F5\t27% AF7/F5\t34% AF3/F5\t53% AF3\t \tAlcohol cues\t17% FPz\t21%FPz/FP1\t36% FPz/FP2\t50% FP2/AF3\t \tTobacco cues\t10% FPz\t28% FPz\t45% FPz/FP2\t60% FPz\t \t
#Text=For the group as a whole, the EEG 10-10 coordinate FPz had the largest percentage of hotspots within a 2 cm (11%), 3 cm (19%), 4 cm (32%), and 5 cm (49%) distance.
108-1	19795-19798	TMS	_	
108-2	19799-19807	distance	_	
108-3	19808-19815	results	_	
108-4	19816-19819	The	_	
108-5	19820-19830	percentage	_	
108-6	19831-19833	of	_	
108-7	19834-19842	hotspots	_	
108-8	19843-19849	within	_	
108-9	19850-19857	several	_	
108-10	19858-19863	fixed	_	
108-11	19864-19873	distances	_	
108-12	19874-19878	from	_	
108-13	19879-19882	the	_	
108-14	19883-19889	closed	_	
108-15	19890-19898	cortical	_	
108-16	19899-19907	location	_	
108-17	19908-19910	as	_	
108-18	19911-19918	defined	_	
108-19	19919-19921	by	_	
108-20	19922-19925	the	_	
108-21	19926-19935	Euclidean	_	
108-22	19936-19947	projections	_	
108-23	19948-19950	of	_	
108-24	19951-19954	EEG	_	
108-25	19955-19957	10	_	
108-26	19957-19958	-	_	
108-27	19958-19960	10	_	
108-28	19961-19971	coordinate	_	
108-29	19972-19978	system	_	
108-30	19979-19980	(	_	
108-31	19980-19981	a	_	
108-32	19982-19988	system	_	
108-33	19989-19994	often	_	
108-34	19995-19999	used	_	
108-35	20000-20003	for	_	
108-36	20004-20013	targeting	_	
108-37	20014-20029	neuromodulation	_	
108-38	20030-20040	strategies	_	
108-39	20040-20041	)	_	
108-40	20043-20044	2	_	
108-41	20045-20047	cm	_	
108-42	20048-20049	3	_	
108-43	20050-20052	cm	_	
108-44	20053-20054	4	_	
108-45	20055-20057	cm	_	
108-46	20058-20059	5	_	
108-47	20060-20062	cm	_	
108-48	20065-20068	All	_	
108-49	20069-20077	hotspots	_	
108-50	20078-20081	11%	_	
108-51	20082-20085	FPz	_	
108-52	20086-20089	19%	_	
108-53	20090-20093	FPz	_	
108-54	20094-20097	32%	_	
108-55	20098-20101	FPz	_	
108-56	20101-20102	/	_	
108-57	20102-20105	FP2	_	
108-58	20106-20109	49%	_	
108-59	20110-20113	FPz	_	
108-60	20116-20125	Subgroups	_	
108-61	20125-20126	:	_	
108-62	20129-20136	Cocaine	_	
108-63	20137-20141	cues	_	
108-64	20142-20145	17%	_	
108-65	20146-20149	AF7	_	
108-66	20149-20150	/	_	
108-67	20150-20152	F5	_	
108-68	20153-20156	27%	_	
108-69	20157-20160	AF7	_	
108-70	20160-20161	/	_	
108-71	20161-20163	F5	_	
108-72	20164-20167	34%	_	
108-73	20168-20171	AF3	_	
108-74	20171-20172	/	_	
108-75	20172-20174	F5	_	
108-76	20175-20178	53%	_	
108-77	20179-20182	AF3	_	
108-78	20185-20192	Alcohol	_	
108-79	20193-20197	cues	_	
108-80	20198-20201	17%	_	
108-81	20202-20205	FPz	_	
108-82	20206-20209	21%	_	
108-83	20209-20212	FPz	_	
108-84	20212-20213	/	_	
108-85	20213-20216	FP1	_	
108-86	20217-20220	36%	_	
108-87	20221-20224	FPz	_	
108-88	20224-20225	/	_	
108-89	20225-20228	FP2	_	
108-90	20229-20232	50%	_	
108-91	20233-20236	FP2	_	
108-92	20236-20237	/	_	
108-93	20237-20240	AF3	_	
108-94	20243-20250	Tobacco	_	
108-95	20251-20255	cues	_	
108-96	20256-20259	10%	_	
108-97	20260-20263	FPz	_	
108-98	20264-20267	28%	_	
108-99	20268-20271	FPz	_	
108-100	20272-20275	45%	_	
108-101	20276-20279	FPz	_	
108-102	20279-20280	/	_	
108-103	20280-20283	FP2	_	
108-104	20284-20287	60%	_	
108-105	20288-20291	FPz	_	
108-106	20295-20298	For	_	
108-107	20299-20302	the	_	
108-108	20303-20308	group	_	
108-109	20309-20311	as	_	
108-110	20312-20313	a	_	
108-111	20314-20319	whole	_	
108-112	20319-20320	,	_	
108-113	20321-20324	the	_	
108-114	20325-20328	EEG	_	
108-115	20329-20331	10	_	
108-116	20331-20332	-	_	
108-117	20332-20334	10	_	
108-118	20335-20345	coordinate	_	
108-119	20346-20349	FPz	_	
108-120	20350-20353	had	_	
108-121	20354-20357	the	_	
108-122	20358-20365	largest	_	
108-123	20366-20376	percentage	_	
108-124	20377-20379	of	_	
108-125	20380-20388	hotspots	_	
108-126	20389-20395	within	_	
108-127	20396-20397	a	_	
108-128	20398-20399	2	_	
108-129	20400-20402	cm	_	
108-130	20403-20404	(	_	
108-131	20404-20407	11%	_	
108-132	20407-20408	)	_	
108-133	20408-20409	,	_	
108-134	20410-20411	3	_	
108-135	20412-20414	cm	_	
108-136	20415-20416	(	_	
108-137	20416-20419	19%	_	
108-138	20419-20420	)	_	
108-139	20420-20421	,	_	
108-140	20422-20423	4	_	
108-141	20424-20426	cm	_	
108-142	20427-20428	(	_	
108-143	20428-20431	32%	_	
108-144	20431-20432	)	_	
108-145	20432-20433	,	_	
108-146	20434-20437	and	_	
108-147	20438-20439	5	_	
108-148	20440-20442	cm	_	
108-149	20443-20444	(	_	
108-150	20444-20447	49%	_	
108-151	20447-20448	)	_	
108-152	20449-20457	distance	_	
108-153	20457-20458	.	_	

#Text=FPz was also the best location for alcohol cues and smoking cues (Fig. 3b, Table 2).
109-1	20459-20462	FPz	_	
109-2	20463-20466	was	_	
109-3	20467-20471	also	_	
109-4	20472-20475	the	_	
109-5	20476-20480	best	_	
109-6	20481-20489	location	_	
109-7	20490-20493	for	_	
109-8	20494-20501	alcohol	_	
109-9	20502-20506	cues	_	
109-10	20507-20510	and	_	
109-11	20511-20518	smoking	_	
109-12	20519-20523	cues	_	
109-13	20524-20525	(	_	
109-14	20525-20528	Fig	_	
109-15	20528-20529	.	_	
109-16	20530-20532	3b	_	
109-17	20532-20533	,	_	
109-18	20534-20539	Table	_	
109-19	20540-20541	2	_	
109-20	20541-20542	)	_	
109-21	20542-20543	.	_	

#Text=The hotspots associated with cocaine cue-reactivity were closest to AF3, AF7, and AF5 likely driven by points in the anterior insula.
110-1	20544-20547	The	_	
110-2	20548-20556	hotspots	_	
110-3	20557-20567	associated	_	
110-4	20568-20572	with	_	
110-5	20573-20580	cocaine	_	
110-6	20581-20595	cue-reactivity	_	
110-7	20596-20600	were	_	
110-8	20601-20608	closest	_	
110-9	20609-20611	to	_	
110-10	20612-20615	AF3	_	
110-11	20615-20616	,	_	
110-12	20617-20620	AF7	_	
110-13	20620-20621	,	_	
110-14	20622-20625	and	_	
110-15	20626-20629	AF5	_	
110-16	20630-20636	likely	_	
110-17	20637-20643	driven	_	
110-18	20644-20646	by	_	
110-19	20647-20653	points	_	
110-20	20654-20656	in	_	
110-21	20657-20660	the	_	
110-22	20661-20669	anterior	_	
110-23	20670-20676	insula	_	
110-24	20676-20677	.	_	

#Text=Discussion
#Text=Understanding the common or divergent patterns of drug-cue reactivity in multiple substance dependent populations is particularly important given the growing momentum for developing a neural-circuit based treatment (e.g. rTMS) for cue-evoked craving in cocaine, alcohol, and nicotine dependent individuals.
111-1	20678-20688	Discussion	_	
111-2	20689-20702	Understanding	_	
111-3	20703-20706	the	_	
111-4	20707-20713	common	_	
111-5	20714-20716	or	_	
111-6	20717-20726	divergent	_	
111-7	20727-20735	patterns	_	
111-8	20736-20738	of	_	
111-9	20739-20747	drug-cue	_	
111-10	20748-20758	reactivity	_	
111-11	20759-20761	in	_	
111-12	20762-20770	multiple	_	
111-13	20771-20780	substance	_	
111-14	20781-20790	dependent	_	
111-15	20791-20802	populations	_	
111-16	20803-20805	is	_	
111-17	20806-20818	particularly	_	
111-18	20819-20828	important	_	
111-19	20829-20834	given	_	
111-20	20835-20838	the	_	
111-21	20839-20846	growing	_	
111-22	20847-20855	momentum	_	
111-23	20856-20859	for	_	
111-24	20860-20870	developing	_	
111-25	20871-20872	a	_	
111-26	20873-20887	neural-circuit	_	
111-27	20888-20893	based	_	
111-28	20894-20903	treatment	_	
111-29	20904-20905	(	_	
111-30	20905-20908	e.g	_	
111-31	20908-20909	.	_	
111-32	20910-20914	rTMS	_	
111-33	20914-20915	)	_	
111-34	20916-20919	for	_	
111-35	20920-20930	cue-evoked	_	
111-36	20931-20938	craving	_	
111-37	20939-20941	in	_	
111-38	20942-20949	cocaine	_	
111-39	20949-20950	,	_	
111-40	20951-20958	alcohol	_	
111-41	20958-20959	,	_	
111-42	20960-20963	and	_	
111-43	20964-20972	nicotine	_	
111-44	20973-20982	dependent	_	
111-45	20983-20994	individuals	_	
111-46	20994-20995	.	_	

#Text=Here, for the first time, we report the results of a large prospective evaluation of cue-reactivity in substance dependent individuals that all performed a standardized drug-cue reactivity paradigm with the stimuli tailored to their drug of choice.
112-1	20996-21000	Here	_	
112-2	21000-21001	,	_	
112-3	21002-21005	for	_	
112-4	21006-21009	the	_	
112-5	21010-21015	first	_	
112-6	21016-21020	time	_	
112-7	21020-21021	,	_	
112-8	21022-21024	we	_	
112-9	21025-21031	report	_	
112-10	21032-21035	the	_	
112-11	21036-21043	results	_	
112-12	21044-21046	of	_	
112-13	21047-21048	a	_	
112-14	21049-21054	large	_	
112-15	21055-21066	prospective	_	
112-16	21067-21077	evaluation	_	
112-17	21078-21080	of	_	
112-18	21081-21095	cue-reactivity	_	
112-19	21096-21098	in	_	
112-20	21099-21108	substance	_	
112-21	21109-21118	dependent	_	
112-22	21119-21130	individuals	_	
112-23	21131-21135	that	_	
112-24	21136-21139	all	_	
112-25	21140-21149	performed	_	
112-26	21150-21151	a	_	
112-27	21152-21164	standardized	_	
112-28	21165-21173	drug-cue	_	
112-29	21174-21184	reactivity	_	
112-30	21185-21193	paradigm	_	
112-31	21194-21198	with	_	
112-32	21199-21202	the	_	
112-33	21203-21210	stimuli	_	
112-34	21211-21219	tailored	_	
112-35	21220-21222	to	_	
112-36	21223-21228	their	_	
112-37	21229-21233	drug	_	
112-38	21234-21236	of	_	
112-39	21237-21243	choice	_	
112-40	21243-21244	.	_	

#Text=This study demonstrates that the medial prefrontal & anterior cingulate cortex are the most consistently activated clusters in cocaine cue-reactivity, alcohol cue-reactivity, and cigarette cue-reactivity – with the left and right lateral prefrontal cortices including the insula also being consistent concentrations of cue-evoked activity.
113-1	21245-21249	This	_	
113-2	21250-21255	study	_	
113-3	21256-21268	demonstrates	_	
113-4	21269-21273	that	_	
113-5	21274-21277	the	_	
113-6	21278-21284	medial	_	
113-7	21285-21295	prefrontal	_	
113-8	21296-21297	&	_	
113-9	21298-21306	anterior	_	
113-10	21307-21316	cingulate	_	
113-11	21317-21323	cortex	_	
113-12	21324-21327	are	_	
113-13	21328-21331	the	_	
113-14	21332-21336	most	_	
113-15	21337-21349	consistently	_	
113-16	21350-21359	activated	_	
113-17	21360-21368	clusters	_	
113-18	21369-21371	in	_	
113-19	21372-21379	cocaine	_	
113-20	21380-21394	cue-reactivity	_	
113-21	21394-21395	,	_	
113-22	21396-21403	alcohol	_	
113-23	21404-21418	cue-reactivity	_	
113-24	21418-21419	,	_	
113-25	21420-21423	and	_	
113-26	21424-21433	cigarette	_	
113-27	21434-21448	cue-reactivity	_	
113-28	21449-21450	–	_	
113-29	21451-21455	with	_	
113-30	21456-21459	the	_	
113-31	21460-21464	left	_	
113-32	21465-21468	and	_	
113-33	21469-21474	right	_	
113-34	21475-21482	lateral	_	
113-35	21483-21493	prefrontal	_	
113-36	21494-21502	cortices	_	
113-37	21503-21512	including	_	
113-38	21513-21516	the	_	
113-39	21517-21523	insula	_	
113-40	21524-21528	also	_	
113-41	21529-21534	being	_	
113-42	21535-21545	consistent	_	
113-43	21546-21560	concentrations	_	
113-44	21561-21563	of	_	
113-45	21564-21574	cue-evoked	_	
113-46	21575-21583	activity	_	
113-47	21583-21584	.	_	

#Text=When placed in the context of their proximity to putative cortical locations for brain stimulation delivery, the frontal pole is the closest location to the highest percentage of points in all populations.
114-1	21585-21589	When	_	
114-2	21590-21596	placed	_	
114-3	21597-21599	in	_	
114-4	21600-21603	the	_	
114-5	21604-21611	context	_	
114-6	21612-21614	of	_	
114-7	21615-21620	their	_	
114-8	21621-21630	proximity	_	
114-9	21631-21633	to	_	
114-10	21634-21642	putative	_	
114-11	21643-21651	cortical	_	
114-12	21652-21661	locations	_	
114-13	21662-21665	for	_	
114-14	21666-21671	brain	_	
114-15	21672-21683	stimulation	_	
114-16	21684-21692	delivery	_	
114-17	21692-21693	,	_	
114-18	21694-21697	the	_	
114-19	21698-21705	frontal	_	
114-20	21706-21710	pole	_	
114-21	21711-21713	is	_	
114-22	21714-21717	the	_	
114-23	21718-21725	closest	_	
114-24	21726-21734	location	_	
114-25	21735-21737	to	_	
114-26	21738-21741	the	_	
114-27	21742-21749	highest	_	
114-28	21750-21760	percentage	_	
114-29	21761-21763	of	_	
114-30	21764-21770	points	_	
114-31	21771-21773	in	_	
114-32	21774-21777	all	_	
114-33	21778-21789	populations	_	
114-34	21789-21790	.	_	

#Text=Transdiagnostic consistency of the MPFC/ACC as an area evoked by drug-cues
#Text=Data from this investigation suggest that when targeting craving circuitry with brain stimulation protocols there are at least three locations that could be targeted.
115-1	21791-21806	Transdiagnostic	_	
115-2	21807-21818	consistency	_	
115-3	21819-21821	of	_	
115-4	21822-21825	the	_	
115-5	21826-21830	MPFC	_	
115-6	21830-21831	/	_	
115-7	21831-21834	ACC	_	
115-8	21835-21837	as	_	
115-9	21838-21840	an	_	
115-10	21841-21845	area	_	
115-11	21846-21852	evoked	_	
115-12	21853-21855	by	_	
115-13	21856-21865	drug-cues	_	
115-14	21866-21870	Data	_	
115-15	21871-21875	from	_	
115-16	21876-21880	this	_	
115-17	21881-21894	investigation	_	
115-18	21895-21902	suggest	_	
115-19	21903-21907	that	_	
115-20	21908-21912	when	_	
115-21	21913-21922	targeting	_	
115-22	21923-21930	craving	_	
115-23	21931-21940	circuitry	_	
115-24	21941-21945	with	_	
115-25	21946-21951	brain	_	
115-26	21952-21963	stimulation	_	
115-27	21964-21973	protocols	_	
115-28	21974-21979	there	_	
115-29	21980-21983	are	_	
115-30	21984-21986	at	_	
115-31	21987-21992	least	_	
115-32	21993-21998	three	_	
115-33	21999-22008	locations	_	
115-34	22009-22013	that	_	
115-35	22014-22019	could	_	
115-36	22020-22022	be	_	
115-37	22023-22031	targeted	_	
115-38	22031-22032	.	_	

#Text=The highest likelihood is the medial prefrontal cortex.
116-1	22033-22036	The	_	
116-2	22037-22044	highest	_	
116-3	22045-22055	likelihood	_	
116-4	22056-22058	is	_	
116-5	22059-22062	the	_	
116-6	22063-22069	medial	_	
116-7	22070-22080	prefrontal	_	
116-8	22081-22087	cortex	_	
116-9	22087-22088	.	_	

#Text=When all significant hot spots were included in the analysis, 40% of these were in this MPFC/ACC cluster.
117-1	22089-22093	When	_	
117-2	22094-22097	all	_	
117-3	22098-22109	significant	_	
117-4	22110-22113	hot	_	
117-5	22114-22119	spots	_	
117-6	22120-22124	were	_	
117-7	22125-22133	included	_	
117-8	22134-22136	in	_	
117-9	22137-22140	the	_	
117-10	22141-22149	analysis	_	
117-11	22149-22150	,	_	
117-12	22151-22154	40%	_	
117-13	22155-22157	of	_	
117-14	22158-22163	these	_	
117-15	22164-22168	were	_	
117-16	22169-22171	in	_	
117-17	22172-22176	this	_	
117-18	22177-22181	MPFC	_	
117-19	22181-22182	/	_	
117-20	22182-22185	ACC	_	
117-21	22186-22193	cluster	_	
117-22	22193-22194	.	_	

#Text=This high prevalence is consistent with prior studies in the field.
118-1	22195-22199	This	_	
118-2	22200-22204	high	_	
118-3	22205-22215	prevalence	_	
118-4	22216-22218	is	_	
118-5	22219-22229	consistent	_	
118-6	22230-22234	with	_	
118-7	22235-22240	prior	_	
118-8	22241-22248	studies	_	
118-9	22249-22251	in	_	
118-10	22252-22255	the	_	
118-11	22256-22261	field	_	
118-12	22261-22262	.	_	

#Text=A meta-analysis of alcohol users, for example, evaluated 28 alcohol cue-reactivity studies.
119-1	22263-22264	A	_	
119-2	22265-22278	meta-analysis	_	
119-3	22279-22281	of	_	
119-4	22282-22289	alcohol	_	
119-5	22290-22295	users	_	
119-6	22295-22296	,	_	
119-7	22297-22300	for	_	
119-8	22301-22308	example	_	
119-9	22308-22309	,	_	
119-10	22310-22319	evaluated	_	
119-11	22320-22322	28	_	
119-12	22323-22330	alcohol	_	
119-13	22331-22345	cue-reactivity	_	
119-14	22346-22353	studies	_	
119-15	22353-22354	.	_	

#Text=They demonstrated that among alcohol users alcohol cues consistently elicited activation in the ventral striatum, anterior cingulate and ventral medial prefrontal cortex.
120-1	22355-22359	They	_	
120-2	22360-22372	demonstrated	_	
120-3	22373-22377	that	_	
120-4	22378-22383	among	_	
120-5	22384-22391	alcohol	_	
120-6	22392-22397	users	_	
120-7	22398-22405	alcohol	_	
120-8	22406-22410	cues	_	
120-9	22411-22423	consistently	_	
120-10	22424-22432	elicited	_	
120-11	22433-22443	activation	_	
120-12	22444-22446	in	_	
120-13	22447-22450	the	_	
120-14	22451-22458	ventral	_	
120-15	22459-22467	striatum	_	
120-16	22467-22468	,	_	
120-17	22469-22477	anterior	_	
120-18	22478-22487	cingulate	_	
120-19	22488-22491	and	_	
120-20	22492-22499	ventral	_	
120-21	22500-22506	medial	_	
120-22	22507-22517	prefrontal	_	
120-23	22518-22524	cortex	_	
120-24	22524-22525	.	_	

#Text=A similar meta-analysis of smoking studies evaluated 11 smoking cue-reactivity studies.
121-1	22526-22527	A	_	
121-2	22528-22535	similar	_	
121-3	22536-22549	meta-analysis	_	
121-4	22550-22552	of	_	
121-5	22553-22560	smoking	_	
121-6	22561-22568	studies	_	
121-7	22569-22578	evaluated	_	
121-8	22579-22581	11	_	
121-9	22582-22589	smoking	_	
121-10	22590-22604	cue-reactivity	_	
121-11	22605-22612	studies	_	
121-12	22612-22613	.	_	

#Text=They found that smoking cues reliably evoke larger fMRI responses than neutral cues in the visual system (consistent with Hanlon et al.), precuneus (consistent with Courtney et al 2014), cingulate cortex, medial prefrontal cortex, insula, and the dorsal striatum.
122-1	22614-22618	They	_	
122-2	22619-22624	found	_	
122-3	22625-22629	that	_	
122-4	22630-22637	smoking	_	
122-5	22638-22642	cues	_	
122-6	22643-22651	reliably	_	
122-7	22652-22657	evoke	_	
122-8	22658-22664	larger	_	
122-9	22665-22669	fMRI	_	
122-10	22670-22679	responses	_	
122-11	22680-22684	than	_	
122-12	22685-22692	neutral	_	
122-13	22693-22697	cues	_	
122-14	22698-22700	in	_	
122-15	22701-22704	the	_	
122-16	22705-22711	visual	_	
122-17	22712-22718	system	_	
122-18	22719-22720	(	_	
122-19	22720-22730	consistent	_	
122-20	22731-22735	with	_	
122-21	22736-22742	Hanlon	_	
122-22	22743-22745	et	_	
122-23	22746-22748	al	_	
122-24	22748-22749	.	_	
122-25	22749-22750	)	_	
122-26	22750-22751	,	_	
122-27	22752-22761	precuneus	_	
122-28	22762-22763	(	_	
122-29	22763-22773	consistent	_	
122-30	22774-22778	with	_	
122-31	22779-22787	Courtney	_	
122-32	22788-22790	et	_	
122-33	22791-22793	al	_	
122-34	22794-22798	2014	_	
122-35	22798-22799	)	_	
122-36	22799-22800	,	_	
122-37	22801-22810	cingulate	_	
122-38	22811-22817	cortex	_	
122-39	22817-22818	,	_	
122-40	22819-22825	medial	_	
122-41	22826-22836	prefrontal	_	
122-42	22837-22843	cortex	_	
122-43	22843-22844	,	_	
122-44	22845-22851	insula	_	
122-45	22851-22852	,	_	
122-46	22853-22856	and	_	
122-47	22857-22860	the	_	
122-48	22861-22867	dorsal	_	
122-49	22868-22876	striatum	_	
122-50	22876-22877	.	_	

#Text=The first and only meta-analysis to evaluate common and divergent patterns of cue-reactivity across alcohol, smoking and cocaine users demonstrated that activity in the anterior cingulate cortex and striatum was the common feature across drug groups.
123-1	22878-22881	The	_	
123-2	22882-22887	first	_	
123-3	22888-22891	and	_	
123-4	22892-22896	only	_	
123-5	22897-22910	meta-analysis	_	
123-6	22911-22913	to	_	
123-7	22914-22922	evaluate	_	
123-8	22923-22929	common	_	
123-9	22930-22933	and	_	
123-10	22934-22943	divergent	_	
123-11	22944-22952	patterns	_	
123-12	22953-22955	of	_	
123-13	22956-22970	cue-reactivity	_	
123-14	22971-22977	across	_	
123-15	22978-22985	alcohol	_	
123-16	22985-22986	,	_	
123-17	22987-22994	smoking	_	
123-18	22995-22998	and	_	
123-19	22999-23006	cocaine	_	
123-20	23007-23012	users	_	
123-21	23013-23025	demonstrated	_	
123-22	23026-23030	that	_	
123-23	23031-23039	activity	_	
123-24	23040-23042	in	_	
123-25	23043-23046	the	_	
123-26	23047-23055	anterior	_	
123-27	23056-23065	cingulate	_	
123-28	23066-23072	cortex	_	
123-29	23073-23076	and	_	
123-30	23077-23085	striatum	_	
123-31	23086-23089	was	_	
123-32	23090-23093	the	_	
123-33	23094-23100	common	_	
123-34	23101-23108	feature	_	
123-35	23109-23115	across	_	
123-36	23116-23120	drug	_	
123-37	23121-23127	groups	_	
123-38	23127-23128	.	_	

#Text=The compatibility of the results from the present study with these previous large metanalyses are encouraging, as one of the challenges of meta-analyses is that the investigators often do not have access to the raw data.
124-1	23129-23132	The	_	
124-2	23133-23146	compatibility	_	
124-3	23147-23149	of	_	
124-4	23150-23153	the	_	
124-5	23154-23161	results	_	
124-6	23162-23166	from	_	
124-7	23167-23170	the	_	
124-8	23171-23178	present	_	
124-9	23179-23184	study	_	
124-10	23185-23189	with	_	
124-11	23190-23195	these	_	
124-12	23196-23204	previous	_	
124-13	23205-23210	large	_	
124-14	23211-23222	metanalyses	_	
124-15	23223-23226	are	_	
124-16	23227-23238	encouraging	_	
124-17	23238-23239	,	_	
124-18	23240-23242	as	_	
124-19	23243-23246	one	_	
124-20	23247-23249	of	_	
124-21	23250-23253	the	_	
124-22	23254-23264	challenges	_	
124-23	23265-23267	of	_	
124-24	23268-23281	meta-analyses	_	
124-25	23282-23284	is	_	
124-26	23285-23289	that	_	
124-27	23290-23293	the	_	
124-28	23294-23307	investigators	_	
124-29	23308-23313	often	_	
124-30	23314-23316	do	_	
124-31	23317-23320	not	_	
124-32	23321-23325	have	_	
124-33	23326-23332	access	_	
124-34	23333-23335	to	_	
124-35	23336-23339	the	_	
124-36	23340-23343	raw	_	
124-37	23344-23348	data	_	
124-38	23348-23349	.	_	

#Text=Consequently, they rely upon the details reported by the individual study authors (who typically use slightly different paradigms, MRI scanning protocols, statistical processing packages, etc).
125-1	23350-23362	Consequently	_	
125-2	23362-23363	,	_	
125-3	23364-23368	they	_	
125-4	23369-23373	rely	_	
125-5	23374-23378	upon	_	
125-6	23379-23382	the	_	
125-7	23383-23390	details	_	
125-8	23391-23399	reported	_	
125-9	23400-23402	by	_	
125-10	23403-23406	the	_	
125-11	23407-23417	individual	_	
125-12	23418-23423	study	_	
125-13	23424-23431	authors	_	
125-14	23432-23433	(	_	
125-15	23433-23436	who	_	
125-16	23437-23446	typically	_	
125-17	23447-23450	use	_	
125-18	23451-23459	slightly	_	
125-19	23460-23469	different	_	
125-20	23470-23479	paradigms	_	
125-21	23479-23480	,	_	
125-22	23481-23484	MRI	_	
125-23	23485-23493	scanning	_	
125-24	23494-23503	protocols	_	
125-25	23503-23504	,	_	
125-26	23505-23516	statistical	_	
125-27	23517-23527	processing	_	
125-28	23528-23536	packages	_	
125-29	23536-23537	,	_	
125-30	23538-23541	etc	_	
125-31	23541-23542	)	_	
125-32	23542-23543	.	_	

#Text=In the present study we demonstrate that in a large cohort of individuals that performed a standardized drug cue reactivity paradigm on a given MRI scanner, using the same preprocessing pipeline, and a task that differed only in the drug-cue, there was consistent activity in the medial prefrontal cortex.
126-1	23544-23546	In	_	
126-2	23547-23550	the	_	
126-3	23551-23558	present	_	
126-4	23559-23564	study	_	
126-5	23565-23567	we	_	
126-6	23568-23579	demonstrate	_	
126-7	23580-23584	that	_	
126-8	23585-23587	in	_	
126-9	23588-23589	a	_	
126-10	23590-23595	large	_	
126-11	23596-23602	cohort	_	
126-12	23603-23605	of	_	
126-13	23606-23617	individuals	_	
126-14	23618-23622	that	_	
126-15	23623-23632	performed	_	
126-16	23633-23634	a	_	
126-17	23635-23647	standardized	_	
126-18	23648-23652	drug	_	
126-19	23653-23656	cue	_	
126-20	23657-23667	reactivity	_	
126-21	23668-23676	paradigm	_	
126-22	23677-23679	on	_	
126-23	23680-23681	a	_	
126-24	23682-23687	given	_	
126-25	23688-23691	MRI	_	
126-26	23692-23699	scanner	_	
126-27	23699-23700	,	_	
126-28	23701-23706	using	_	
126-29	23707-23710	the	_	
126-30	23711-23715	same	_	
126-31	23716-23729	preprocessing	_	
126-32	23730-23738	pipeline	_	
126-33	23738-23739	,	_	
126-34	23740-23743	and	_	
126-35	23744-23745	a	_	
126-36	23746-23750	task	_	
126-37	23751-23755	that	_	
126-38	23756-23764	differed	_	
126-39	23765-23769	only	_	
126-40	23770-23772	in	_	
126-41	23773-23776	the	_	
126-42	23777-23785	drug-cue	_	
126-43	23785-23786	,	_	
126-44	23787-23792	there	_	
126-45	23793-23796	was	_	
126-46	23797-23807	consistent	_	
126-47	23808-23816	activity	_	
126-48	23817-23819	in	_	
126-49	23820-23823	the	_	
126-50	23824-23830	medial	_	
126-51	23831-23841	prefrontal	_	
126-52	23842-23848	cortex	_	
126-53	23848-23849	.	_	

#Text=This consistency furthers the notion that this is a transdiagnostic feature of the addiction phenotype, rather than a finding which is isolated to a specific drug using group.
127-1	23850-23854	This	_	
127-2	23855-23866	consistency	_	
127-3	23867-23875	furthers	_	
127-4	23876-23879	the	_	
127-5	23880-23886	notion	_	
127-6	23887-23891	that	_	
127-7	23892-23896	this	_	
127-8	23897-23899	is	_	
127-9	23900-23901	a	_	
127-10	23902-23917	transdiagnostic	_	
127-11	23918-23925	feature	_	
127-12	23926-23928	of	_	
127-13	23929-23932	the	_	
127-14	23933-23942	addiction	_	
127-15	23943-23952	phenotype	_	
127-16	23952-23953	,	_	
127-17	23954-23960	rather	_	
127-18	23961-23965	than	_	
127-19	23966-23967	a	_	
127-20	23968-23975	finding	_	
127-21	23976-23981	which	_	
127-22	23982-23984	is	_	
127-23	23985-23993	isolated	_	
127-24	23994-23996	to	_	
127-25	23997-23998	a	_	
127-26	23999-24007	specific	_	
127-27	24008-24012	drug	_	
127-28	24013-24018	using	_	
127-29	24019-24024	group	_	
127-30	24024-24025	.	_	

#Text=Consistent variability within each drug-cue reactivity group: left and right lateral prefrontal cortex
#Text=One of the most surprising results from this investigation was the remarkably consistent distribution that each of the drug using groups had into each of the clusters.
128-1	24026-24036	Consistent	_	
128-2	24037-24048	variability	_	
128-3	24049-24055	within	_	
128-4	24056-24060	each	_	
128-5	24061-24069	drug-cue	_	
128-6	24070-24080	reactivity	_	
128-7	24081-24086	group	_	
128-8	24086-24087	:	_	
128-9	24088-24092	left	_	
128-10	24093-24096	and	_	
128-11	24097-24102	right	_	
128-12	24103-24110	lateral	_	
128-13	24111-24121	prefrontal	_	
128-14	24122-24128	cortex	_	
128-15	24129-24132	One	_	
128-16	24133-24135	of	_	
128-17	24136-24139	the	_	
128-18	24140-24144	most	_	
128-19	24145-24155	surprising	_	
128-20	24156-24163	results	_	
128-21	24164-24168	from	_	
128-22	24169-24173	this	_	
128-23	24174-24187	investigation	_	
128-24	24188-24191	was	_	
128-25	24192-24195	the	_	
128-26	24196-24206	remarkably	_	
128-27	24207-24217	consistent	_	
128-28	24218-24230	distribution	_	
128-29	24231-24235	that	_	
128-30	24236-24240	each	_	
128-31	24241-24243	of	_	
128-32	24244-24247	the	_	
128-33	24248-24252	drug	_	
128-34	24253-24258	using	_	
128-35	24259-24265	groups	_	
128-36	24266-24269	had	_	
128-37	24270-24274	into	_	
128-38	24275-24279	each	_	
128-39	24280-24282	of	_	
128-40	24283-24286	the	_	
128-41	24287-24295	clusters	_	
128-42	24295-24296	.	_	

#Text=The k-means algorithm did not take drug-use class into account for the classification.
129-1	24297-24300	The	_	
129-2	24301-24308	k-means	_	
129-3	24309-24318	algorithm	_	
129-4	24319-24322	did	_	
129-5	24323-24326	not	_	
129-6	24327-24331	take	_	
129-7	24332-24340	drug-use	_	
129-8	24341-24346	class	_	
129-9	24347-24351	into	_	
129-10	24352-24359	account	_	
129-11	24360-24363	for	_	
129-12	24364-24367	the	_	
129-13	24368-24382	classification	_	
129-14	24382-24383	.	_	

#Text=There was an unbiased distribution of the points into clusters.
130-1	24384-24389	There	_	
130-2	24390-24393	was	_	
130-3	24394-24396	an	_	
130-4	24397-24405	unbiased	_	
130-5	24406-24418	distribution	_	
130-6	24419-24421	of	_	
130-7	24422-24425	the	_	
130-8	24426-24432	points	_	
130-9	24433-24437	into	_	
130-10	24438-24446	clusters	_	
130-11	24446-24447	.	_	

#Text=The optimal solution was 3 clusters.
131-1	24448-24451	The	_	
131-2	24452-24459	optimal	_	
131-3	24460-24468	solution	_	
131-4	24469-24472	was	_	
131-5	24473-24474	3	_	
131-6	24475-24483	clusters	_	
131-7	24483-24484	.	_	

#Text=It was after those clusters were identified and the point classified that the drug use assignments and genders were assigned to the index of each point.
132-1	24485-24487	It	_	
132-2	24488-24491	was	_	
132-3	24492-24497	after	_	
132-4	24498-24503	those	_	
132-5	24504-24512	clusters	_	
132-6	24513-24517	were	_	
132-7	24518-24528	identified	_	
132-8	24529-24532	and	_	
132-9	24533-24536	the	_	
132-10	24537-24542	point	_	
132-11	24543-24553	classified	_	
132-12	24554-24558	that	_	
132-13	24559-24562	the	_	
132-14	24563-24567	drug	_	
132-15	24568-24571	use	_	
132-16	24572-24583	assignments	_	
132-17	24584-24587	and	_	
132-18	24588-24595	genders	_	
132-19	24596-24600	were	_	
132-20	24601-24609	assigned	_	
132-21	24610-24612	to	_	
132-22	24613-24616	the	_	
132-23	24617-24622	index	_	
132-24	24623-24625	of	_	
132-25	24626-24630	each	_	
132-26	24631-24636	point	_	
132-27	24636-24637	.	_	

#Text=In doing so it became clear that the data was distributed equally amongst the points for each drug class.
133-1	24638-24640	In	_	
133-2	24641-24646	doing	_	
133-3	24647-24649	so	_	
133-4	24650-24652	it	_	
133-5	24653-24659	became	_	
133-6	24660-24665	clear	_	
133-7	24666-24670	that	_	
133-8	24671-24674	the	_	
133-9	24675-24679	data	_	
133-10	24680-24683	was	_	
133-11	24684-24695	distributed	_	
133-12	24696-24703	equally	_	
133-13	24704-24711	amongst	_	
133-14	24712-24715	the	_	
133-15	24716-24722	points	_	
133-16	24723-24726	for	_	
133-17	24727-24731	each	_	
133-18	24732-24736	drug	_	
133-19	24737-24742	class	_	
133-20	24742-24743	.	_	

#Text=This distribution did not change when the results were restricted to 1 point per individual.
134-1	24744-24748	This	_	
134-2	24749-24761	distribution	_	
134-3	24762-24765	did	_	
134-4	24766-24769	not	_	
134-5	24770-24776	change	_	
134-6	24777-24781	when	_	
134-7	24782-24785	the	_	
134-8	24786-24793	results	_	
134-9	24794-24798	were	_	
134-10	24799-24809	restricted	_	
134-11	24810-24812	to	_	
134-12	24813-24814	1	_	
134-13	24815-24820	point	_	
134-14	24821-24824	per	_	
134-15	24825-24835	individual	_	
134-16	24835-24836	.	_	

#Text=Implications for brain stimulation
#Text=This large individual variability may provide insight into the inconsistent outcomes of previous research using TMS for cue-induced craving.
135-1	24837-24849	Implications	_	
135-2	24850-24853	for	_	
135-3	24854-24859	brain	_	
135-4	24860-24871	stimulation	_	
135-5	24872-24876	This	_	
135-6	24877-24882	large	_	
135-7	24883-24893	individual	_	
135-8	24894-24905	variability	_	
135-9	24906-24909	may	_	
135-10	24910-24917	provide	_	
135-11	24918-24925	insight	_	
135-12	24926-24930	into	_	
135-13	24931-24934	the	_	
135-14	24935-24947	inconsistent	_	
135-15	24948-24956	outcomes	_	
135-16	24957-24959	of	_	
135-17	24960-24968	previous	_	
135-18	24969-24977	research	_	
135-19	24978-24983	using	_	
135-20	24984-24987	TMS	_	
135-21	24988-24991	for	_	
135-22	24992-25003	cue-induced	_	
135-23	25004-25011	craving	_	
135-24	25011-25012	.	_	

#Text=An early study demonstrated that one session of 20 Hz stimulation to the left dorsolateral PFC (LDLPFC) had no influence on craving.
136-1	25013-25015	An	_	
136-2	25016-25021	early	_	
136-3	25022-25027	study	_	
136-4	25028-25040	demonstrated	_	
136-5	25041-25045	that	_	
136-6	25046-25049	one	_	
136-7	25050-25057	session	_	
136-8	25058-25060	of	_	
136-9	25061-25063	20	_	
136-10	25064-25066	Hz	_	
136-11	25067-25078	stimulation	_	
136-12	25079-25081	to	_	
136-13	25082-25085	the	_	
136-14	25086-25090	left	_	
136-15	25091-25103	dorsolateral	_	
136-16	25104-25107	PFC	_	
136-17	25108-25109	(	_	
136-18	25109-25115	LDLPFC	_	
136-19	25115-25116	)	_	
136-20	25117-25120	had	_	
136-21	25121-25123	no	_	
136-22	25124-25133	influence	_	
136-23	25134-25136	on	_	
136-24	25137-25144	craving	_	
136-25	25144-25145	.	_	

#Text=In contrast, Amiaz and colleagues demonstrated that 10 sessions of stimulation (20 Hz) to the LDLPFC led to significant, though transient, reductions in craving.
137-1	25146-25148	In	_	
137-2	25149-25157	contrast	_	
137-3	25157-25158	,	_	
137-4	25159-25164	Amiaz	_	
137-5	25165-25168	and	_	
137-6	25169-25179	colleagues	_	
137-7	25180-25192	demonstrated	_	
137-8	25193-25197	that	_	
137-9	25198-25200	10	_	
137-10	25201-25209	sessions	_	
137-11	25210-25212	of	_	
137-12	25213-25224	stimulation	_	
137-13	25225-25226	(	_	
137-14	25226-25228	20	_	
137-15	25229-25231	Hz	_	
137-16	25231-25232	)	_	
137-17	25233-25235	to	_	
137-18	25236-25239	the	_	
137-19	25240-25246	LDLPFC	_	
137-20	25247-25250	led	_	
137-21	25251-25253	to	_	
137-22	25254-25265	significant	_	
137-23	25265-25266	,	_	
137-24	25267-25273	though	_	
137-25	25274-25283	transient	_	
137-26	25283-25284	,	_	
137-27	25285-25295	reductions	_	
137-28	25296-25298	in	_	
137-29	25299-25306	craving	_	
137-30	25306-25307	.	_	

#Text=A recent study selected the medial superior frontal gyrus as a target for stimulation based on functional imaging data.
138-1	25308-25309	A	_	
138-2	25310-25316	recent	_	
138-3	25317-25322	study	_	
138-4	25323-25331	selected	_	
138-5	25332-25335	the	_	
138-6	25336-25342	medial	_	
138-7	25343-25351	superior	_	
138-8	25352-25359	frontal	_	
138-9	25360-25365	gyrus	_	
138-10	25366-25368	as	_	
138-11	25369-25370	a	_	
138-12	25371-25377	target	_	
138-13	25378-25381	for	_	
138-14	25382-25393	stimulation	_	
138-15	25394-25399	based	_	
138-16	25400-25402	on	_	
138-17	25403-25413	functional	_	
138-18	25414-25421	imaging	_	
138-19	25422-25426	data	_	
138-20	25426-25427	.	_	

#Text=Their group then demonstrated that 10 Hz stimulation to this area, which overlaps with Cluster 1 in our study, increased craving to smoking cues.
139-1	25428-25433	Their	_	
139-2	25434-25439	group	_	
139-3	25440-25444	then	_	
139-4	25445-25457	demonstrated	_	
139-5	25458-25462	that	_	
139-6	25463-25465	10	_	
139-7	25466-25468	Hz	_	
139-8	25469-25480	stimulation	_	
139-9	25481-25483	to	_	
139-10	25484-25488	this	_	
139-11	25489-25493	area	_	
139-12	25493-25494	,	_	
139-13	25495-25500	which	_	
139-14	25501-25509	overlaps	_	
139-15	25510-25514	with	_	
139-16	25515-25522	Cluster	_	
139-17	25523-25524	1	_	
139-18	25525-25527	in	_	
139-19	25528-25531	our	_	
139-20	25532-25537	study	_	
139-21	25537-25538	,	_	
139-22	25539-25548	increased	_	
139-23	25549-25556	craving	_	
139-24	25557-25559	to	_	
139-25	25560-25567	smoking	_	
139-26	25568-25572	cues	_	
139-27	25572-25573	.	_	

#Text=Although individual variability in the craving hot spot observed in our investigation may contribute to these mixed results, it is still unclear whether targeting the hot spots for craving directly will maximize therapeutic efficacy.
140-1	25574-25582	Although	_	
140-2	25583-25593	individual	_	
140-3	25594-25605	variability	_	
140-4	25606-25608	in	_	
140-5	25609-25612	the	_	
140-6	25613-25620	craving	_	
140-7	25621-25624	hot	_	
140-8	25625-25629	spot	_	
140-9	25630-25638	observed	_	
140-10	25639-25641	in	_	
140-11	25642-25645	our	_	
140-12	25646-25659	investigation	_	
140-13	25660-25663	may	_	
140-14	25664-25674	contribute	_	
140-15	25675-25677	to	_	
140-16	25678-25683	these	_	
140-17	25684-25689	mixed	_	
140-18	25690-25697	results	_	
140-19	25697-25698	,	_	
140-20	25699-25701	it	_	
140-21	25702-25704	is	_	
140-22	25705-25710	still	_	
140-23	25711-25718	unclear	_	
140-24	25719-25726	whether	_	
140-25	25727-25736	targeting	_	
140-26	25737-25740	the	_	
140-27	25741-25744	hot	_	
140-28	25745-25750	spots	_	
140-29	25751-25754	for	_	
140-30	25755-25762	craving	_	
140-31	25763-25771	directly	_	
140-32	25772-25776	will	_	
140-33	25777-25785	maximize	_	
140-34	25786-25797	therapeutic	_	
140-35	25798-25806	efficacy	_	
140-36	25806-25807	.	_	

#Text=Although most neuroimaging investigations of cue-elicited craving are interested in patterns of neural activity that characterize a population as a whole, the results of this study demonstrate that there is a large variance in the location of peak brain activity during cue-elicited craving.
141-1	25808-25816	Although	_	
141-2	25817-25821	most	_	
141-3	25822-25834	neuroimaging	_	
141-4	25835-25849	investigations	_	
141-5	25850-25852	of	_	
141-6	25853-25865	cue-elicited	_	
141-7	25866-25873	craving	_	
141-8	25874-25877	are	_	
141-9	25878-25888	interested	_	
141-10	25889-25891	in	_	
141-11	25892-25900	patterns	_	
141-12	25901-25903	of	_	
141-13	25904-25910	neural	_	
141-14	25911-25919	activity	_	
141-15	25920-25924	that	_	
141-16	25925-25937	characterize	_	
141-17	25938-25939	a	_	
141-18	25940-25950	population	_	
141-19	25951-25953	as	_	
141-20	25954-25955	a	_	
141-21	25956-25961	whole	_	
141-22	25961-25962	,	_	
141-23	25963-25966	the	_	
141-24	25967-25974	results	_	
141-25	25975-25977	of	_	
141-26	25978-25982	this	_	
141-27	25983-25988	study	_	
141-28	25989-26000	demonstrate	_	
141-29	26001-26005	that	_	
141-30	26006-26011	there	_	
141-31	26012-26014	is	_	
141-32	26015-26016	a	_	
141-33	26017-26022	large	_	
141-34	26023-26031	variance	_	
141-35	26032-26034	in	_	
141-36	26035-26038	the	_	
141-37	26039-26047	location	_	
141-38	26048-26050	of	_	
141-39	26051-26055	peak	_	
141-40	26056-26061	brain	_	
141-41	26062-26070	activity	_	
141-42	26071-26077	during	_	
141-43	26078-26090	cue-elicited	_	
141-44	26091-26098	craving	_	
141-45	26098-26099	.	_	

#Text=While the craving hot spots were clustered around the mPFC in 62% of these smokers, hot spots for 38% of the population (predominantly women) were outside of this area.
142-1	26100-26105	While	_	
142-2	26106-26109	the	_	
142-3	26110-26117	craving	_	
142-4	26118-26121	hot	_	
142-5	26122-26127	spots	_	
142-6	26128-26132	were	_	
142-7	26133-26142	clustered	_	
142-8	26143-26149	around	_	
142-9	26150-26153	the	_	
142-10	26154-26158	mPFC	_	
142-11	26159-26161	in	_	
142-12	26162-26165	62%	_	
142-13	26166-26168	of	_	
142-14	26169-26174	these	_	
142-15	26175-26182	smokers	_	
142-16	26182-26183	,	_	
142-17	26184-26187	hot	_	
142-18	26188-26193	spots	_	
142-19	26194-26197	for	_	
142-20	26198-26201	38%	_	
142-21	26202-26204	of	_	
142-22	26205-26208	the	_	
142-23	26209-26219	population	_	
142-24	26220-26221	(	_	
142-25	26221-26234	predominantly	_	
142-26	26235-26240	women	_	
142-27	26240-26241	)	_	
142-28	26242-26246	were	_	
142-29	26247-26254	outside	_	
142-30	26255-26257	of	_	
142-31	26258-26262	this	_	
142-32	26263-26267	area	_	
142-33	26267-26268	.	_	

#Text=Although acquiring functional imaging data before brain stimulation intervention is more expensive and time-consuming, these data suggest individual imaging may be advantageous for tailoring treatment location or to filter participants before the clinical intervention.
143-1	26269-26277	Although	_	
143-2	26278-26287	acquiring	_	
143-3	26288-26298	functional	_	
143-4	26299-26306	imaging	_	
143-5	26307-26311	data	_	
143-6	26312-26318	before	_	
143-7	26319-26324	brain	_	
143-8	26325-26336	stimulation	_	
143-9	26337-26349	intervention	_	
143-10	26350-26352	is	_	
143-11	26353-26357	more	_	
143-12	26358-26367	expensive	_	
143-13	26368-26371	and	_	
143-14	26372-26386	time-consuming	_	
143-15	26386-26387	,	_	
143-16	26388-26393	these	_	
143-17	26394-26398	data	_	
143-18	26399-26406	suggest	_	
143-19	26407-26417	individual	_	
143-20	26418-26425	imaging	_	
143-21	26426-26429	may	_	
143-22	26430-26432	be	_	
143-23	26433-26445	advantageous	_	
143-24	26446-26449	for	_	
143-25	26450-26459	tailoring	_	
143-26	26460-26469	treatment	_	
143-27	26470-26478	location	_	
143-28	26479-26481	or	_	
143-29	26482-26484	to	_	
143-30	26485-26491	filter	_	
143-31	26492-26504	participants	_	
143-32	26505-26511	before	_	
143-33	26512-26515	the	_	
143-34	26516-26524	clinical	_	
143-35	26525-26537	intervention	_	
143-36	26537-26538	.	_	

#Text=Limitations
#Text=In order to provide some common framework to compare this study to other studies, the anatomical data from all participants was spatially normalized to a standard anatomical template (MNI).
144-1	26539-26550	Limitations	_	
144-2	26551-26553	In	_	
144-3	26554-26559	order	_	
144-4	26560-26562	to	_	
144-5	26563-26570	provide	_	
144-6	26571-26575	some	_	
144-7	26576-26582	common	_	
144-8	26583-26592	framework	_	
144-9	26593-26595	to	_	
144-10	26596-26603	compare	_	
144-11	26604-26608	this	_	
144-12	26609-26614	study	_	
144-13	26615-26617	to	_	
144-14	26618-26623	other	_	
144-15	26624-26631	studies	_	
144-16	26631-26632	,	_	
144-17	26633-26636	the	_	
144-18	26637-26647	anatomical	_	
144-19	26648-26652	data	_	
144-20	26653-26657	from	_	
144-21	26658-26661	all	_	
144-22	26662-26674	participants	_	
144-23	26675-26678	was	_	
144-24	26679-26688	spatially	_	
144-25	26689-26699	normalized	_	
144-26	26700-26702	to	_	
144-27	26703-26704	a	_	
144-28	26705-26713	standard	_	
144-29	26714-26724	anatomical	_	
144-30	26725-26733	template	_	
144-31	26734-26735	(	_	
144-32	26735-26738	MNI	_	
144-33	26738-26739	)	_	
144-34	26739-26740	.	_	

#Text=Although there was minimal spatial distortion in this cohort, normalization compromises the spatial precision of these data.
145-1	26741-26749	Although	_	
145-2	26750-26755	there	_	
145-3	26756-26759	was	_	
145-4	26760-26767	minimal	_	
145-5	26768-26775	spatial	_	
145-6	26776-26786	distortion	_	
145-7	26787-26789	in	_	
145-8	26790-26794	this	_	
145-9	26795-26801	cohort	_	
145-10	26801-26802	,	_	
145-11	26803-26816	normalization	_	
145-12	26817-26828	compromises	_	
145-13	26829-26832	the	_	
145-14	26833-26840	spatial	_	
145-15	26841-26850	precision	_	
145-16	26851-26853	of	_	
145-17	26854-26859	these	_	
145-18	26860-26864	data	_	
145-19	26864-26865	.	_	

#Text=Additionally, this cohort contained a large range of cigarettes smoked per day (8–40), years of smoking (2–40) and age (20–55 years).
146-1	26866-26878	Additionally	_	
146-2	26878-26879	,	_	
146-3	26880-26884	this	_	
146-4	26885-26891	cohort	_	
146-5	26892-26901	contained	_	
146-6	26902-26903	a	_	
146-7	26904-26909	large	_	
146-8	26910-26915	range	_	
146-9	26916-26918	of	_	
146-10	26919-26929	cigarettes	_	
146-11	26930-26936	smoked	_	
146-12	26937-26940	per	_	
146-13	26941-26944	day	_	
146-14	26945-26946	(	_	
146-15	26946-26947	8	_	
146-16	26947-26948	–	_	
146-17	26948-26950	40	_	
146-18	26950-26951	)	_	
146-19	26951-26952	,	_	
146-20	26953-26958	years	_	
146-21	26959-26961	of	_	
146-22	26962-26969	smoking	_	
146-23	26970-26971	(	_	
146-24	26971-26972	2	_	
146-25	26972-26973	–	_	
146-26	26973-26975	40	_	
146-27	26975-26976	)	_	
146-28	26977-26980	and	_	
146-29	26981-26984	age	_	
146-30	26985-26986	(	_	
146-31	26986-26988	20	_	
146-32	26988-26989	–	_	
146-33	26989-26991	55	_	
146-34	26992-26997	years	_	
146-35	26997-26998	)	_	
146-36	26998-26999	.	_	

#Text=It is possible that the individual variability of “hot spots” would be lower with a more uniform cohort.
147-1	27000-27002	It	_	
147-2	27003-27005	is	_	
147-3	27006-27014	possible	_	
147-4	27015-27019	that	_	
147-5	27020-27023	the	_	
147-6	27024-27034	individual	_	
147-7	27035-27046	variability	_	
147-8	27047-27049	of	_	
147-9	27050-27051	“	_	
147-10	27051-27054	hot	_	
147-11	27055-27060	spots	_	
147-12	27060-27061	”	_	
147-13	27062-27067	would	_	
147-14	27068-27070	be	_	
147-15	27071-27076	lower	_	
147-16	27077-27081	with	_	
147-17	27082-27083	a	_	
147-18	27084-27088	more	_	
147-19	27089-27096	uniform	_	
147-20	27097-27103	cohort	_	
147-21	27103-27104	.	_	

#Text=It is also possible that these results from non-treatment seeking individuals will not broadly generalize to treatment-seeking smokers, cocaine users, and alcohol users.
148-1	27105-27107	It	_	
148-2	27108-27110	is	_	
148-3	27111-27115	also	_	
148-4	27116-27124	possible	_	
148-5	27125-27129	that	_	
148-6	27130-27135	these	_	
148-7	27136-27143	results	_	
148-8	27144-27148	from	_	
148-9	27149-27162	non-treatment	_	
148-10	27163-27170	seeking	_	
148-11	27171-27182	individuals	_	
148-12	27183-27187	will	_	
148-13	27188-27191	not	_	
148-14	27192-27199	broadly	_	
148-15	27200-27210	generalize	_	
148-16	27211-27213	to	_	
148-17	27214-27231	treatment-seeking	_	
148-18	27232-27239	smokers	_	
148-19	27239-27240	,	_	
148-20	27241-27248	cocaine	_	
148-21	27249-27254	users	_	
148-22	27254-27255	,	_	
148-23	27256-27259	and	_	
148-24	27260-27267	alcohol	_	
148-25	27268-27273	users	_	
148-26	27273-27274	.	_	

#Text=Cue-reactivity among treatment-seeking individuals may be different than non-treatment seeking individuals.
149-1	27275-27289	Cue-reactivity	_	
149-2	27290-27295	among	_	
149-3	27296-27313	treatment-seeking	_	
149-4	27314-27325	individuals	_	
149-5	27326-27329	may	_	
149-6	27330-27332	be	_	
149-7	27333-27342	different	_	
149-8	27343-27347	than	_	
149-9	27348-27361	non-treatment	_	
149-10	27362-27369	seeking	_	
149-11	27370-27381	individuals	_	
149-12	27381-27382	.	_	

#Text=Additionally, it is important to note that the relationship between being treatment-seeking, receiving treatment, and stopping drug use varies between drug classes.
150-1	27383-27395	Additionally	_	
150-2	27395-27396	,	_	
150-3	27397-27399	it	_	
150-4	27400-27402	is	_	
150-5	27403-27412	important	_	
150-6	27413-27415	to	_	
150-7	27416-27420	note	_	
150-8	27421-27425	that	_	
150-9	27426-27429	the	_	
150-10	27430-27442	relationship	_	
150-11	27443-27450	between	_	
150-12	27451-27456	being	_	
150-13	27457-27474	treatment-seeking	_	
150-14	27474-27475	,	_	
150-15	27476-27485	receiving	_	
150-16	27486-27495	treatment	_	
150-17	27495-27496	,	_	
150-18	27497-27500	and	_	
150-19	27501-27509	stopping	_	
150-20	27510-27514	drug	_	
150-21	27515-27518	use	_	
150-22	27519-27525	varies	_	
150-23	27526-27533	between	_	
150-24	27534-27538	drug	_	
150-25	27539-27546	classes	_	
150-26	27546-27547	.	_	

#Text=For example, treatment-seeking alcohol users often stop drinking alcohol all together before they enter intensive outpatient treatment.
151-1	27548-27551	For	_	
151-2	27552-27559	example	_	
151-3	27559-27560	,	_	
151-4	27561-27578	treatment-seeking	_	
151-5	27579-27586	alcohol	_	
151-6	27587-27592	users	_	
151-7	27593-27598	often	_	
151-8	27599-27603	stop	_	
151-9	27604-27612	drinking	_	
151-10	27613-27620	alcohol	_	
151-11	27621-27624	all	_	
151-12	27625-27633	together	_	
151-13	27634-27640	before	_	
151-14	27641-27645	they	_	
151-15	27646-27651	enter	_	
151-16	27652-27661	intensive	_	
151-17	27662-27672	outpatient	_	
151-18	27673-27682	treatment	_	
151-19	27682-27683	.	_	

#Text=Treatment seeking tobacco users, however, are typically instructed to continue smoking for several weeks after they initiate pharmacotherapy (e.g. varenicline).
152-1	27684-27693	Treatment	_	
152-2	27694-27701	seeking	_	
152-3	27702-27709	tobacco	_	
152-4	27710-27715	users	_	
152-5	27715-27716	,	_	
152-6	27717-27724	however	_	
152-7	27724-27725	,	_	
152-8	27726-27729	are	_	
152-9	27730-27739	typically	_	
152-10	27740-27750	instructed	_	
152-11	27751-27753	to	_	
152-12	27754-27762	continue	_	
152-13	27763-27770	smoking	_	
152-14	27771-27774	for	_	
152-15	27775-27782	several	_	
152-16	27783-27788	weeks	_	
152-17	27789-27794	after	_	
152-18	27795-27799	they	_	
152-19	27800-27808	initiate	_	
152-20	27809-27824	pharmacotherapy	_	
152-21	27825-27826	(	_	
152-22	27826-27829	e.g	_	
152-23	27829-27830	.	_	
152-24	27831-27842	varenicline	_	
152-25	27842-27843	)	_	
152-26	27843-27844	.	_	

#Text=These treatment-related variables may also effect the temporal progression of cue-reactivity in each of these groups.
153-1	27845-27850	These	_	
153-2	27851-27868	treatment-related	_	
153-3	27869-27878	variables	_	
153-4	27879-27882	may	_	
153-5	27883-27887	also	_	
153-6	27888-27894	effect	_	
153-7	27895-27898	the	_	
153-8	27899-27907	temporal	_	
153-9	27908-27919	progression	_	
153-10	27920-27922	of	_	
153-11	27923-27937	cue-reactivity	_	
153-12	27938-27940	in	_	
153-13	27941-27945	each	_	
153-14	27946-27948	of	_	
153-15	27949-27954	these	_	
153-16	27955-27961	groups	_	
153-17	27961-27962	.	_	

#Text=When moving brain stimulation forward as a putative tool to dampen drug-cue reactivity in treatment-seeking individuals the differences in current standards of treatment will all have to be considered as important treatment variables.
154-1	27963-27967	When	_	
154-2	27968-27974	moving	_	
154-3	27975-27980	brain	_	
154-4	27981-27992	stimulation	_	
154-5	27993-28000	forward	_	
154-6	28001-28003	as	_	
154-7	28004-28005	a	_	
154-8	28006-28014	putative	_	
154-9	28015-28019	tool	_	
154-10	28020-28022	to	_	
154-11	28023-28029	dampen	_	
154-12	28030-28038	drug-cue	_	
154-13	28039-28049	reactivity	_	
154-14	28050-28052	in	_	
154-15	28053-28070	treatment-seeking	_	
154-16	28071-28082	individuals	_	
154-17	28083-28086	the	_	
154-18	28087-28098	differences	_	
154-19	28099-28101	in	_	
154-20	28102-28109	current	_	
154-21	28110-28119	standards	_	
154-22	28120-28122	of	_	
154-23	28123-28132	treatment	_	
154-24	28133-28137	will	_	
154-25	28138-28141	all	_	
154-26	28142-28146	have	_	
154-27	28147-28149	to	_	
154-28	28150-28152	be	_	
154-29	28153-28163	considered	_	
154-30	28164-28166	as	_	
154-31	28167-28176	important	_	
154-32	28177-28186	treatment	_	
154-33	28187-28196	variables	_	
154-34	28196-28197	.	_	

#Text=Summary
#Text=The results of this study provide critical information on the spatial distribution of craving “hot spot” in substance abusers.
155-1	28198-28205	Summary	_	
155-2	28206-28209	The	_	
155-3	28210-28217	results	_	
155-4	28218-28220	of	_	
155-5	28221-28225	this	_	
155-6	28226-28231	study	_	
155-7	28232-28239	provide	_	
155-8	28240-28248	critical	_	
155-9	28249-28260	information	_	
155-10	28261-28263	on	_	
155-11	28264-28267	the	_	
155-12	28268-28275	spatial	_	
155-13	28276-28288	distribution	_	
155-14	28289-28291	of	_	
155-15	28292-28299	craving	_	
155-16	28300-28301	“	_	
155-17	28301-28304	hot	_	
155-18	28305-28309	spot	_	
155-19	28309-28310	”	_	
155-20	28311-28313	in	_	
155-21	28314-28323	substance	_	
155-22	28324-28331	abusers	_	
155-23	28331-28332	.	_	

#Text=Moving forward it will be important to determine whether one should choose to stimulate the primary site of craving directly or to apply rTMS to neighboring regions.
156-1	28333-28339	Moving	_	
156-2	28340-28347	forward	_	
156-3	28348-28350	it	_	
156-4	28351-28355	will	_	
156-5	28356-28358	be	_	
156-6	28359-28368	important	_	
156-7	28369-28371	to	_	
156-8	28372-28381	determine	_	
156-9	28382-28389	whether	_	
156-10	28390-28393	one	_	
156-11	28394-28400	should	_	
156-12	28401-28407	choose	_	
156-13	28408-28410	to	_	
156-14	28411-28420	stimulate	_	
156-15	28421-28424	the	_	
156-16	28425-28432	primary	_	
156-17	28433-28437	site	_	
156-18	28438-28440	of	_	
156-19	28441-28448	craving	_	
156-20	28449-28457	directly	_	
156-21	28458-28460	or	_	
156-22	28461-28463	to	_	
156-23	28464-28469	apply	_	
156-24	28470-28474	rTMS	_	
156-25	28475-28477	to	_	
156-26	28478-28489	neighboring	_	
156-27	28490-28497	regions	_	
156-28	28497-28498	.	_	

#Text=More explicitly, should we (1) stimulate at the site of the ‘hot spot’ to push the signal down in that area or should we (2) stimulate in a neighboring neural circuit to pull the activity away from the ‘hot spot’?
157-1	28499-28503	More	_	
157-2	28504-28514	explicitly	_	
157-3	28514-28515	,	_	
157-4	28516-28522	should	_	
157-5	28523-28525	we	_	
157-6	28526-28527	(	_	
157-7	28527-28528	1	_	
157-8	28528-28529	)	_	
157-9	28530-28539	stimulate	_	
157-10	28540-28542	at	_	
157-11	28543-28546	the	_	
157-12	28547-28551	site	_	
157-13	28552-28554	of	_	
157-14	28555-28558	the	_	
157-15	28559-28560	‘	_	
157-16	28560-28563	hot	_	
157-17	28564-28568	spot	_	
157-18	28568-28569	’	_	
157-19	28570-28572	to	_	
157-20	28573-28577	push	_	
157-21	28578-28581	the	_	
157-22	28582-28588	signal	_	
157-23	28589-28593	down	_	
157-24	28594-28596	in	_	
157-25	28597-28601	that	_	
157-26	28602-28606	area	_	
157-27	28607-28609	or	_	
157-28	28610-28616	should	_	
157-29	28617-28619	we	_	
157-30	28620-28621	(	_	
157-31	28621-28622	2	_	
157-32	28622-28623	)	_	
157-33	28624-28633	stimulate	_	
157-34	28634-28636	in	_	
157-35	28637-28638	a	_	
157-36	28639-28650	neighboring	_	
157-37	28651-28657	neural	_	
157-38	28658-28665	circuit	_	
157-39	28666-28668	to	_	
157-40	28669-28673	pull	_	
157-41	28674-28677	the	_	
157-42	28678-28686	activity	_	
157-43	28687-28691	away	_	
157-44	28692-28696	from	_	
157-45	28697-28700	the	_	
157-46	28701-28702	‘	_	
157-47	28702-28705	hot	_	
157-48	28706-28710	spot	_	
157-49	28710-28711	’	_	
157-50	28711-28712	?	_	

#Text=From one perspective, we might expect to get maximal, sustained attenuation of cue-induced craving with an extended course of repetitive TMS directly over the hot spot.
158-1	28713-28717	From	_	
158-2	28718-28721	one	_	
158-3	28722-28733	perspective	_	
158-4	28733-28734	,	_	
158-5	28735-28737	we	_	
158-6	28738-28743	might	_	
158-7	28744-28750	expect	_	
158-8	28751-28753	to	_	
158-9	28754-28757	get	_	
158-10	28758-28765	maximal	_	
158-11	28765-28766	,	_	
158-12	28767-28776	sustained	_	
158-13	28777-28788	attenuation	_	
158-14	28789-28791	of	_	
158-15	28792-28803	cue-induced	_	
158-16	28804-28811	craving	_	
158-17	28812-28816	with	_	
158-18	28817-28819	an	_	
158-19	28820-28828	extended	_	
158-20	28829-28835	course	_	
158-21	28836-28838	of	_	
158-22	28839-28849	repetitive	_	
158-23	28850-28853	TMS	_	
158-24	28854-28862	directly	_	
158-25	28863-28867	over	_	
158-26	28868-28871	the	_	
158-27	28872-28875	hot	_	
158-28	28876-28880	spot	_	
158-29	28880-28881	.	_	

#Text=Due to the high spatial variability in the locus of peak cue-reactivity, the effectiveness of a stimulation therapy may be maximized by using functional imaging to tailor the TMS focus for each individual.
159-1	28882-28885	Due	_	
159-2	28886-28888	to	_	
159-3	28889-28892	the	_	
159-4	28893-28897	high	_	
159-5	28898-28905	spatial	_	
159-6	28906-28917	variability	_	
159-7	28918-28920	in	_	
159-8	28921-28924	the	_	
159-9	28925-28930	locus	_	
159-10	28931-28933	of	_	
159-11	28934-28938	peak	_	
159-12	28939-28953	cue-reactivity	_	
159-13	28953-28954	,	_	
159-14	28955-28958	the	_	
159-15	28959-28972	effectiveness	_	
159-16	28973-28975	of	_	
159-17	28976-28977	a	_	
159-18	28978-28989	stimulation	_	
159-19	28990-28997	therapy	_	
159-20	28998-29001	may	_	
159-21	29002-29004	be	_	
159-22	29005-29014	maximized	_	
159-23	29015-29017	by	_	
159-24	29018-29023	using	_	
159-25	29024-29034	functional	_	
159-26	29035-29042	imaging	_	
159-27	29043-29045	to	_	
159-28	29046-29052	tailor	_	
159-29	29053-29056	the	_	
159-30	29057-29060	TMS	_	
159-31	29061-29066	focus	_	
159-32	29067-29070	for	_	
159-33	29071-29075	each	_	
159-34	29076-29086	individual	_	
159-35	29086-29087	.	_	

#Text=Alternatively, one might choose a scalp location that will work to stimulate craving networks in 68% of individuals, and then use image guidance in non-responders.
160-1	29088-29101	Alternatively	_	
160-2	29101-29102	,	_	
160-3	29103-29106	one	_	
160-4	29107-29112	might	_	
160-5	29113-29119	choose	_	
160-6	29120-29121	a	_	
160-7	29122-29127	scalp	_	
160-8	29128-29136	location	_	
160-9	29137-29141	that	_	
160-10	29142-29146	will	_	
160-11	29147-29151	work	_	
160-12	29152-29154	to	_	
160-13	29155-29164	stimulate	_	
160-14	29165-29172	craving	_	
160-15	29173-29181	networks	_	
160-16	29182-29184	in	_	
160-17	29185-29188	68%	_	
160-18	29189-29191	of	_	
160-19	29192-29203	individuals	_	
160-20	29203-29204	,	_	
160-21	29205-29208	and	_	
160-22	29209-29213	then	_	
160-23	29214-29217	use	_	
160-24	29218-29223	image	_	
160-25	29224-29232	guidance	_	
160-26	29233-29235	in	_	
160-27	29236-29250	non-responders	_	
160-28	29250-29251	.	_	

#Text=Cue associated craving is one of the most well established, transdiagnostic markers of addiction.
161-1	29252-29255	Cue	_	
161-2	29256-29266	associated	_	
161-3	29267-29274	craving	_	
161-4	29275-29277	is	_	
161-5	29278-29281	one	_	
161-6	29282-29284	of	_	
161-7	29285-29288	the	_	
161-8	29289-29293	most	_	
161-9	29294-29298	well	_	
161-10	29299-29310	established	_	
161-11	29310-29311	,	_	
161-12	29312-29327	transdiagnostic	_	
161-13	29328-29335	markers	_	
161-14	29336-29338	of	_	
161-15	29339-29348	addiction	_	
161-16	29348-29349	.	_	

#Text=Many studies have assessed the spatial topography of cue-associated neural activity in specific drug classes independently.
162-1	29350-29354	Many	_	
162-2	29355-29362	studies	_	
162-3	29363-29367	have	_	
162-4	29368-29376	assessed	_	
162-5	29377-29380	the	_	
162-6	29381-29388	spatial	_	
162-7	29389-29399	topography	_	
162-8	29400-29402	of	_	
162-9	29403-29417	cue-associated	_	
162-10	29418-29424	neural	_	
162-11	29425-29433	activity	_	
162-12	29434-29436	in	_	
162-13	29437-29445	specific	_	
162-14	29446-29450	drug	_	
162-15	29451-29458	classes	_	
162-16	29459-29472	independently	_	
162-17	29472-29473	.	_	

#Text=This is the first study to assess the spatial distribution of drug cue-evoked brain activity in multiple substance dependent groups who performed a standardized drug-cue reactivity paradigm at the same research center using cues tailored to their drug of choice.
163-1	29474-29478	This	_	
163-2	29479-29481	is	_	
163-3	29482-29485	the	_	
163-4	29486-29491	first	_	
163-5	29492-29497	study	_	
163-6	29498-29500	to	_	
163-7	29501-29507	assess	_	
163-8	29508-29511	the	_	
163-9	29512-29519	spatial	_	
163-10	29520-29532	distribution	_	
163-11	29533-29535	of	_	
163-12	29536-29540	drug	_	
163-13	29541-29551	cue-evoked	_	
163-14	29552-29557	brain	_	
163-15	29558-29566	activity	_	
163-16	29567-29569	in	_	
163-17	29570-29578	multiple	_	
163-18	29579-29588	substance	_	
163-19	29589-29598	dependent	_	
163-20	29599-29605	groups	_	
163-21	29606-29609	who	_	
163-22	29610-29619	performed	_	
163-23	29620-29621	a	_	
163-24	29622-29634	standardized	_	
163-25	29635-29643	drug-cue	_	
163-26	29644-29654	reactivity	_	
163-27	29655-29663	paradigm	_	
163-28	29664-29666	at	_	
163-29	29667-29670	the	_	
163-30	29671-29675	same	_	
163-31	29676-29684	research	_	
163-32	29685-29691	center	_	
163-33	29692-29697	using	_	
163-34	29698-29702	cues	_	
163-35	29703-29711	tailored	_	
163-36	29712-29714	to	_	
163-37	29715-29720	their	_	
163-38	29721-29725	drug	_	
163-39	29726-29728	of	_	
163-40	29729-29735	choice	_	
163-41	29735-29736	.	_	

#Text=Considered together these data suggest that there are at least three “hot spots” consistently observed in cocaine, alcohol, and nicotine using individuals.
164-1	29737-29747	Considered	_	
164-2	29748-29756	together	_	
164-3	29757-29762	these	_	
164-4	29763-29767	data	_	
164-5	29768-29775	suggest	_	
164-6	29776-29780	that	_	
164-7	29781-29786	there	_	
164-8	29787-29790	are	_	
164-9	29791-29793	at	_	
164-10	29794-29799	least	_	
164-11	29800-29805	three	_	
164-12	29806-29807	“	_	
164-13	29807-29810	hot	_	
164-14	29811-29816	spots	_	
164-15	29816-29817	”	_	
164-16	29818-29830	consistently	_	
164-17	29831-29839	observed	_	
164-18	29840-29842	in	_	
164-19	29843-29850	cocaine	_	
164-20	29850-29851	,	_	
164-21	29852-29859	alcohol	_	
164-22	29859-29860	,	_	
164-23	29861-29864	and	_	
164-24	29865-29873	nicotine	_	
164-25	29874-29879	using	_	
164-26	29880-29891	individuals	_	
164-27	29891-29892	.	_	

#Text=These data may be used to inform target selection for brain stimulation treatment development which seeks to attenuate engagement of these circuits during drug cue exposure.
165-1	29893-29898	These	_	
165-2	29899-29903	data	_	
165-3	29904-29907	may	_	
165-4	29908-29910	be	_	
165-5	29911-29915	used	_	
165-6	29916-29918	to	_	
165-7	29919-29925	inform	_	
165-8	29926-29932	target	_	
165-9	29933-29942	selection	_	
165-10	29943-29946	for	_	
165-11	29947-29952	brain	_	
165-12	29953-29964	stimulation	_	
165-13	29965-29974	treatment	_	
165-14	29975-29986	development	_	
165-15	29987-29992	which	_	
165-16	29993-29998	seeks	_	
165-17	29999-30001	to	_	
165-18	30002-30011	attenuate	_	
165-19	30012-30022	engagement	_	
165-20	30023-30025	of	_	
165-21	30026-30031	these	_	
165-22	30032-30040	circuits	_	
165-23	30041-30047	during	_	
165-24	30048-30052	drug	_	
165-25	30053-30056	cue	_	
165-26	30057-30065	exposure	_	
165-27	30065-30066	.	_	

#Text=Electronic supplementary material
#Text=Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
166-1	30067-30077	Electronic	_	
166-2	30078-30091	supplementary	_	
166-3	30092-30100	material	_	
166-4	30101-30112	Publisher's	_	
166-5	30113-30117	note	_	
166-6	30117-30118	:	_	
166-7	30119-30127	Springer	_	
166-8	30128-30134	Nature	_	
166-9	30135-30142	remains	_	
166-10	30143-30150	neutral	_	
166-11	30151-30155	with	_	
166-12	30156-30162	regard	_	
166-13	30163-30165	to	_	
166-14	30166-30180	jurisdictional	_	
166-15	30181-30187	claims	_	
166-16	30188-30190	in	_	
166-17	30191-30200	published	_	
166-18	30201-30205	maps	_	
166-19	30206-30209	and	_	
166-20	30210-30223	institutional	_	
166-21	30224-30236	affiliations	_	
166-22	30236-30237	.	_	

#Text=Electronic supplementary material
#Text=Supplementary Information accompanies this paper at (10.1038/s41398-018-0220-9).
167-1	30238-30248	Electronic	_	
167-2	30249-30262	supplementary	_	
167-3	30263-30271	material	_	
167-4	30272-30285	Supplementary	_	
167-5	30286-30297	Information	_	
167-6	30298-30309	accompanies	_	
167-7	30310-30314	this	_	
167-8	30315-30320	paper	_	
167-9	30321-30323	at	_	
167-10	30324-30325	(	_	
167-11	30325-30332	10.1038	_	
167-12	30332-30333	/	_	
167-13	30333-30339	s41398	_	
167-14	30339-30340	-	_	
167-15	30340-30343	018	_	
167-16	30343-30344	-	_	
167-17	30344-30348	0220	_	
167-18	30348-30349	-	_	
167-19	30349-30350	9	_	
167-20	30350-30351	)	_	
167-21	30351-30352	.	_	

#Text=Conflict of interest
#Text=CH has served as a consultant for Brain Research & Development Services.
168-1	30353-30361	Conflict	_	
168-2	30362-30364	of	_	
168-3	30365-30373	interest	_	
168-4	30374-30376	CH	_	
168-5	30377-30380	has	_	
168-6	30381-30387	served	_	
168-7	30388-30390	as	_	
168-8	30391-30392	a	_	
168-9	30393-30403	consultant	_	
168-10	30404-30407	for	_	
168-11	30408-30413	Brain	_	
168-12	30414-30422	Research	_	
168-13	30423-30424	&	_	
168-14	30425-30436	Development	_	
168-15	30437-30445	Services	_	
168-16	30445-30446	.	_	

#Text=The other authors declare that they have no conflict of interest.
169-1	30447-30450	The	_	
169-2	30451-30456	other	_	
169-3	30457-30464	authors	_	
169-4	30465-30472	declare	_	
169-5	30473-30477	that	_	
169-6	30478-30482	they	_	
169-7	30483-30487	have	_	
169-8	30488-30490	no	_	
169-9	30491-30499	conflict	_	
169-10	30500-30502	of	_	
169-11	30503-30511	interest	_	
169-12	30511-30512	.	_	

#Text=References
#Text=Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta‐analysis and systematic review
#Text=Craving is associated with smoking relapse: findings from three prospective studies
#Text=Does extinction of responses to cigarette cues occur during smoking cessation?
170-1	30513-30523	References	_	
170-2	30524-30534	Functional	_	
170-3	30535-30547	neuroimaging	_	
170-4	30548-30555	studies	_	
170-5	30556-30558	of	_	
170-6	30559-30566	alcohol	_	
170-7	30567-30570	cue	_	
170-8	30571-30581	reactivity	_	
170-9	30581-30582	:	_	
170-10	30583-30584	a	_	
170-11	30585-30597	quantitative	_	
170-12	30598-30611	meta‐analysis	_	
170-13	30612-30615	and	_	
170-14	30616-30626	systematic	_	
170-15	30627-30633	review	_	
170-16	30634-30641	Craving	_	
170-17	30642-30644	is	_	
170-18	30645-30655	associated	_	
170-19	30656-30660	with	_	
170-20	30661-30668	smoking	_	
170-21	30669-30676	relapse	_	
170-22	30676-30677	:	_	
170-23	30678-30686	findings	_	
170-24	30687-30691	from	_	
170-25	30692-30697	three	_	
170-26	30698-30709	prospective	_	
170-27	30710-30717	studies	_	
170-28	30718-30722	Does	_	
170-29	30723-30733	extinction	_	
170-30	30734-30736	of	_	
170-31	30737-30746	responses	_	
170-32	30747-30749	to	_	
170-33	30750-30759	cigarette	_	
170-34	30760-30764	cues	_	
170-35	30765-30770	occur	_	
170-36	30771-30777	during	_	
170-37	30778-30785	smoking	_	
170-38	30786-30795	cessation	_	
170-39	30795-30796	?	_	

#Text=Neural substrates of cue reactivity: association with treatment outcomes and relapse
#Text=Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies
#Text=Repeated high-frequency transcranial magnetic stimulation over the dorsolateral prefrontal cortex reduces cigarette craving and consumption
#Text=Repetitive transcranial magnetic stimulation of the superior frontal gyrus modulates craving for cigarettes
#Text=High-frequency repetitive transcranial magnetic stimulation decreases cigarette smoking
#Text=Differential brain activity in alcoholics and social drinkers to alcohol cues: relationship to craving
#Text=Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people
#Text=David A & Vassilvitskii S.
171-1	30797-30803	Neural	_	
171-2	30804-30814	substrates	_	
171-3	30815-30817	of	_	
171-4	30818-30821	cue	_	
171-5	30822-30832	reactivity	_	
171-6	30832-30833	:	_	
171-7	30834-30845	association	_	
171-8	30846-30850	with	_	
171-9	30851-30860	treatment	_	
171-10	30861-30869	outcomes	_	
171-11	30870-30873	and	_	
171-12	30874-30881	relapse	_	
171-13	30882-30889	Factors	_	
171-14	30890-30900	modulating	_	
171-15	30901-30907	neural	_	
171-16	30908-30918	reactivity	_	
171-17	30919-30921	to	_	
171-18	30922-30926	drug	_	
171-19	30927-30931	cues	_	
171-20	30932-30934	in	_	
171-21	30935-30944	addiction	_	
171-22	30944-30945	:	_	
171-23	30946-30947	a	_	
171-24	30948-30954	survey	_	
171-25	30955-30957	of	_	
171-26	30958-30963	human	_	
171-27	30964-30976	neuroimaging	_	
171-28	30977-30984	studies	_	
171-29	30985-30993	Repeated	_	
171-30	30994-31008	high-frequency	_	
171-31	31009-31021	transcranial	_	
171-32	31022-31030	magnetic	_	
171-33	31031-31042	stimulation	_	
171-34	31043-31047	over	_	
171-35	31048-31051	the	_	
171-36	31052-31064	dorsolateral	_	
171-37	31065-31075	prefrontal	_	
171-38	31076-31082	cortex	_	
171-39	31083-31090	reduces	_	
171-40	31091-31100	cigarette	_	
171-41	31101-31108	craving	_	
171-42	31109-31112	and	_	
171-43	31113-31124	consumption	_	
171-44	31125-31135	Repetitive	_	
171-45	31136-31148	transcranial	_	
171-46	31149-31157	magnetic	_	
171-47	31158-31169	stimulation	_	
171-48	31170-31172	of	_	
171-49	31173-31176	the	_	
171-50	31177-31185	superior	_	
171-51	31186-31193	frontal	_	
171-52	31194-31199	gyrus	_	
171-53	31200-31209	modulates	_	
171-54	31210-31217	craving	_	
171-55	31218-31221	for	_	
171-56	31222-31232	cigarettes	_	
171-57	31233-31247	High-frequency	_	
171-58	31248-31258	repetitive	_	
171-59	31259-31271	transcranial	_	
171-60	31272-31280	magnetic	_	
171-61	31281-31292	stimulation	_	
171-62	31293-31302	decreases	_	
171-63	31303-31312	cigarette	_	
171-64	31313-31320	smoking	_	
171-65	31321-31333	Differential	_	
171-66	31334-31339	brain	_	
171-67	31340-31348	activity	_	
171-68	31349-31351	in	_	
171-69	31352-31362	alcoholics	_	
171-70	31363-31366	and	_	
171-71	31367-31373	social	_	
171-72	31374-31382	drinkers	_	
171-73	31383-31385	to	_	
171-74	31386-31393	alcohol	_	
171-75	31394-31398	cues	_	
171-76	31398-31399	:	_	
171-77	31400-31412	relationship	_	
171-78	31413-31415	to	_	
171-79	31416-31423	craving	_	
171-80	31424-31430	Effect	_	
171-81	31431-31433	of	_	
171-82	31434-31444	naltrexone	_	
171-83	31445-31448	and	_	
171-84	31449-31460	ondansetron	_	
171-85	31461-31463	on	_	
171-86	31464-31471	alcohol	_	
171-87	31472-31483	cue-induced	_	
171-88	31484-31494	activation	_	
171-89	31495-31497	of	_	
171-90	31498-31501	the	_	
171-91	31502-31509	ventral	_	
171-92	31510-31518	striatum	_	
171-93	31519-31521	in	_	
171-94	31522-31539	alcohol-dependent	_	
171-95	31540-31546	people	_	
171-96	31547-31552	David	_	
171-97	31553-31554	A	_	
171-98	31555-31556	&	_	
171-99	31557-31570	Vassilvitskii	_	
171-100	31571-31572	S	_	
171-101	31572-31573	.	_	

#Text=“K-means++: The Advantages of Careful Seeding.”
172-1	31574-31575	“	_	
172-2	31575-31582	K-means	_	
172-3	31582-31583	+	_	
172-4	31583-31584	+	_	
172-5	31584-31585	:	_	
172-6	31586-31589	The	_	
172-7	31590-31600	Advantages	_	
172-8	31601-31603	of	_	
172-9	31604-31611	Careful	_	
172-10	31612-31619	Seeding	_	
172-11	31619-31620	.	_	
172-12	31620-31621	”	_	

#Text=SODA ‘07: Proceedings of the Eighteenth Annual ACM-SIAM Symposium on Discrete Algorithms.
173-1	31622-31626	SODA	_	
173-2	31627-31628	‘	_	
173-3	31628-31630	07	_	
173-4	31630-31631	:	_	
173-5	31632-31643	Proceedings	_	
173-6	31644-31646	of	_	
173-7	31647-31650	the	_	
173-8	31651-31661	Eighteenth	_	
173-9	31662-31668	Annual	_	
173-10	31669-31677	ACM-SIAM	_	
173-11	31678-31687	Symposium	_	
173-12	31688-31690	on	_	
173-13	31691-31699	Discrete	_	
173-14	31700-31710	Algorithms	_	
173-15	31710-31711	.	_	

#Text=Society for Industrial and Applied Mathematics, 2007, pp. 1027–35.
174-1	31712-31719	Society	_	
174-2	31720-31723	for	_	
174-3	31724-31734	Industrial	_	
174-4	31735-31738	and	_	
174-5	31739-31746	Applied	_	
174-6	31747-31758	Mathematics	_	
174-7	31758-31759	,	_	
174-8	31760-31764	2007	_	
174-9	31764-31765	,	_	
174-10	31766-31768	pp	_	
174-11	31768-31769	.	_	
174-12	31770-31774	1027	_	
174-13	31774-31775	–	_	
174-14	31775-31777	35	_	
174-15	31777-31778	.	_	

#Text=Visual cortex activation to drug cues: a meta-analysis of functional neuroimaging papers in addiction and substance abuse literature
#Text=Neural substrates of smoking cue reactivity: a meta-analysis of fMRI studies
#Text=Common biology of craving across legal and illegal drugs - a quantitative meta-analysis of cue-reactivity brain response.
175-1	31779-31785	Visual	_	
175-2	31786-31792	cortex	_	
175-3	31793-31803	activation	_	
175-4	31804-31806	to	_	
175-5	31807-31811	drug	_	
175-6	31812-31816	cues	_	
175-7	31816-31817	:	_	
175-8	31818-31819	a	_	
175-9	31820-31833	meta-analysis	_	
175-10	31834-31836	of	_	
175-11	31837-31847	functional	_	
175-12	31848-31860	neuroimaging	_	
175-13	31861-31867	papers	_	
175-14	31868-31870	in	_	
175-15	31871-31880	addiction	_	
175-16	31881-31884	and	_	
175-17	31885-31894	substance	_	
175-18	31895-31900	abuse	_	
175-19	31901-31911	literature	_	
175-20	31912-31918	Neural	_	
175-21	31919-31929	substrates	_	
175-22	31930-31932	of	_	
175-23	31933-31940	smoking	_	
175-24	31941-31944	cue	_	
175-25	31945-31955	reactivity	_	
175-26	31955-31956	:	_	
175-27	31957-31958	a	_	
175-28	31959-31972	meta-analysis	_	
175-29	31973-31975	of	_	
175-30	31976-31980	fMRI	_	
175-31	31981-31988	studies	_	
175-32	31989-31995	Common	_	
175-33	31996-32003	biology	_	
175-34	32004-32006	of	_	
175-35	32007-32014	craving	_	
175-36	32015-32021	across	_	
175-37	32022-32027	legal	_	
175-38	32028-32031	and	_	
175-39	32032-32039	illegal	_	
175-40	32040-32045	drugs	_	
175-41	32046-32047	-	_	
175-42	32048-32049	a	_	
175-43	32050-32062	quantitative	_	
175-44	32063-32076	meta-analysis	_	
175-45	32077-32079	of	_	
175-46	32080-32094	cue-reactivity	_	
175-47	32095-32100	brain	_	
175-48	32101-32109	response	_	
175-49	32109-32110	.	_	

#Text=Abstinence-induced changes in self-report craving correlate with event-related FMRI responses to smoking cues
#Text=Brain activation to cocaine cues and motivation/treatment status
#Text=Identifying neurobiological phenotypes associated with alcohol use disorder severity
#Text=Prefrontal responses to drug cues: a neurocognitive analysis
176-1	32111-32129	Abstinence-induced	_	
176-2	32130-32137	changes	_	
176-3	32138-32140	in	_	
176-4	32141-32152	self-report	_	
176-5	32153-32160	craving	_	
176-6	32161-32170	correlate	_	
176-7	32171-32175	with	_	
176-8	32176-32189	event-related	_	
176-9	32190-32194	FMRI	_	
176-10	32195-32204	responses	_	
176-11	32205-32207	to	_	
176-12	32208-32215	smoking	_	
176-13	32216-32220	cues	_	
176-14	32221-32226	Brain	_	
176-15	32227-32237	activation	_	
176-16	32238-32240	to	_	
176-17	32241-32248	cocaine	_	
176-18	32249-32253	cues	_	
176-19	32254-32257	and	_	
176-20	32258-32268	motivation	_	
176-21	32268-32269	/	_	
176-22	32269-32278	treatment	_	
176-23	32279-32285	status	_	
176-24	32286-32297	Identifying	_	
176-25	32298-32313	neurobiological	_	
176-26	32314-32324	phenotypes	_	
176-27	32325-32335	associated	_	
176-28	32336-32340	with	_	
176-29	32341-32348	alcohol	_	
176-30	32349-32352	use	_	
176-31	32353-32361	disorder	_	
176-32	32362-32370	severity	_	
176-33	32371-32381	Prefrontal	_	
176-34	32382-32391	responses	_	
176-35	32392-32394	to	_	
176-36	32395-32399	drug	_	
176-37	32400-32404	cues	_	
176-38	32404-32405	:	_	
176-39	32406-32407	a	_	
176-40	32408-32422	neurocognitive	_	
176-41	32423-32431	analysis	_	
